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Abstract 
Introduction: Identification of the increased risk of intrapartum fetal compromise prior to labour is 
an obstetric challenge. Globally, intrapartum hypoxia remains a major contributor to stillbirth, 
hypoxic ischemic encephalopathy and cerebral palsy. For parents and families, the psychosocial and 
financial impact ($1.5 billion in Australia) of these complications are profound and long-lasting. The 
majority of these catastrophic events occur despite a lack of obvious risk factors. 
Objectives: To explore the relationship between feto-placental and feto-maternal Doppler ultrasound 
variables and maternal serum placental growth factor (PlGF) concentration with adverse perinatal 
outcomes (caesarean for intrapartum fetal compromise, CS-IFC; operative delivery of any kind for 
intrapartum fetal compromise, Op-IFC; or composite neonatal outcome, CNO) in low risk 
pregnancies from 36 weeks’ gestation. Additionally, to determine the screening performance of these 
variables. 
Methods: A prospective, observational, panel study of low risk women was conducted at Mater 
Mothers’ Hospital, Brisbane. Women were eligible to participate if they were normotensive with an 
appropriately grown singleton fetus, uncomplicated pregnancy and anticipating a vaginal delivery 
beyond 36 weeks’ gestation. Women underwent fortnightly assessment of various feto-placental and 
feto-maternal Doppler parameters, estimated fetal weight and maternal PlGF quantification. Maternal 
characteristics, ultrasound and PlGF data, intrapartum and neonatal outcomes were recorded. For 
each assessment and for the last assessment preceding delivery, ultrasound and PlGF variables were 
assessed for their distribution and association with outcomes. Additionally, the rate of change in the 
individual variables was tested for association with outcomes for the different gestation intervals at 
assessment. Finally, the screening performance of ultrasound and PlGF parameters were tested in 
isolation and combination for raw and gestation-adjusted (regression and centiles) variables. 
Results: From May 2014 to September 2016, 483 women participated in the study, with exclusions 
predominantly for missing data and planned cesarean delivery. For the Doppler parameters, the 
following associations were demonstrated: the umbilical artery pulsatility index (PI) was higher at 40 
weeks’ gestation for babies in the adverse Op-IFC outcome group; the middle cerebral artery PI was 
lower in the adverse outcome groups for CS-IFC (40 weeks’ gestation), Op-IFC (36, 38, 40 weeks’ 
gestation and last assessment) and CNO (last assessment) groups; the cerebroplacental ratio was 
lower in the adverse outcome groups for CS-IFC (40 weeks’ gestation and last assessment), Op-IFC 
(38 and 40 weeks’ gestation and last assessment) and CNO (40 weeks’ gestation and last assessment); 
weight-adjusted umbilical venous flow rate was lower in the adverse outcomes groups for CS-IFC 
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(38 weeks’ gestation), Op-IFC (38 weeks’ gestation and last assessment) and CNO (last assessment); 
the uterine artery PI was higher in the adverse outcomes groups for CS-IFC (40 weeks’ gestation and 
last assessment), Op-IFC (38 weeks’ gestation and last assessment) and CNO (38 weeks’ gestation 
and last assessment); estimated fetal weight centile was lower in the adverse outcomes group for Op-
IFC (38 weeks’ gestation and last assessment).  
The rate of change in the cerebroplacental ratio, weight-adjusted umbilical venous flow rate and 
uterine artery PI was different between those with and without the CS-IFC, Op-IFC and CNO 
outcomes.  
Maternal PlGF was lower at last assessment preceding delivery amongst those with Op-IFC outcome 
and all assessments for the CNO outcome. However, sub-analysis of women who had PlGF assay 
performed on the Alere Triage platform demonstrated that maternal PlGF levels were lower at 38 and 
40 weeks’ gestation and at last assessment preceding delivery. The rate of change in maternal PlGF, 
irrespective of assay platform, was no different between the outcome groups.  
Screening performance, as determined by the area under the receiver-operator characteristic 
(AUROC) curves, was highest for CS-IFC when gestation-adjusted centiles for the cerebroplacental 
ratio (or middle cerebral artery PI), uterine artery PI and PlGF levels (Alere platform) were used in 
combination (AUROC curve = 0.94 and 0.95, respectively). In screening for Op-IFC, the highest 
AUROC curve (0.76) was produced by a combination of the middle cerebral artery PI, weight-
adjusted umbilical venous flow rate, uterine artery PI and nulliparity that were not adjusted for 
gestation at assessment. In screening for CNO, the equal highest AUROC curve (0.67) was produced 
by either a combination of the cerebroplacental ratio, uterine artery PI and gestation at delivery, 
unadjusted for gestation at assessment, or a combination of gestation-adjusted (centile) for PlGF 
(DELFIA platform), uterine artery PI and gestation at delivery. 
Conclusion: Various ultrasound parameters and lower maternal PlGF levels are associated with CS-
IFC, Op-IFC and CNO. The rate of change in these parameters did not differ between the outcome 
groups. The combination of predictors (ultrasound and maternal PlGF) for CS-IFC and Op-IFC 
provided significant improvement in screening performance compared to their use in isolation and 
may provide benefit as part of a screening algorithm. Significantly, these results are an improvement 
on current intrapartum fetal heart rate monitoring. 
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Chapter 1: Literature review 
1.1 Introduction 
Globally, intrapartum complications remain a major contributor to adverse perinatal outcomes such 
as stillbirth, hypoxic-ischaemic brain injury and long term neurodevelopmental disability. Despite 
technological advances and the introduction and widespread use of intrapartum fetal heart rate (FHR) 
monitoring over the past 40 years, the rate of cerebral palsy in developed countries has not decreased.1 
Hypoxic ischaemic encephalopathy is the strongest and most consistent risk factor for cerebral palsy 
in term infants,2 a condition that now costs Australia over $1.5 billion annually.3 In terms of disability 
adjusted life years (DALYs), most recent WHO estimates show that DALYs due to birth asphyxia 
are 1.3 times greater than those associated with diabetes and over 80% of those attributable to 
AIDS/HIV.4 Furthermore, the impact of stillbirth in psychosocial and financial terms is enormous 
and long lasting.5 Intrapartum complications affect individuals, communities and nations with far-
reaching implications, making this a global health challenge. 
In Australia, hypoxic peripartum death is the third leading cause of death in singletons at term (≥37 
weeks),6 a population that represents 92.5% of Australian births.7 Rates of fetal distress (intrapartum 
fetal compromise, IFC) range from 87.6 per 1000 births in Tasmania to 182.1 in Queensland.7 
Furthermore, IFC is frequently cited as the primary indication for caesarean section, ranging from 
11.5% of caesarean births in Queensland up to 15.9% in Tasmania.7  
Caesarean sections under emergency conditions are known to have poorer maternal and newborn 
outcomes than planned caesarean sections.8 In particular, higher risk of fetal death, neonatal death 
and neonatal intensive care unit admission ≥7 days have been associated with caesarean deliveries, 
even after adjustment for confounding factors.9,10  
Obstetrics is challenged by the imperfect tools available for accurate classification and identification 
of fetuses that become distressed in labour. Antenatal clinical risk assessment is primarily based on 
maternal medical and psychosocial history and investigations such as ultrasound in the index 
pregnancy. However, antenatal risk assessment fails to identify up to 63% of babies who suffer 
intrapartum hypoxia,11 supporting the view that a better antenatal risk classification system is 
warranted. As such, many investigators have proposed various antenatal risk classification methods, 
all with the aim of identifying these high risk pregnancies prior to birth. However, Cochrane 
systematic reviews of various assessment methods including the admission CTG,12 fetal pulse 
oximetry13 and others (vibroacoustic stimulation,14 liquor assessment,15 fetal16 and maternal17 
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Dopplers) have demonstrated no overall improvement in perinatal outcomes. They have, however, 
resulted in an increase in intervention rates, particularly caesarean section (CS). 
The underlying cause of IFC is not entirely clear. Whilst acute catastrophic events such as cord 
prolapse, uterine rupture or placental abruption account for some cases of IFC, the overwhelming 
majority are likely to arise from the inability of the fetus to withstand the repeated acute episodes of 
hypoxia during labour. During contractions intrauterine pressures can exceed 150mmHg and blood 
flow velocities can decrease by up to 60%,18 with intrauterine pressures of just 35mmHg shown to 
obliterate uterine artery end diastolic flow.19  
1.1.1 Establishment of the placenta 
The placenta is the functional interface between mother and fetus, providing nutrition and removing 
waste products during pregnancy. Consequently, successful placental development is critical to a 
healthy pregnancy. Development of the placenta commences with rapid proliferation of the 
trophoblast and development of the chorionic villi during the first four weeks following fertilisation. 
By nine weeks of gestation (five weeks after fertilisation), maternal-fetal gaseous exchange is 
established permitting transfer of oxygen, nutrients, electrolytes and hormones to the fetus and 
eliminating metabolic waste products (particularly carbon dioxide) from the fetus.20  
Between five and six weeks’ gestation, new vessels begin to grow from the primary villi, a process 
known as vasculogenesis. These new vessels grow in length, eventually curling into the available 
space within the terminal villi, thus becoming closely positioned adjacent to the maternal blood and 
maximising exchange with the intervillous space.20 Vasculogenesis is the predominant growth of fetal 
placental capillaries during the first half of pregnancy, after which time angiogenesis accelerates.21  
Establishment of the placenta also involves remodelling of the uterine arteries from high resistance 
to low resistance vessels. This occurs via thinning of the muscular layer of the spiral arteries, the 
terminal branches of the uterine arteries, by the invasive extravillous cytotrophoblasts, thereby 
reducing the vascular resistance and increasing the maternal blood flow entering the intervillous 
space.22 The exact physiology of this process is not completely understood but maternal and fetal 
factors have been identified in the process, including growth factors, steroid hormones, 
immunological factors, inhibitors and transcription factors.23 Successful endovascular invasion and 
transformation of the uterine arteries is a critical step in healthy placental development. Implantation 
and trophoblast invasion is closely linked to pregnancy outcome. Initially, poor endovascular invasion 
was mainly associated with pre-eclampsia (PET) but has since been associated with a range of other 
conditions such as miscarriage,24 placental abruption25 growth restriction26 and stillbirth.27,28  
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1.1.2 Suboptimal placental function 
Suboptimal placental function, previously known as placental insufficiency, essentially means an 
imbalance between placental supply and fetal demand. That is, a shortfall exists between the placental 
delivery of energy, nutrients and gases and the fetus’ requirements in order for it to reach its 
predetermined growth potential. The fetus responds to a hypoxic intrauterine environment with 
selective vasodilation of vessels in the brain, myocardium and adrenal glands. These vascular changes 
results in preferential shunting of blood to its most vital organs at the expense of the limbs and less 
vital organs. This hemodynamic pattern, also known as brain sparing, was first reported by Saling29 
in 1966. Evidence linking fetal hypoxia to brain sparing was provided by Peeters et al. in 1979.30 
Whilst brain sparing may serve as a protective fetal response to acute hypoxia, there is evidence to 
show it is not entirely benign. Fetal cerebral redistribution has been associated with poorer 
neurodevelopmental outcomes in two year old children, including communication, problem solving 
and personal-social skills.31 Furthermore, secondary intrauterine effects of altered fetal 
hemodynamics are reduced renal perfusion leading to reduced amniotic fluid volume, decreased limb 
perfusion leading to limb wasting, decreased fetal movements shown by altered FHR patterns, 
reduced liver perfusion and subcutaneous abdominal fat deposition leading to slowing in abdominal 
circumference growth. If this gradual deterioration of the fetal condition continues, its adaptation to 
hypoxia becomes exhausted. At this stage the fetus can no longer maintain the hemodynamic 
redistribution (fetal decompensation) and, finally, fetal death occurs.32  
Intrapartum fetal asphyxia/hypoxia was previously thought to be the primary cause of cerebral palsy. 
However, more recent reports from population based studies have shown that intrapartum events 
account for just 8-28% of cerebral palsy cases33,34 and term deliveries account for 65% of cases of 
cerebral palsy.35 The suggestion that cerebral palsy is primarily a developmental condition is now 
widely published and accepted. The overall prevalence of cerebral palsy is low, accounting for 2-3 
per 1000,1,36 but carries a lifelong burden of disease and negative financial impact. 
In the context of placental dysfunction, the association between late pregnancy complications and 
adverse neonatal outcomes,37 is well documented. Additionally, placental dysfunction is implicated 
in long term compromise of frontal neural networks, as demonstrated by lower intelligent quotients 
and neuropsychological deficit in 9 year old children who were underwent late onset growth 
restriction as fetuses.38 Although there is currently no diagnostic test for suboptimal placental 
function, its presence is inferred from characteristic feto-placental ultrasound perfusion 
parameters.32,39 Biomarkers in maternal blood are also emerging as promising non-invasive indicators 
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of placental function. Whilst the combined screening performance of spectral Doppler and biomarkers 
have been investigated in at-risk pregnancies40 at/or prior to 36 weeks,41-43 this performance has not 
been reported in a low risk population at term. 
Fetal growth restriction (FGR) can be subdivided into early onset, occurring before 32-34 weeks’ 
gestation, and late onset thereafter.44 Whilst both groups demonstrate decreased fetal growth velocity, 
early onset growth restriction is characterised by more severe placental disease and hypoxia and 
systemic hemodynamic changes.45 In early onset growth restriction, the most common sequence of 
hemodynamic changes are increased umbilical artery (UA) resistance, followed by brain sparing and 
venous changes as the fetal condition deteriorates.32  Conversely, late onset FGR exhibits more subtle 
changes 45 with generally normal UA spectral Doppler flow but decreased resistance in the middle 
cerebral artery (MCA) is often evident.46  
Whilst fetuses with late onset growth restriction are better able to adapt to a hypoxic environment 
than their premature counterparts, they remain at risk of adverse perinatal outcomes, particularly 
stillbirth.47 Late onset growth restriction has been shown to be a significant contributor to term, non-
anomalous singleton stillbirths in 26% of cases.48 These babies are also significantly more likely to 
be born in poor condition with higher rates of acidosis, Apgar score ≤3 at 5 minutes, delivery room 
intubation, seizures during their first day of life, sepsis and death.49  Additionally, FGR at term is a 
recognised risk factor for IFC and subsequent CS50 and poorer neurodevelopmental outcomes.38,51-53 
Growth restricted fetuses, even at term, are thus at risk of significant morbidity and mortality 
extending from the antenatal period through to adulthood. 
Late onset placental dysfunction and subsequent growth restriction have demonstrable global 
impacts. Worldwide, late onset growth restriction affects far more individuals than early onset 
FGR.45,54 The association with early term delivery and the subsequent increase in incidence of 
readmission and higher health costs during the first year of life55 mean that whilst late onset FGR is 
frequently considered less severe than its early onset equivalent, in terms of numbers of affected 
individuals, late onset disease has far wider impact. Additionally, early term compared to full term 
delivery is associated with poorer neurodevelopmental outcomes,56 coupled with a lifelong increase 
in risk of cardiovascular disease and diabetes amongst those born with FGR.57-59 Growth restriction 
represents the highest potentially modifiable risk factor for stillbirth, with undetected cases of growth 
restriction having almost five times the risk of stillbirth than their detected counterparts.47 Placental 
disease represents the leading cause of antepartum stillbirths, with reported proportions ranging from 
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23-65%.60 Placental disease has been identified in 25% of cases as the leading cause of stillbirth at 
term, representing the single greatest identifiable cause.60 
1.1.3 Intrapartum fetal compromise 
Parturition poses the greatest stress to the feto-placental unit of the entire pregnancy. During labour, 
contractions can reduce placental perfusion by up to 60% and intrauterine pressures can exceed 
150mmHg,18 thus reducing oxygen delivery to the fetus. IFC is understood to reflect fetal hypoxia, 
which may be caused by acute intrapartum events, such as placental abruption, uterine rupture and 
cord prolapse. However, in fetuses without these events it is hypothesised that IFC develops due to a 
pre-existing vulnerability in these pregnancies. The vulnerability is thought to be a state of pre-
existing or chronic hypoxia, such as that observed in FGR fetuses.61 Whilst chronic hypoxia can arise 
from placental, maternal or fetal origins, the greatest contributor to FGR is placental insufficiency.62,63 
Fetal hemodynamic changes (brain sparing circulation) have been demonstrated in response to 
hypoxia64 in order to reduce the overall oxygen demand and preserve vital organs. This compensatory 
mechanism is adequate for a healthy feto-placental unit to withstand acute episodes of hypoxia during 
labour. However, in pregnancies already complicated by late onset growth restriction/placental 
dysfunction, the added stress of contractions during labour is thought to create an acutely hypoxic 
environment for a fetus which has no further adaptive capacity to compensate for the acute hypoxic 
event and IFC ensues.  
Whilst detection of and prompt delivery for IFC can be readily achieved in high income countries 
such as Australia, this is vastly different in low and middle income countries. In Australia, 99.2% of 
births occur in a hospital or birthing centre.7 Of these, emergency caesarean deliveries for IFC range 
from 11.5% to 15.9%,7 although some institutional data suggests that 31% of emergency CS that 
occur at term are due to IFC.8  
The at-risk fetus is frequently used to describe a fetus at increased risk of placental dysfunction and 
its sequelae in the form of intrapartum complications and neonatal morbidities. However, based on 
the best available evidence from various Cochrane systematic reviews, no reliable test for IFC 
currently exists and further research is urgently needed.13,16,65-68 Current attempts to identify the at-
risk fetus are based on maternal medical and obstetric history in previous pregnancies as well as the 
index pregnancy, coupled with current clinical status. The focus of my PhD is antenatal identification 
of pregnancies that develop IFC as a result of placental dysfunction. The following section will detail 
past and current methods to identify the at-risk fetus. 
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1.2 Methods to identify the at-risk fetus 
Identification of the at-risk fetus within an apparently healthy cohort of women has been a 
longstanding obstetric challenge. Despite a range of attempts to address this issue, various systematic 
reviews have concluded that no screening method has resulted in improved perinatal 
outcomes.13,16,65,67-69.  Intrapartum FHR monitoring, whilst not reducing the risk of severe outcomes 
is associated with a reduction in neonatal seizures, fetal scalp blood sampling and lower instrumental 
birth rates. 65 68 However, this has been accompanied by a rise in caesarean deliveries for presumed 
IFC and no reduction in measures of neonatal well-being (acidosis, low Apgar score, resuscitation, 
neonatal intensive care unit admissions, neonatal encephalopathy or cerebral palsy). Overall, there is 
currently no single method that can be considered as the gold standard for identification of a fetus at 
risk of intrapartum compromise. 
1.2.1 Antepartum assessment 
1.2.1.1 Vibroacoustic stimulation 
Vibroacoustic stimulation refers to brief periods of acoustic stimuli by holding an electronic device 
just above the maternal abdomen to elucidate a fetal response. Vibroacoustic stimulation has been 
used in conjunction with other antenatal tests of fetal well-being to prompt the fetus into a reactive 
period after observation of a period of fetal quiescence. For example, vibroacoustic stimulation has 
been used following a non-reactive cardiotocograph (CTG) or low fetal movement count. Some 
investigators have found that the fetal response to vibroacoustic stimulation is an indication of fetal 
well-being and utilisation of vibroacoustic stimulation reduces the false positive rate of a non-reactive 
CTG, maternal reporting of reduced fetal movements or low-scoring ultrasound biophysical profile 
assessment, thereby reducing subsequent intervention.70,71 However, there have also been safety 
concerns regarding fetal well-being with reports of fetal bradycardia72 and maternal concern 
regarding vigorous fetal movements71 in response to the acoustic stimulus. The latest Cochrane 
systematic review concluded that whilst vibroacoustic stimulation reduced FHR observation time and 
the false positive rate of non-reactive cardiotocography, further trials to establish optimum testing 
methodology, safety and diagnostic performance were required.14 
1.2.1.2 Meconium stained liquor 
Meconium passage in utero is an obstetric concern ever since its association with reduced fetal 
activity was first reported by Jesse in 1888.73 Meconium stained liquor is rare prior to 34 weeks of 
gestation and the incidence increases with advancing gestation, to approximately 20% of deliveries 
at term.74 Whilst most fetuses born with meconium stained liquor will have an uncomplicated 
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postnatal course, approximately 5% develop meconium aspiration syndrome.75 This is characterised 
by inhalation of meconium, rendering the pulmonary surfactant inactive and pneumonitis develops. 
In some cases the newborn condition deteriorates further with severe hypoxia, pulmonary 
hypertension and, ultimately, death of the newborn.76 Studies have demonstrated the presence of 
meconium stained liquor is associated with various adverse perinatal outcomes, including fetal 
acidosis, low Apgar score, respiratory distress, neonatal unit admission and neonatal seizures,74 
although the absolute risk of these perinatal complications remains low. For example, the incidence 
of UA blood pH≤7 in a study of over 40,000 deliveries with clear versus meconium stained liquor 
increased from 3 to 7 per 1000 births.74 Whilst theories exist regarding the cause of meconium stained 
liquor, none is universally accepted.74 Interestingly, meconium stained liquor has also been associated 
with decreased resistance in the MCA, which suggests that meconium passage is part of the fetal 
stress response.77  
1.2.1.3 Biophysical profile score 
The fetal biophysical profile was developed in the 1980s as a means to evaluate fetal well-being 
through ultrasound assessment of fetal movements, fetal tone, amniotic fluid volume and FHR 
patterns.78 A reduction in fetal movements has been associated with poorer neonatal condition, IFC 
and even stillbirth,79,80 whilst animal studies have shown that fetal breathing movements may cease 
during episodes of maternal hypoxia.81,82 Initial reports suggested that the biophysical profile score 
could identify the ‘at risk’ fetus,83,84 although they were soon followed by criticism that the technique 
was too labour intensive. The modified biophysical profile score then emerged, requiring only CTG 
and amniotic fluid volume assessment.85 However, a Cochrane systematic review on biophysical 
profile assessment and the modified biophysical profile assessment in high risk pregnancies 
concluded that there was no maternal or fetal benefit with its use. Rather, the rate of intervention 
increased within the pregnancy groups who underwent biophysical profile assessment.86 Given this 
poor screening performance result in high risk pregnancies, biophysical profile scoring has not been 
recommended in low risk populations. 
1.2.1.4 Estimation of fetal weight 
In preterm and growth restricted populations, being small for gestational age (SGA) is strongly linked 
to adverse neonatal outcomes and poorer neurodevelopmental achievement extending into 
adulthood.87 Additionally, growth restriction is an independent risk factor for antenatal stillbirth, with 
a relative risk of stillbirth 5.7-10.0 times higher than normally grown counterparts.47 As such, various 
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methods to assess fetal size are used, including symphyseal-fundal height, abdominal palpation and 
ultrasound estimation of fetal weight.  
Symphyseal-fundal height assessment is a widely used tool to assess fetal size. It refers to the 
longitudinal measurement of the maternal abdomen in centimetres from the pubic symphysis to the 
uterine fundus and requires only a tape measure and appropriate training. In normal pregnancy, from 
20 weeks gestation this measurement approximates the gestation in weeks. Symphyseal-fundal height 
assessment has poor sensitivity, with reported sensitivities of 17.3% to 33%, although variation exists 
in reported sensitivity between studies due to symphyseal-fundal height being used in conjunction 
with ultrasound.88,89  
Abdominal palpation has also been widely used and describes clinical assessment via palpation of the 
uterus and comparison with anatomical landmarks. This method of assessment has poor performance, 
with sensitivities of 21% and 28% for the detection of fetuses with birthweight <10th and <3rd centile, 
respectively.90 The most recent review of symphyseal-fundal height and abdominal palpation in 
screening for FGR concluded that no clear benefit was demonstrated.91 
Estimation of fetal weight from biometric measurements determined by ultrasound has been 
performed since the 1980s. It is commonly performed in clinical practice subsequent to identification 
of risk factors such as reduced symphyseal-fundal height, maternal medical conditions or reduced 
fetal movements.92 Various formulae93 have been developed for the estimation of fetal weight, based 
on the fetal biparietal diameter, head circumference, abdominal circumference and femur length, or 
combination thereof. The associated growth charts provide a population reference for the estimated 
fetal weight (EFW) of an individual fetus and assessment of growth if serial ultrasound scans are 
performed. This population-based approach has been criticised since the late 1990s, as proponents of 
customised charts have shown that individualised assessment of fetal size is more sensitive and 
specific for the detection of FGR at birth.94 For example, Mongelli and Gardosi95 showed that a 
customised birth weight (BW) chart reduced the number of false positive results by 27.5% and 
correctly identified 2.3% of babies who had birth weights <10th centile but were missed by population 
based growth charts. Recently, however, a large systematic review96 concluded that neither 
customised nor population based growth charts were superior and this should be investigated further 
in future trials. 
In addition to the EFW or EFW centile (EFWc), the change in EFW has been proposed as a possible 
screening tool for late onset FGR.97 This theory emerged due to the fact that fetuses with birth weights 
>10th centile represent 50% of stillbirths,47 suggesting that fetuses whose EFW remains above the 
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10th centile may also be at risk of placental insufficiency and suboptimal growth. Therefore changes 
in growth velocity rather than a single weight estimation may be more informative. A recent 
prospective study by MacDonald et al.97 showed that amongst appropriately grown fetuses that 
underwent ultrasound EFW assessment at 28 and 36 weeks’ gestation, for each 1% decrease in EFWc 
the incidence of neonatal acidosis and low body fat increased by 2.4% and 3.3%, respectively. Other 
authors have demonstrated similar trends between a reduction in growth velocity and adverse 
perinatal outcomes,89,98 although these studies included fetuses with EFW <10th centile. 
1.2.1.5 Doppler ultrasound 
The Doppler Effect was first described in 1842 by Christian Doppler, an Austrian physicist. It 
describes the frequency change that occurs between a transmitted and received sound wave due to 
relative movement of a target object. Knowledge of the difference between these frequencies, and 
angle of transmission and object, permits calculation of the relative speed and direction of the target 
object.99 This phenomenon forms the basis for ultrasound assessment of hemodynamics, which has 
been increasingly evident in obstetrics since 1977 when it was first used to observe the spectral trace 
from the UA and vein, and the suggestion was made that it may provide useful information in 
pregnancies affected by PET and growth restriction.100 In 1982 the first report was published of 
altered UA resistance in association with poor fetal outcomes.101 This provided the first demonstrated 
link between fetal well-being, placental function and fetal hemodynamic change. Subsequently, 
assessment of feto-placental hemodynamics with ultrasound has been widely developed and used 
clinically. Feto-placental hemodynamic assessment currently involves interrogation of the UA, 
umbilical vein (UV), ductus venosus, MCA and maternal uterine arteries.  
1.2.1.5.1 Umbilical artery 
The UA has a characteristic saw-tooth appearance on spectral Doppler display, with positive flow 
throughout the cardiac cycle and throughout normal gestation. (Figure 1) End diastolic flow velocities 
reduce as the pregnancy progresses,102 reflecting a reduction in placental vascular resistance with 
advancing gestation. Initial studies suggested that placental insufficiency could be suspected by 
alterations in the spectral Doppler shape and/or indices of the UA. The association between the 
spectral Doppler trace of the UA and adverse fetal outcomes soon followed,103 whereby a low 
proportion of end diastolic flow relative to the peak systolic flow (increased UA pulsatility index, PI; 
UA resistance index, RI; or systolic/diastolic ratio, SD ratio) was associated with FGR.104 This was 
coupled with the suggestion that worsening UA-PI occurs prior to detectable deterioration in fetal 
growth.105 Subsequently, histological evidence of placental dysfunction, including increased numbers 
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of syncytial knots, trophoblast giant cells, intervillous fibrin deposition and maternal underperfusion, 
have been associated with deterioration of UA end diastolic flow,106 thus correlating placental 
abnormalities to deterioration in the UA-PI. 
Figure 1 Umbilical artery spectral Doppler 
 
(Bligh, L; 2016.) 
 
Figure 2 Umbilical artery pulsatility index vs. gestation: 5th. 50th & 95th centiles.  
 
(Taken from: Parra‐Cordero M, et al. Fetal arterial and venous Doppler pulsatility index and time 
averaged velocity ranges. Prenatal Diagnosis 2007; 27(13): 1251-7.) 
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1.2.1.5.2 Umbilical vein 
As the vessel that carries oxygenated blood from the placenta to the fetus, the UV has also been 
investigated for its possible association with adverse perinatal outcomes. Ultrasound reports of 
umbilical venous flow were first reported by Gill et al.107 in 1980, observing that growth restricted 
fetuses had lower UV flow than their appropriately grown counterparts. This was followed by the 
association of umbilical venous pulsations with intrapartum CTG abnormalities.108 In normal 
pregnancy, absolute umbilical venous flow is monophasic (Figure 3, below), with a linear increase in 
velocity throughout gestation.109 Rigano et al.110 have shown however, that umbilical venous blood 
volume per unit of fetal tissue more accurately reflects fetal condition, and umbilical venous flow 
volume corrected for fetal weight or abdominal circumference decreases throughout gestation. 
(Figure 4). Initially, the primary factor thought to influence umbilical venous hemodynamics was the 
ductus venosus sphincter.111 However, a subsequent study using an ovine model demonstrated that 
umbilical venous flow was primarily influenced by the central venous pressure and FHR,112 
concordant with reports showing poor fetal outcomes, including neonatal death, for fetuses with 
umbilical venous pulsations.113,114 Nevertheless, since the initial reports associating umbilical venous 
flow rate with FGR and IFC, there have been few publications regarding the value of umbilical venous 
flow perhaps due to a lack of standardised measurement technique115 and absence of compelling 
predictive value. 
 
Figure 3 Umbilical vein spectral Doppler  
 
(Bligh, L; 2016.) 
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Figure 4 Normalised umbilical venous flow vs. gestation. 
 
(Flo K, et al. Longitudinal reference ranges for umbilical vein blood flow at a free loop of the 
umbilical cord. Ultrasound in Obstetrics and Gynecology. 2010;36(5):567-72.) 
 
1.2.1.5.3 Middle cerebral artery 
Doppler ultrasound patterns from fetal cerebral vessels was first reported by Van den Wijngaard et 
al.116 in 1989. The initial report detailed blood flow patterns in the anterior, middle and posterior 
cerebral arteries and the internal carotid artery in normal and growth restricted fetuses from 25 to 41 
weeks’ gestation, concluding that the PI in all intracranial vessels was significantly reduced in growth 
restricted fetuses compared to their normally grown counterparts. This report demonstrated the link 
between brain sparing circulation and spectral Doppler changes. Although Doppler assessment of 
various cerebral vessels has been reported, the course of the MCA is best suited to colour flow 
mapping and hence Doppler evaluation. The coronal suture provides a consistent acoustic window to 
insonate the MCA, allowing a Doppler angle of close to 0 degrees throughout pregnancy. (Figure 5) 
In normal pregnancy, the MCA-PI increases until 28 weeks’ gestation and then gradually declines to 
term (Figure 6) 
 
13 
 
Figure 5 Middle cerebral artery spectral Doppler 
 
(Bligh, L; 2016.) 
 
Figure 6 Middle cerebral artery pulsatility index vs. gestation.  
 
(Taken from: Fetal arterial and venous Doppler pulsatility index and time averaged velocity ranges. 
Parra-Cordero M, et al. Prenat Diagn. 2007 Dec; 27(13): 1251-7.) 
Following initial reports of altered fetal cerebral hemodynamics in at-risk fetuses, conflicting results 
emerged regarding the association between the MCA Doppler changes and poor fetal condition. Some 
reported increased cerebral resistance indices117 whilst others reported no difference.118 However, 
further reports have confirmed that whilst the MCA pulsatility may not be reduced in all small for 
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gestational age (SGA) fetuses, reduced MCA pulsatility is associated with poorer perinatal 
outcomes,119 including IFC,120-122 low Apgar score,123 neonatal acidosis,123 neonatal intensive care 
unit admission120 and low birth weight.124 Reduced MCA-PI is now a recognised risk factor for poor 
perinatal outcome, independent of increased pulsatility in the UA.46,122,125 
Alterations in MCA flow appear to be directly associated with fetal hypoxia. In 1991, Campbell et 
al.126 showed that hypoxia in SGA fetuses was associated with lower resistance in the MCA. Over a 
decade later, Kassanos et al.127 demonstrated that amongst a population of term fetuses with non-
reassuring CTG patterns, intrapartum MCA-PI was significantly lower amongst those with fetal scalp 
oxygen saturation readings <30% than those with oxygen saturation >30%. Furthermore, this study 
temporally linked fetal cerebral redistribution with acute fetal hypoxia and demonstrated that the first 
Doppler index to exhibit change consistent with brain sparing was the MCA-PI. This was followed 
by changes in the MCA-RI, UA-PI and UA-RI.  
1.2.1.5.4 Cerebroplacental ratio 
The cerebroplacental ratio (CPR) is the simple ratio of the MCA-PI to the UA-PI.128 Improvement in 
duplex Doppler ultrasound technology during the 1980s and the search for evidence of brain sparing 
led to investigation of cerebral blood flow in comparison to UA blood flow. Arbeille et al.128 reported 
that a low cerebroumbilical ratio (CU ratio or CPR), a ratio of cerebral to placental resistance, was 
associated with maternal hypertension, growth restriction and poor fetal outcome. The CPR normally 
increases with advancing gestation, reaching a peak around 34 weeks’ gestation, before gradually 
declining to term. (Figure 7). 
Figure 7 CPR vs. gestation 
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(Taken from: Ebbing C, et al. Middle cerebral artery blood flow velocities and pulsatility index and 
the cerebroplacental pulsatility ratio: longitudinal reference ranges and terms for serial 
measurements. Ultrasound Obstet Gynecol 2007; 30(3): 287-96.) 
After some initial enthusiasm, interest in the CPR faded somewhat as UA Doppler in isolation was 
increasingly used to guide management of growth restricted fetuses.129 However, as late onset growth 
restriction became recognised as a distinct entity in contrast to its early onset counterpart, there was 
a resurgence of interest in the CPR. From the turn of this century there have been numerous 
publications evaluating the utility of the CPR in various high and low risk populations.130 Studies 
have now shown that a low CPR is associated with IFC,131 stillbirth,132 failure to reach a fetus’ growth 
potential,133,134 neonatal morbidity (acidosis at birth, low Apgar score and/or neonatal unit 
admission),89,135-137 even in term fetuses. Indeed, a recent systematic review138 and expert opinion 
articles139,140 have suggested that the utility of the CPR should be assessed in low risk populations to 
screen for late pregnancy complications.  
A large retrospective study by Akolekar et al. at 30-34 weeks’ gestation showed that the CPR was 
weakly predictive of intrapartum complications,141 with sensitivity of 5-11% at a false positive rate 
of approximately 5%. However, for a subgroup of women in this study who delivered within 2 weeks 
of ultrasound assessment, the sensitivity rose to 50% for a false positive rate of 23%. A further study 
of pregnancies late in the third trimester pregnancy again showed a similar pattern; the CPR was 
shown to be weakly predictive of adverse perinatal outcome and sensitivity improved to 50% for a 
false positive rate of 10% when pregnancies who delivered within 2 weeks of ultrasound assessment 
were analysed.142 However, when performed within 72 hours of birth, a prospective study at term 
demonstrated that a low CPR (<10th centile) in a low risk population increased the odds of requiring 
an emergency caesarean delivery for IFC by over 6 times, compared to those with CPR >10th 
centile.131 This study also showed that a CPR <10th centile was also associated with IFC being 
diagnosed at any time during labour. Other research groups have used a threshold of 0.6765 multiples 
of the median (MoM),133 which equates to the 5th centile, and shown that a low CPR is associated 
with sequelae of placental dysfunction, including fetal hypoxemia, growth restriction,133 poor acid-
base status at term143 and neonatal unit admission.135 Although much has been published about the 
CPR in the at-risk population, little is known about the changes of the CPR and of its associations 
with adverse intrapartum and neonatal outcomes in a low risk population at term. 
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1.2.1.5.5 Uterine artery  
The uterine arteries are the primary arterial vascular supply for the uterus and, hence the placenta. In 
normal pregnancy, the uterine arteries have high peak systolic velocities and end diastolic velocities 
on spectral Doppler ultrasound (Figure 8). Thus, the successful transformation of the spiral arteries 
to low resistance vessels through the invasion of trophoblasts is reflected by appropriately decreasing 
PI with advancing gestation. Given the physical conversion of spiral arteries seen in normal 
pregnancies and aberrations in this process noted in pathological pregnancies144,145 blood flow 
patterns in uterine arteries have been investigated for their association with placental insufficiency 
and subsequent adverse perinatal outcomes particularly in FGR122,146,147 and PET.148,149 Vergani et 
al.147 demonstrated that growth restricted fetuses delivered ≥34 weeks of gestation with an elevated 
uterine artery PI were more likely to be delivered by CS, particularly for non-reassuring fetal status, 
earlier in gestation and had lower birthweight centiles than those with normal uterine artery PI. 
Further reports have supported these findings,150,151 although the sensitivity of the uterine artery 
resistance to identify PET or growth restriction is higher for severe compared to mild disease.148,152 
For example, when screen positive is defined as bilateral notching of the uterine arteries or mean PI 
exceeding 1.45 at 23 to 24 weeks’ gestation, sensitivity of 90% for a 7% false positive rate is achieved 
for the detection of PET <34 weeks’ gestation, reducing to 45% and 6%, respectively, if PET at any 
gestation is the specified outcome.152  Consequently, uterine artery spectral Doppler has been 
suggested as a potential screening tool for pregnancies complicated by placental dysfunction.151 
Figure 8 Uterine artery spectral Doppler 
 
(Bligh, L; 2016.) 
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Figure 9 Mean uterine artery pulsatility index vs. gestational age. Estimated 5th, 50th and 95th 
centiles. 
 
(Taken from: Gómez O, Figueras F, Fernández S, Bennasar M, Martínez JM, Puerto B, et al. 
Reference ranges for uterine artery mean pulsatility index at 11–41 weeks. Ultrasound Obstet 
Gynecol 2008; 32(2): 128-32.) 
1.2.1.6 Ultrasound safety 
Ultrasound has been used as an imaging modality in obstetrics for over 30 years. The theoretical risks 
associated with ultrasound include heating and cavitation, although these effects are negligible with 
appropriately qualified and skilled operators with modern machines. A World Health Organisation 
meta-analysis published in 2009153 confirmed that according to the available evidence, the use of B-
mode and Doppler ultrasound during pregnancy was not associated with adverse maternal outcome, 
adverse perinatal outcome, abnormal childhood growth and neurological development, childhood 
malignancy, compromised intellectual performance or mental disease. The only positive finding was 
a weak association with non-righthandedness in boys if the fetus was exposed to multiple ultrasound 
scans. 
1.2.1.7 Biomarkers of placental dysfunction 
Beyond aneuploidy screening, biochemical markers have been widely investigated for their 
association with and prediction of adverse perinatal outcomes. In particular, biomarkers in the 
maternal compartment which reflect placental dysfunction have been investigated in the context of 
growth restriction, PET and stillbirth.154,155 Although over 400 placental biomarkers have been 
described,156 only the following, in the maternal compartment, will be discussed in this Thesis as they 
can be easily acquired and measured: pregnancy associated plasma protein A (PAPP-A), human 
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chorionic gonadotropin, (hCG), human placental lactogen (hPL), soluble endoglin (sEng), soluble 
fms-like tyrosine kinase-1 (sFLT-1) and placental growth factor (PlGF). 
1.2.1.7.1 Pregnancy associated plasma protein A 
PAPP-A is perhaps the most well-known biomarker of placental dysfunction due to its use in first 
trimester aneuploidy screening. Although PAPP-A was first reported by Lin et al.157 in 1974, its role 
in fetal growth was not reported until 1999.158 PAPP-A cleaves insulin-like growth factor binding 
protein (IGFBP4) from IGF, thereby creating a bioavailable form of IGF which then stimulates fetal 
growth.158 Significantly altered levels of maternal serum PAPP-A were first associated with 
aneuploidy, growth restriction and PET,159 and have since been associated with intrapartum 
complications, particularly IFC requiring emergency caesarean,160 and reduced placental 
vascularisation on 3D ultrasound in the first trimester.161 
1.2.1.7.2 Human chorionic gonadotropin 
Human chorionic gonadotropin (hCG), first reported in 1927,162 is produced by the trophectoderm 
and is detectable in maternal serum and urine from the first week post conception, reaching a peak 
concentration at nine weeks gestation. After a steady decline in concentration, hCG levels then 
stabilise through the second and third trimesters of pregnancy.163 Whilst associations between altered 
hCG and aneuploidy are well established,164 reports linking hCG and adverse outcomes originating 
from placental dysfunction have been mixed. Studies in euploid fetuses have associated elevated hCG 
levels with PET165,166 and pregnancy induced hypertension,166, whilst lower levels have been reported 
in pregnancies with FGR,167 any yet others have reported no association with FGR166,168 or PET.168 
1.2.1.7.3 Human placental lactogen 
Josimovich and MacLaren were the first to report of hPL in 1962.169 Human placental lactogen was 
subsequently identified as originating from syncytiotrophoblasts170 and is believed to play a role in 
fetal growth through stimulation of IGF production.171 Its concentration in maternal serum increases 
rapidly to 32 weeks of pregnancy, thereafter continuing to increase at a slower rate.169 Initially, a 
reduced concentration of hPL was associated with adverse pregnancy outcomes originating from 
placental dysfunction, including FGR and stillbirth,169 and more recently reduced levels have been 
associated with adverse neonatal outcomes such as acidosis, low Apgar score and neonatal unit 
admission.28 To date, no intrapartum outcomes have been reported in association with hPL. 
1.2.1.7.4 Soluble endoglin 
Soluble endoglin is a fragment of the endoglin glycoprotein that is highly expressed on vascular 
endothelium and placental syncytiotrophoblasts.172 sEng levels normally increase throughout 
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pregnancy, tripling in concentration by term compared to pre-pregnancy levels for uncomplicated 
pregnancies.173 It has been shown to have an anti-angiogenic role, acting as a co-receptor for 
transforming growth factors β1 and β3,174 thus limiting placental vascular growth and development. 
sEng has been shown to be upregulated in pregnancies that develop PET or growth restriction 
compared to normal pregnancies.173,175 Case-control studies have demonstrated significantly higher 
sEng in second trimester pregnancies that develop PET176 with odds ratios for developing pre-term 
PET and SGA of 14.9 and 2.9 for women with elevated sEng.177 In a cohort study of growth restricted 
vs. control fetuses, Stepan et al.178 showed for the first time that sEng was higher in normotensive 
women with growth restricted fetuses compared to controls. However, a study of sEng in low risk 
nulliparous women demonstrated poor diagnostic performance (AUROC 0.53)179 for the prediction 
of PET. Whilst sEng may have a role in screening high risk women for PET, it appears to have a very 
limited role in screening a low risk population.  
1.2.1.7.5 Placental growth factor 
In 1990, Maglione et al.180 first described PlGF after isolating it from a placental sample. They 
established that PlGF was a protein related to vascular endothelial growth factor (VEGF, known at 
the time as vascular permeability factor) able to stimulate endothelial cell line growth. Since then it 
has been shown that PlGF is released primarily by the syncytiotrophoblast, with smaller amounts 
secreted by the fetal heart, lung, thyroid, skeletal muscle and adipose tissue.181 Four isoforms of PlGF 
have been identified; PlGF1, PlGF2, PlGF3 and PlGF4, each characterised by differing size and 
binding affinities.182 Whilst the precise physiological action of PlGF and its isoforms is not clear, it 
is known to bind specifically to the VEGFR-1 receptor (also known as soluble fms-like tyrosine 
kinase 1, sFlt1)21 and has a pivotal role in placental angiogenesis, inducing vasodilation of uterine, 
myometrial, mesenteric, and subcutaneous arteries.183 This effect is particularly pronounced in uterine 
arteries during pregnancy, suggesting that PlGF contributes to uterine vascular remodelling during 
gestation. Using some platforms, PlGF levels can be measured rapidly using a point-of-care assay 
with an individual result in as little as 15 minutes184 or large scale throughput with laboratory 
processing of multiple samples simultaneously. As illustrated in Figure 10, PlGF in normal pregnancy 
rises until approximately 32 weeks gestation, before decreasing to term, whilst in pregnancies which 
develop PET, PlGF levels are significantly lower throughout pregnancy.185 
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Figure 10 Mean PlGF in normal and preeclamptic pregnancies 
 
(From: Levine RJ, Maynard SE, Qian CMS, et al. Circulating Angiogenic Factors and the Risk of 
Preeclampsia. The New England Journal of Medicine 2004; 350(7): 672-83.) 
Maternal circulating PlGF levels in the first trimester have also been investigated. Multiple studies 
have shown an association between reduced levels of PlGF in the late first trimester and subsequent 
development of hypertensive disorders of pregnancy.186-188 To date, there are no studies assessing the 
association between first trimester PlGF and fetal compromise in labour. 
More data exists on PlGF in the second and third trimesters of pregnancy and its association with 
growth restriction and hypertensive disorders. In a prospective multicentre study involving 625 
women at 20-35 weeks gestation with high risk of PET, reduced maternal levels of PlGF were 
strongly associated with the development of early onset PET.189 Furthermore, work by Benton et 
al.184,190 in a cohort of SGA age fetuses, showed that low PlGF was associated with a greater degree 
of abnormal placental morphology. The low levels of PlGF in both clinical situations likely reflect 
similar underlying pathology whereby defective trophoblast invasion leads to altered expression of 
angiogenic-related factors and subsequent placental dysfunction. To date no studies have investigated 
the relationship between PlGF levels in late pregnancy and intrapartum outcomes in low risk women 
with appropriately grown fetuses. A recent expert review140 recommended further research into PlGF 
and other biomarkers of placental function to assess their predictive value regarding intrapartum 
compromise. 
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1.2.1.7.6 Soluble fms-like tyrosine kinase 1 
sFlt1 is an anti-angiogenic receptor, found in trophoblasts, that binds to circulating PlGF, VEGF-A 
and VEGF-B.191 In normal pregnancy anti-angiogenic factors, such as sFlt, are balanced with 
angiogenic factors to provide adequate myometrial invasion without excessive invasion, as occurs in 
placental accreta.23 However, high levels of anti-angiogenic factors, such as sFlt, appear to impede 
normal cytotrophoblast invasion of the myometrium and uterine spiral arteries, characteristics that 
are hallmarks of PET.192-194 24-26As such, sFlt concentrations have been shown to be higher in PET 
and growth restriction. 
1.2.2 Intrapartum monitoring for fetal compromise 
1.2.2.1 Cardiotocography 
Fetal heart monitoring as a means of assessing fetal well-being was first described by Kergaradec, a 
French physician, in 1822.195 In its infancy, FHR monitoring described the association made between 
fetal bradycardia and poor fetal condition, with Schwartz suggesting a link between fetal acidosis and 
FHR patterns.196 A rudimentary form of FHR monitoring was developed by Cremer in the early 
1900s, whereby electrodes were placed on the presenting fetal part and a heart trace was obtained.197 
Almost 150 years after Kergaradec suggested the association between FHR patterns and fetal well-
being, Callagan29 described how ultrasound could be used for FHR monitoring, thus presenting a non-
invasive means to assess fetal well-being.  
FHR monitoring techniques progressed rapidly during the 1960s and 1970s. In 1969, Kubli198  
reported an association between FHR patterns and fetal acidosis. This was soon followed by studies 
in rhesus monkeys which described characteristic FHR patterns and duration of bradycardia that were 
associated with various levels of uterine perfusion and therefore oxygen delivery to the fetus.199 By 
the mid-1970s, the transition of FHR monitoring into clinical practice had occurred, without research 
trials convincingly reporting benefit from its use.  
Various Cochrane systematic reviews have investigated the impact of the use of cardiotocography on 
maternal and neonatal outcomes.65,200,201 These have consistently shown that rates of intervention 
(operative vaginal and caesarean deliveries) have increased with little improvement in neonatal 
outcomes. Additionally, a five-fold increase in the rate of caesarean deliveries since the introduction 
of cardiotocography has been reported. Whilst other changes in obstetrics during this period may have 
contributed to this large increase in caesarean deliveries, the impact on mothers and newborns is clear. 
Emergency caesarean deliveries compared to their non-emergency equivalent result in poorer 
neonatal outcomes, including Apgar <7 at 1 and 5 minutes, pH <7.2, respiratory distress, neonatal 
22 
 
resuscitation, neonatal intensive care unit admission and neonatal seizure rate.8 Maternal outcomes 
for planned CS compared to their emergency equivalent are also poorer, with haemorrhage, 
intraoperative, puerperal, infectious and severe complications all reported to be more frequent for 
emergency caesarean procedures.202 Since the widespread use of intrapartum FHR monitoring, 
reports have shown a halving of neonatal seizure rate.65 However, in developed countries this has not 
resulted in a reduction in hypoxic ischemic encephalopathy or cerebral palsy.65 
Cardiotocography offers high sensitivity but poor specificity when applied as a screening test to low 
risk women. Whilst cardiotocography has high sensitivity for the detection of fetal hypoxia, its ability 
to discriminate between truly hypoxic and normal fetuses has stymied its potential benefits.203 In a 
study of 5522 low risk women, the presence of late decelerations was associated with positive 
predictive values of 34% - 53% for pH <7.1.204 Additionally, the false positive rate for the prediction 
of cerebral palsy has been reported as high as 99.8%.205 Furthermore,  inter-observer agreement 
occurs in only 22% to 29% of cases,206 whilst intra-observer concordance occurs in just 79% of 
cases.206 Subsequently, professional bodies across countries have attempted to standardise 
interpretation of FHR patterns.206-209 Despite these efforts to improve consistency of interpretation, 
neonatal outcomes remain largely unchanged and intervention rates remain elevated.65 
1.2.2.2 Fetal electrocardiogram 
Fetal electrocardiography (ECG) and its association with intrapartum hypoxia was first described in 
animal models by Rosen and Kjellmer in 1975.210 Fetal ECG is obtained by placing electrodes onto 
the fetal scalp after membrane rupture. Similar to adult ECG, the shape of the QRST complex in the 
fetus can be used to interpret well-being. The S-T and P-R intervals have been assessed for their 
ability to predict adverse intrapartum and neonatal outcomes. The S-T interval is a comparison of T-
wave elevation relative to the S-wave, whilst the P-R interval is a measure of time. It was shown in 
animal models211 that as the fetus experiences progressively worsening hypoxia, bradycardia and T 
wave elevation also occur. This S-T interval change has been the focus of several large trials. In a 
large multicentre, randomised trial comparing neonatal outcomes in women who underwent 
intrapartum CTG monitoring alone compared to fetal ECG used in combination with CTG, there was 
no reduction in CS rates nor improvement in neonatal outcomes (neonatal death, seizure rate, acidosis, 
intubation or neonatal encephalopathy) from the addition of fetal ECG compared to CTG alone.212 
Whilst this study reported a reduction in the rate of fetal scalp lactate sampling and instrumental 
vaginal deliveries, a Cochrane Systematic Review68 suggested that no net benefit was gained by the 
addition of fetal ECG to CTG in over 27,000 women studied. 
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1.2.2.3 Fetal blood sampling (pH and lactate) 
Fetal blood sampling refers to the analysis of a sample of capillary blood obtained from the fetal 
scalp. It was first described by Saling in 1964 to test fetal pH and represented a significant advance 
in assessing the fetal status during parturition.213 Two methods have been described for analysis – pH 
and lactate assessment. Both methods require the membranes to be ruptured, 3cm or more of cervical 
dilatation to allow passage of an amnioscope and laceration of the fetal scalp for blood collection. pH 
testing requires a significantly greater volume of fetal blood than lactate sampling (30-50µL vs. 5 
µL), takes approximately twice the duration for analysis (120s vs. 230s), is subject to a higher rate of 
sampling attempts and sampling failure and a higher rate of false negative results.214,215 Subsequently, 
fetal lactate sampling has been recommended67,216 as a superior test for identification of a truly 
hypoxic fetus in the presence of an abnormal intrapartum CTG, although cost effectiveness evidence 
is lacking.67 Nevertheless, the key limitation of fetal scalp sampling is its inability to identify 
irreversible hypoxic injury. 
1.2.2.4 Fetal pulse oximetry 
Pulse oximetry measures the level of functional oxygen saturation through the differential absorption 
of red and infra-red light by oxyhemoglobin and deoxyhemoglobin.217 It has revolutionised medical 
monitoring since its development during the Second World War due to its ability to provide 
continuous, accurate, non-invasive and real-time oxygenation information. For these reasons, pulse 
oximeters were then adapted and applied to the fetus in the intrapartum setting, as reported by Peat 
and colleagues in 1988.218 Purpose-built oximeters that could attach or clip onto the fetal head were 
soon developed and investigated as an adjunct measure of fetal well-being, secondary to 
cardiotocography. Strengths of this approach are the ability to contemporaneously quantify the level 
of fetal oxygenation in a manner that is reportedly acceptable to women.13 However, it has two 
important drawbacks. Firstly, failure to obtain a reading occurs in up to 30% of cases219 due to loss 
of contact between the device and the fetus, which is unacceptably high for a diagnostic tool. 
Secondly, there has been no reported improvement in outcomes such as a reduction in overall 
outcomes (rates of CS, acidosis or Apgar scores, length of hospital stay, neonatal intensive care unit 
admissions, death or skin trauma).13 Furthermore, surprisingly some studies have suggested that fetal 
pulse oximetry is associated with higher rates of shoulder dystocia.220 Hence, the use of fetal pulse 
oximetry has not been recommended for clinical use and the most recent Cochrane review suggests 
the pursuit of another method to assess intrapartum fetal well-being is preferable.13 
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1.3 Summary 
IFC and intrapartum hypoxia related morbidities are important health issues globally. Current 
antepartum screening methods fail to identify the majority of cases of intrapartum hypoxia, 
particularly in the apparently low risk population. There is an imperative for better risk stratification 
within a low risk population to identify women at risk of IFC. 
Intrapartum FHR monitoring, the current gold standard to diagnose IFC, offers sensitive detection of 
IFC but with the significant disadvantage of increasing medical interventions due to its high false 
positive rate. Ideally, the high sensitivity of intrapartum FHR monitoring would be best used in a 
population where the incidence of the condition is high, thereby increasing specificity in detection of 
IFC. Those fetuses with presumed IFC based on FHR monitoring could then undergo fetal scalp 
lactate sampling to identify the truly hypoxic fetus in need of urgent delivery. The intervention, fetal 
scalp lactate sampling and/or rapid delivery, could then be targeted appropriately to those with IFC 
with fewer false-positive cases and therefore fewer unnecessary interventions. Such an approach 
requires identification of the at-risk fetus with sufficient time between screening and labour for 
discussion with the woman regarding delivery planning. 
To improve perinatal outcomes for fetuses at risk of IFC and its sequelae, results must be available 
and action taken in a timely manner to prevent hypoxic brain injury. Perhaps the fetus who is 
identified as having IFC in labour has already undergone hemodynamic redistribution and chronic 
hypoxia to the extent that brain injury has already occurred. Thus, for a screening test to result in 
improved perinatal outcomes it needs to be both predictive of IFC and provide timely results, coupled 
with an intervention to prevent or mitigate the risk of fetal brain injury. If such a screening test were 
available, this would represent a significant opportunity for improvement in perinatal outcomes. 
Whilst screening may provide advantages, the potential for a screening test to result in adverse 
outcomes is also possible. A positive result from a screening test may lead to increased maternal and 
clinician anxiety with subsequent increase in intervention rates. However, the objective of a screening 
test in prevention of hypoxic fetal injury is to reduce the false positive rate of FHR monitoring by 
tailoring its use to the high risk group where screening performance is enhanced. Currently, 
intrapartum FHR monitoring is used indiscriminately in high income countries and increased 
intervention rates have been observed. Alternatively, women identified as low risk by screening could 
be afforded a lower risk model of care with less intensive intrapartum monitoring and higher 
thresholds for intervention, thereby reducing the rate of unnecessary interventions. One could argue 
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that individualised risk stratification by an effective, non-invasive screening test may reduce the rate 
of unnecessary interventions, reduce anxiety and improve perinatal outcomes. 
Fetal and maternal hemodynamics and PlGF have emerged as promising screening tools for 
pregnancy complications arising from placental dysfunction. Previous data131,221 from our group has 
shown that the CPR performed within 72 hours of delivery is predictive of IFC and adverse neonatal 
outcomes. Clearly, this timeframe requirement is not practical or easily translatable to a clinical 
setting. Similarly, PlGF has been shown to be highly sensitive for the detection of placental 
dysfunction associated with PET,189 when measured up to two weeks remote from delivery, and 
growth restriction.184 However, neither hemodynamics nor PlGF have been investigated for their 
associations and/or screening performance with adverse intrapartum and neonatal outcomes, up to 
two weeks prior to delivery, in low risk women at term. Furthermore, little is known about 
longitudinal change in fetal hemodynamics & PlGF in late pregnancy and their association with 
adverse outcomes in low risk women at term. 
Thus, the overarching aim of this study was to determine if an ultrasound scan and maternal PlGF 
quantification performed within two weeks of birth would be predictive of IFC and adverse neonatal 
outcome in a low risk cohort of women. The specific objectives were to determine: 
1. If the UA-PI, MCA-PI, CPR, corrected umbilical venous flow (cUVf) and/or UtA-PI, are 
associated with adverse intrapartum and/or neonatal outcomes. 
2. The screening performance of the UA-PI, MCA-PI, CPR, cUVf and UtA-PI, for intrapartum 
and/or neonatal outcomes. 
3. Whether low maternal PlGF levels are associated with adverse intrapartum and/or neonatal 
outcomes.  
4. The screening performance of maternal PlGF to identify women whose babies develop 
adverse intrapartum and/or neonatal outcomes. 
5. The combined screening performance of the UA-PI, MCA-PI, CPR, cUVf, UtA-PI and/or 
PlGF for adverse intrapartum and/or neonatal outcomes. 
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Chapter 2: Methods 
2.1 Introduction 
This chapter details the methods employed in this study. Briefly, low risk women with singleton 
pregnancies underwent an ultrasound and PlGF blood test fortnightly from 36 weeks. Intrapartum 
and neonatal outcomes were recorded and analysed. The methods described in this chapter apply to 
all subsequent chapters unless specified otherwise. This chapter details the:  
 Ethics, governance and privacy approval  
 Study design 
 Setting  
 Participants 
 Variables 
 Data sources and measurements 
 Bias  
 Sample size 
 Statistical methods 
 Discussion 
2.2 Ethics and governance 
A national ethics application form with appropriate supporting documentation for the study was 
submitted on 18th November, 2013, to the Mater Health Services Human Research Ethics Committee. 
Ethical approval to conduct the study was granted on 30th January, 2014 (Ref No. 
HREC/13/MHS/173, see Appendix A). Research Governance authorisation was then sought, with 
approval granted on 5th May, 2014 (Ref No. RG185, Appendix B). Recruitment efforts began on 6th 
May, 2014, and the first participant was recruited and consented on 8th May, 2014. 
Ethics and Research Governance approvals were subsequently sought for minor amendments during 
the course of the study. The amendments are as follows: 
 April 2015: 
o Application for addition of Amal Alsolai as a principal investigator to the study, 
including an amendment to the study protocol and participant information leaflet on 
23rd April, 2015 (see Appendix C) 
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o Research Governance approval for the amendment was granted on 10th August, 2015 
(see Appendix B) 
2.3 Study design 
This was a prospective, observational, panel study of women in late pregnancy. Components of this 
study were ‘cohort-type’ study designs.  
2.4 Setting 
The study was conducted at Mater Mothers’ Hospital, South Brisbane, Queensland. This is a major 
teaching and tertiary level maternity hospital with an annual birth rate of approximately 10,500 
babies. The study took place from May 2014 to August 2016. 
2.5 Participants 
2.5.1 Screening and recruitment 
Antenatal appointment lists were screened weekly for eligible women ≥28 weeks’ gestation by LB or 
a research midwife. Contact with women identified as eligible following screening was attempted in 
either of two ways. Firstly, eligible women were invited to participate through a participant 
information sheet which was provided by their attending midwife during a routine antenatal clinic 
appointment. The study contact telephone number and email address were included in the information 
sheet from which interested women then initiated contact. Alternatively, eligible women were 
approached in person by a member of the research team during their antenatal visit and offered study 
information and the option of participation.  
For women who were interested in participating, written consent for the study was obtained at the 
first research assessment. Women who participated underwent assessment approximately every two 
weeks from 35+0 weeks to 37+0 weeks until delivery, with ultrasound measurement of fetal biometry 
and hemodynamics, and PlGF measurement at each assessment. The participant journey is 
represented in Figure 11. 
Participant withdrawal was managed as per the study protocol (Appendix G, section 7.3). Briefly, 
women wishing to withdraw were able to inform a team member and their data was destroyed. 
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Figure 11 Participant journey diagram 
 
 
2.5.2 Inclusion and exclusion criteria 
The study inclusion and exclusion criteria were as follows. 
2.5.2.1 Inclusion criteria  
 Maternal age 18 - 50 years of age  
 >35 weeks’ gestation  
 Singleton pregnancy  
 No contraindications to, and planning a vaginal birth 
 Non anomalous fetus with no known chromosomal or genetic anomalies 
 Able to understand the participant information leaflet and provide informed consent.  
2.5.2.2 Exclusion criteria  
 Antenatally identified small for gestational age (EFW <10th centile) or growth restricted fetus 
(UA-PI >95th centile) 
 Pre-eclampsia or gestational hypertension identified prior to enrolment 
 Chromosomal or genetic anomaly 
 Previous CS 
Outcomes
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 Advanced labour (cervix >4cm dilated) 
2.6 Variables 
2.6.1 Predictors 
The study proforma (Appendix D) lists the variables recorded for each woman who participated in 
the study. Participant background information was collected at the first study assessment only, and 
all ultrasound and PlGF data was collected at each study assessment. The methods for ultrasound and 
PlGF measurement are detailed in the following sections (Ultrasound and Placental growth factor). 
2.6.2 Outcomes 
Women who participated in the study were managed according to the hospital’s policies and 
guidelines. Intrapartum and neonatal details as per the study proforma were collected within 72 hours 
of delivery. Intrapartum outcomes were initially entered onto a study proforma (Appendix D) before 
transfer to the study’s electronic database. All births were recorded according to mode of delivery 
(vaginal, instrumental, caesarean) and operative (caesarean and instrumental) births were sub-
classified according to the indication for delivery (intrapartum fetal compromise, IFC, or not). IFC, 
or non-reassuring fetal status, was determined contemporaneously by the treating obstetric team on 
the basis of an abnormal FHR pattern and/ or high fetal scalp lactate (>4.0mmol/L). Additionally, all 
FHR recordings were independently reviewed and classified based on the criteria detailed in the 
Royal Australian and New Zealand College of Obstetricians and Gynaecologists FHR guidelines207 
by a single experienced obstetrician (SK). Intrapartum FHR classification was recorded as either 
normal, suspicious or pathological. This classification system is very similar to those published by 
the National Institute of Clinical Excellence208 in the United Kingdom and the American College of 
Obstetricians and Gynaecologists,206 as outlined in Table 1. Birthweight centiles were calculated from 
Fenton et al.222 reference values, which are both gestation- and sex-specific. 
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Table 1. Summary of CTG classification systems: RANZCOG, RCOG and ACOG. 
 RANZCOG* RCOG# ACOG^ 
Normal    
Baseline rate  110 - 160bpm Normal 100 - 160bpm Category I 110bpm - 160bpm 
Baseline variability  6 - 25bpm  5bpm or more  Moderate 
Accelerations  15bpm for 15 seconds    Present or absent 
Decelerations  None  None or early  None 
Abnormal       
Baseline rate Unlikely  100 - 109bpm Non-
reassuring 
161 - 180bpm Category II <110bpm or 
>160bpm 
Baseline variability    <5 for 30 - 90min  <5bpm or >25bpm 
Accelerations  Absent     Absent  
Decelerations   Early or variable (no 
complicating features) 
 Variable or late  Periodic or episodic 
Baseline rate Maybe  >160bpm or rising baseline  Not applicable  Not applicable 
Baseline variability  Reduced (3 - 5bpm)     
Accelerations       
Decelerations   Complicated variable or late or 
prolonged 
    
Baseline rate Likely  <100bpm for >5min Abnormal <100 or >180bpm Category III <110bpm 
Baseline variability  Absent (<3bpm)  <5 for >90min  Absent  
Accelerations       
Decelerations  Complicated variable or late 
with reduced or absent baseline 
variability; sinusoidal 
 Variable or late lasting >30min; or 
bradycardia/prolonged deceleration 
≥3min 
 Recurrent, late or 
variable; sinusoidal 
*The Royal Australian and New Zealand College of Obstetricians and Gynaecologists, 2014. 
#RCOG, as per: National Institute of Health and Care Excellence, 2014. 
^American College of Obstetricians & Gynecologists, 2009.
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Cord blood gas analysis was only performed when clinically indicated, in keeping with hospital 
policy. The trigger events are listed on page 5 of Appendix F.  
The key outcomes for this study are: 
1. CS for IFC (CS-IFC) vs. all other deliveries 
2. Operative delivery (caesarean or instrumental) for IFC (Op-IFC) 
3. Composite neonatal outcome (CNO) vs. all other deliveries. CNO was defined as: 
a.  Acidosis: UA pH <7.00, base deficit ≤-12mmol/L and/or lactate >6mmol/L. These cut-
offs were selected following a literature review of umbilical cord gases thresholds 
associated with acute intrapartum hypoxia and subsequent results and recommendations. 
For acidosis, the International Cerebral Palsy Taskforce advocates thresholds of pH <7.00 
and base deficit of ≤-12mmol/L,223 which has been substantiated by data more recently 
from over one million pregnancies as reported by Iliodromiti et al.224 Although pH has 
been the most widely reported of the cord gases, lactate has recently been shown225 to be 
more sensitive than pH in detecting fetal metabolic acidosis and prediction of subsequent 
neonatal morbidities, with sensitivity and specificity of 46.4% and 94.9% for lactate vs. 
8.9% and 99.8% for pH, respectively. As such, lactate >6 mmol/L was incorporated into 
the acidosis outcome.226 
b.  Low Apgar score: The Apgar score has been used as an index of neonatal condition at 
birth since it was first reported in 1953227 and a recent report supported the continued 
relevance of the Apgar score in the modern context for neonatal assessment.224 The 
International Cerebral Palsy Taskforce223 reports that an Apgar score at birth of <4 after 5 
minutes is associated with a severe acute intrapartum hypoxic event. Consequently, to 
detect more subtle hypoxic events the classification of a low Apgar score for this study 
was defined as <7 at five minute assessment. 
c. NICU admission: Admission to the NICU was classified as either occurring or not. 
2.7 Data sources/measurement 
2.7.1.1 Ultrasound  
B-mode and pulsed Doppler were used to obtain the following data: 
 Fetal biometry: biparietal diameter, head circumference, abdominal circumference and femur 
length 
 UA-PI 
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 MCA-PI 
 Umbilical Vein diameter and time-averaged maximum velocity  
 UtA-PI 
Ultrasound machines used for the study were: 
 Philips Affiniti 70G with a 2-9MHz or 1-5MHz curvilinear transducer 
 Siemens Acuson S2000 with a 3-8MHz curvilinear transducer 
 GE Voluson E8 with a 1-5MHz curvilinear transducer 
Participants and clinicians were blinded to the ultrasound results, except when malpresentation, 
severe oligohydramnios (deepest vertical pocket <1cm) or absent/reversed end diastolic flow in the 
UA or a major structural malformation were detected. If these abnormalities were found, obstetric 
caregivers were immediately informed as these findings would alter clinical management and the 
participant excluded from the final analysis. Women were informed that results would only be 
disclosed under these circumstances. Research ultrasounds were conducted and results recorded 
within a research setting, physically and electronically separate from the clinical setting, where results 
were available only to researchers immediately involved in the study. No formal ultrasound report 
was issued.  The following section details the protocol used to obtain ultrasound data for the study. 
2.7.1.1.1 B-mode 
2.7.1.1.1.1 Fetal biometry 
Fetal biometry (Figure 12, Figure 13 and Figure 14) was measured in accordance with the 
International Society of Ultrasound in Obstetrics and Gynecology’s Practice Guidelines228 and the 
EFW and EFW centile were calculated using Hadlock’s C formula and reference values.229.Head 
biometry was taken from an axial image of the fetal head at the level of the thalami. The biparietal 
diameter was measured at the widest part of the skull, with ‘leading edge to leading edge’ caliper 
placement. The head circumference was measured from the same image with an ellipse placed around 
the outer margin of the skull. The fetal abdominal circumference was measured from an axial section 
of the fetal abdomen at the level of the stomach ‘bubble’ and portal confluence, immediately cephalic 
to the fetal kidneys. Care was taken to avoid excessive transducer pressure and to obtain a round axial 
image of the fetal abdomen. An ellipse was then placed on the outer margin of the skin line of the 
abdomen. Finally, the near-field femur was imaged in a longitudinal axis, with an angle of insonation 
perpendicular to the ultrasound beam to achieve the sharpest diaphyseal-epiphyseal margins. Calipers 
were then placed on the outer echo of each diaphysis and recorded as the femur length. The technique 
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for measurement of fetal biometry described here was performed in duplicate. However, when these 
duplicate measurements were inconsistent (>1mm for biparietal diameter and femur length, or >5mm 
for head or abdominal circumference), they were repeated until consistent measures were obtained 
and the average of the consistent measurements recorded for fetal weight estimation.  
Figure 12 Biparietal diameter and head circumference measurement 
 
(Bligh, 2016). 
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Figure 13 Abdominal circumference measurement 
 
(Bligh, 2016). 
Figure 14 Femur length measurement 
  
(Bligh, 2016). 
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2.7.1.1.1.2 Umbilical vein diameter 
In accordance with the technique described by Barbera et al.,230 a mid-section of free floating UV 
was assessed with pre-processing zoom applied to magnify the vein to occupy at least half of the 
display screen. The longitudinal axis of the cord was oriented perpendicular to the ultrasound beam, 
to optimise image clarity and minimise measurement error. For diameter measurement, calipers were 
placed at the maximum luminal diameter, parallel to the beam axis on a midline section of cord. The 
measurement of UV diameter is displayed in Figure 15. 
2.7.1.1.1.3 Amniotic fluid assessment 
The amniotic fluid volume was assessed by measurement of the deepest vertical pocket. The deepest 
vertical pocket has been shown to be as, if not more reliable than the amniotic fluid index for the 
prediction of adverse pregnancy outcomes.231 Measurement was performed with the woman supine 
and the transducer oriented perpendicular to the floor and the deepest pocket of amniotic fluid with a 
horizontal width of at least 1cm, free of umbilical cord and fetal parts measured.232  
 
Figure 15 Umbilical vein diameter measurement 
 
2.7.1.1.2 Spectral Doppler 
The following technique applies to all spectral traces recorded for the study, with vessel specific 
differences and details noted in the subsequent sections. 
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Women were positioned semi-recumbent with cephalic elevation of 300 and a wedge under the right 
hip to avoid aorto-caval compression. All spectral Doppler traces were obtained after locating the 
relevant vessel in B-mode followed colour Doppler to minimise ultrasound energy exposure to the 
fetus. A beam-vessel angle as close to 0 degrees was used for spectral Doppler measurements and 
angle correction was applied for beam-vessel angles >100.233 The maximum beam-vessel angle 
permitted for measurement was 300 for all vessels with the exception of the uterine arteries, where a 
beam-vessel angle up to 450 was accepted. Pulsed Doppler measurements were recorded when the 
fetus was quiescent to ensure the trace reflected the resting fetal status and for consistency between 
cardiac cycles. A spectral trace over at least 3 cardiac cycles was obtained in triplicate for each vessel 
and the average recorded. In cases where variable results were obtained, up to three repeat 
measurements were taken and the average of the three most technically correct measurements was 
recorded. The automated trace function of the ultrasound machine was used for all arterial waveform 
measurements. Venous waveforms were, however, traced manually.  
The pulse wave Doppler gate was set as wide as possible to include the full vessel width, avoiding 
adjacent structures. The pulse repetition frequency was set high enough to ensure the full velocity 
spectrum of the vessel was included in the spectral display yet sufficiently low to ensure the waveform 
occupied approximately 75% of the spectral display. The vessel wall filter was set to 50-60Hz to 
remove vessel wall artefact without eliminating end diastolic flow from the display. Horizontal sweep 
speed for fetal vessels was set at 50-100mm/s and 40-80mm/sec for uterine artery Doppler assessment 
in order to achieve visual separation of successive waveforms whilst still displaying 4-6 complete 
cardiac cycles on screen. Pulsed wave Doppler gain was adjusted to display waveforms with sufficient 
intensity to optimise the signal-to-noise ratio in the spectral display. 
Centiles in the study for the various Doppler ultrasound parameters (excluding EFW) were internally 
derived from the study population. In addition to exclusions for missing data (intrapartum or 
ultrasound), women with medical conditions (urosepsis, diabetes or chronic hypertension) or adverse 
pregnancy outcomes (IFC, CNO, and shoulder dystocia) were excluded from the population for 
centile calculation. These exclusions were made to ensure a normal population was used for reference 
centile calculation. 
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2.7.1.1.2.1 Umbilical artery 
The UA was always identified in a free-floating mid-section of the umbilical cord. (Figure 16) This 
is because the resistance to blood flow in the UA is known to decrease at the placental end and 
increase at the fetal end. 234  
Figure 16 Umbilical artery spectral Doppler measurement 
 
2.7.1.1.2.2 Umbilical vein 
The same section of UV, as described earlier (page 36) was used for both diameter and spectral 
Doppler assessment in order to maximise accuracy of volume flow calculations.235. As the UV has a 
monophasic waveform, the peak velocity was measured as this also represents the time-averaged 
maximum velocity. (Figure 17)  
2.7.1.1.2.3 Middle cerebral artery 
The MCA was identified on an axial section of the fetal brain at the level of the thalami and wings of 
the sphenoid bone as it courses through the Sylvian fissure. The image was then magnified so the  
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Figure 17 Umbilical vein spectral Doppler measurement 
 
Figure 18 Middle cerebral artery spectral Doppler measurement 
 
region containing the MCA occupied ≥50% of the screen and colour Doppler was then applied to 
guide placement of the pulsed wave Doppler gate to the proximal third of the vessel given that the PI 
of the MCA is known to increase, the further from its origin it is measured.120,236,237 (Figure 18). 
Particular attention was paid to maintain minimal transducer pressure on the maternal abdomen as 
fetal head compression has been shown to increase impedance to blood flow and artificially elevating 
the MCA-PI.238 
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2.7.1.1.2.4 Uterine arteries 
Firstly in a parasagittal view, B-mode imaging was used to identify the cervicocorporeal junction and 
paracervical vascular plexus medial to the external iliac artery. The uterine artery was then identified 
using colour Doppler at its apparent intersection with the external iliac artery along its antero-superior 
course. Pulsed wave Doppler with a gate size approximately equal to the uterine artery diameter was 
then placed over the vessel, 1cm beyond the intersection with the external iliac artery and a spectral 
trace obtained. (Figure 19) As uterine artery blood flow is subject to significant variation along its 
course, this position was chosen to ensure consistent measurements as per the International Society 
for Ultrasound in Obstetrics and Gynecology (ISUOG) Practice Guidelines.239 The contralateral 
uterine artery was also imaged and the mean PI recorded using the same technique. For data analysis, 
the mean of right and left UtA-PIs was recorded. 
Figure 19 Uterine artery spectral Doppler measurement 
 
2.7.1.1.3 Reproducibility 
Excellent intra- and inter-observer variability for the UA-PI and MCA-PI,131,237 and good 
reproducibility for UtA-PI transabdominally,240 have been shown previously. For the purposes of this 
study reproducibility was independently assessed on 20 consecutive cases by LB and AA, with 
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measurements repeated after 15 minutes for assessment of both inter- and intra-observer variability. 
The co-efficient of variation was calculated using the root mean square approach as described by 
Bland241 and the results presented in chapter 3 of this Thesis.  
2.7.1.1.4 Calculations 
2.7.1.1.4.1 CPR 
The CPR was calculated as the simple ratio of the MCA-PI to the UA-PI242: 
CPR ൌ 	MCA	PIUA	PI  
This method was initially described by Gramellini et al. in 1992,242 and has since been used by various 
authors.133,237,243-245 Recent studies have exclusively reported the calculation of the CPR from the 
pulsatility indices of the UA and MCA,139 as described above, as opposed to the resistance index or 
systolic/diastolic (S/D) ratio. This is likely due to the linear relationship between PI and changes in 
vascular resistance, unlike the resistance index (RI) and S/D ratio, which have a parabolic relationship 
with vascular resistance.246 
2.7.1.1.4.2 Umbilical venous flow rate 
The UV was assumed to be cylindrical with laminar flow for the purpose of flow rate calculation.115 
Laminar flow reflects in vivo vessel flow whereby flow is slower at the perimeter of the vessel than 
in the centre of the vessel, due to friction with the vessel walls. Doppler calculation of umbilical 
venous blood flow, as detailed below, has been shown to be accurate and reproducible when 
compared against the gold standard of in vivo flow calculation.115  
Flow is defined as the volume of fluid that passes through a cross-sectional area by the speed of that 
fluid per time unit. Cross-sectional area of the umbilical vein is that of a circle. For volume 
calculation, the cross-sectional area is the measured diameter (D, mm) of the umbilical vein, 
multiplied by the speed of the fluid passing through that area. Time-averaged maximum velocity 
(TAMax, cm/s) is the average maximum speed of fluid in the vessel over the cardiac cycle. However, 
given that flow in a cylindrical vessel is laminar, a multiplication factor of 0.5 is required in the flow 
calculation formula. The formula is built as follows:  
Volume = cross-sectional area x speed 
Volume = πr2 x TAMax 
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Volume = π[D/2]2 x cm/s  
Thus: 
Flow = volume / time 
Flow = π[D/2]2 x cm/s / time 
Flow = π[D/2]2 x cm/s / s 
Flow is expressed by: 
1mL/min = 1cm/s/cm2 x 60 
1mL/min = 1cm/s/cm2 x 60 x 0.5 
1mL/min = 1cm/s/cm2 x 30 
Because 1cm2 = 100mm2 
1mL/min = 1cm/s/100mm2 x 30 
Given that the diameter is expressed in mm2 
1mL/min = 1cm/s/1mm2 x 30/100 
1mL/min = 1cm/s/1mm2 x 0.3 
Thus, umbilical venous flow (mL/min) was calculated using the following formula247: 
Flow (mL/min) = TAMax	ሺcm/sሻ		x	cross	sectional	area	ሺmmଶሻ	x	0.3 
 
2.7.1.2 Placental growth factor 
Maternal PlGF levels were measured using a venous sample obtained at each visit. Hand hygiene and 
aseptic techniques were followed for venepuncture. A tourniquet, alcohol swab, 21 gauge needle and 
vacuum blood collection tube were used, followed by a cotton wool ball and gentle compression at 
the wound site immediately following needle withdrawal. Venous blood was drawn from either a 
vessel in the antecubital fossa or dorsum of the hand. The blood collection tube was marked with a 
minimum of three participant identifiers and time of blood collection. 
 43 
 
Two assay platforms– Triage PlGF Test (Alere, San Diego, CA) and DELFIA Xpress PlGF kit 
(PerkinElmer, Turku, Finland) - were used during the study. The DELFIA system was introduced to 
the hospital’s pathology laboratory midway through the study. Thus, the first 238 women underwent 
PlGF analysis exclusively using the Triage® system followed by parallel testing on both platforms 
for 50 samples. For comparison between platforms, a correction algorithm was developed based on 
these 50 samples, and all subsequent samples were analysed with the DELFIA Xpress PlGF kit. 
2.7.1.2.1 Alere ‘Triage’ PlGF Test 
Quality control and maternal venous blood analysis (Appendix E) was performed in accordance with 
the manufacturer’s instructions.184 The Alere Triage platform is a Fluoro-immunoassay. The plasma 
specimen reacts with fluorescent antibody conjugates and flows through the test cartridge by capillary 
action. Complexes of the fluorescent antibody conjugate are captured on a discrete zone specific to 
PlGF, where the meter detects fluorescence within a specific zone on the cartridge. The concentration 
of PlGF is directly proportional to the fluorescence detected by the meter and displayed both on the 
meter screen and a print out with a unique identifier for an individual sample. 
The Triage platform (Figure 20) reports concentration in the range 12–3000 pg/ml with an overall 
coefficient of variation of 12.8–13.2%.184 
Figure 20: Alere Triage MeterPro 
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Figure 21: Alere Triage PlGF test cartridge 
 
For the Triage PlGF Test, blood was collected in a 9mL ethylenediaminetetraacetic acid (EDTA) 
tube, stored at room temperature and analysed within 4 hours. Serum and plasma were separated from 
the whole blood sample by centrifugation at 3000rpm for 10 minutes. Using a Gilson pipette, 250µL 
of plasma was slowly applied onto the test cartridge (Figure 21). The cartridge was then inserted into 
the meter with the participant’s research identifier entered into the machine. A result was obtained 
after approximately 15 minutes.  
2.7.1.2.2 Perkin-Elmer (DELFIA Xpress) 
Quality control and testing of maternal venous samples using the automated DELFIA Express 
platform (Figure 22) was performed onsite by Mater Pathology in accordance with the manufacturer’s 
guidelines. The DELFIA (dissociation-enhanced lanthanide fluorescent immunoassay) Xpress 
immunoassay (PerkinElmer, Turku, Finland) is a direct sandwich assay in which two antibodies (one 
monoclonal, one polyclonal) are directed against the PlGF molecule. The detection system employs 
fluoroimmunometric technology where the inducer dissociates bound europium ions after removal of 
unbound material as illustrated. (Figure 23). Highly fluorescent chelates are formed between the 
europium ions and components of the inducer and fluorescence in each sample is proportional to the 
concentration of PlGF. The analytical range of the assay is 7 - 4000 pg/mL with an overall coefficient 
of variation within an acceptable range248 of 3.5% to 6.9%. 
Maternal blood was collected in a 9mL serum separator tube and then left to clot for 10 minutes, 
followed by centrifugation at 5000rpm for 10 minutes to separate serum and plasma, as serum was 
used for analysis on the DELFIA Xpress platform. Aliquots of serum were then stored at -4 degrees 
Celsius until batch analysis was performed. For the PlGF assay, serum samples were first allowed to 
thaw at room temperature before 40µL, pipetted by the automated DELFIA Xpress machine, was 
used for analysis. PlGF assay using this platform is fully automated, takes approximately 30 minutes 
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and has the capacity to analyse up to 170 samples per hour. PlGF results were the uploaded onto the 
hospital’s electronic pathology system with each patient clearly highlighted as participating in this 
research study.  
2.7.1.3 Data security 
Study paperwork documentation with participant study details was stored in a locked filing cabinet 
within the Mater Research Institute, accessible only by team members. The study’s electronic 
database was password protected and securely backed-up in accordance with the institution’s privacy 
policy. 
 
Figure 22: DELFIA Xpress 
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Figure 23 DELFIA Xpress PlGF assay principle 
 
2.8 Bias  
Bias within the study was minimised through study design in the pre-trial, trial and post-trial phases. 
Participant eligibility, exclusion criteria and recruitment were clearly defined prior to study 
commencement to avoid selection bias. In order to assess the potential for selection bias, comparisons 
between maternal baseline characteristics and CS-IFC outcome of the study population vs. other 
women with uncomplicated antenatal course who delivered at the institution are made in chapter 3. 
Ultrasound assessment was performed exclusively by two experienced sonographers (LB and AS) 
who applied a protocol systematically to ensure consistent technical reproducibility and, thus, 
avoidance of performance bias. Reproducibility of Doppler measurements was performed on 20 
women in order to assess intra-observer and intra-observer variability, as described in chapter 3. 
Participants and clinicians were blinded to ultrasound results, except where disclosure was clinically 
indicated as specified previously (see section 2.7.1.1), thus avoiding classification bias. PlGF 
quantification on the Alere Triage platform was performed by a single trained operator according to 
a detailed protocol, whilst samples quantified on the DELFIA platform underwent automated 
processing. Additionally, intrapartum FHR classification was conducted by a single experienced 
obstetrician (SK) who was blinded to the study assessment results to minimise classification bias 
and/or interviewer bias. Outcome data was collected from the electronic health record of participants 
by LB, AS or a research midwife and recorded on participants’ proforma. Any inconsistency in health 
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records were cross checked by medical chart review. For neonatal outcomes, classification was 
conducted as per the study protocol by LB and SK.  
2.9 Sample size 
Sample size calculation was performed on CPR data with CS-IFC as the primary outcome. Based on 
data from a previous report,131 36% of babies with CPR <10th centile at last visit had CS-IFC, 
compared with 8% CS-IFC of those with CPR ≥10th centile at last visit. To detect a difference in these 
proportions, with a ratio of 1:9, a total sample size of 150 (15 in <10th centile group and 135 in >10th 
centile group) would be required. However, historical data from Queen Charlotte’s and Chelsea 
Hospital249 shows that CS-IFC rates are 25% for term singletons compared to 22% at Mater Hospital 
8. Thus, to be conservative and assure sufficient sample size, the power was increased to 0.90, 
resulting in a total recruitment sample size of 390 women (39 with CPR <10th centile and 351 with 
CPR ≥10th centile). Sample size calculations were performed with Stata’s “power twoproportions” 
command.250 Recruitment was continued to 483 women to increase statistical precision, account for 
attrition and to enable multivariate analysis. 
2.10 Statistical methods  
The distribution of continuous variables was assessed using graphical methods (stem and leaf plots, 
box plots and histograms). Summary statistics for normally distributed data are reported as mean and 
standard deviation (SD) and for non-normally distributed data are reported as medians and 
interquartile ranges (IQR). Centiles (5th, 10th, 25th, 50th, 75th and 90th) by gestation were estimated 
using Stata’s summarise command, with detail. Association between continuous variables was 
screened using visual inspection of scatterplots and pairwise correlations. Pearson’s correlation was 
used to assess the relationship between normally distributed continuous data and Spearman’s 
correlation was used to assess non-normally distributed data. Comparisons between groups of non-
normally distributed data were tested using Wilcoxon rank-sum test and Kruskal-Wallis test. 
Summary statistics for categorical data are reported as frequencies (number with numerator and 
denominator and percentage). The Chi-square test was used to test for association between categorical 
variables except when event counts ≤5 were encountered, when Fisher’s exact test was used. Age-
related reference centiles for Doppler and PlGF parameters were internally generated from the study 
data using absolute residuals, as described by Altman.251 Further detail regarding statistical methods 
are included in the chapters relevant to the data presented.  
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The significance level for all analyses was set at p ≤0.05. All statistical analysis was performed using 
Stata®, Release 13 statistical analysis program for Windows.250  
2.11 Discussion 
The aim of this chapter was to detail the processes, methods and techniques used in this study. This 
included ethical and governance approvals, study design, setting, participants, variables, data 
sources/measurement, bias, sample size and statistical methods. The sample size calculation for this 
study was based on CPR data from a previous study conducted by Prior et al.131 This reference was 
chosen as it contained the same risk factor (CPR), primary outcome (CS-IFC), comparable study 
population, similar gestation and with a model of pregnancy care that closely matched that offered at 
the Mater Mothers Hospital. The main difference between the study undertaken for this Thesis and 
that conducted by Prior et al.131 is that the previous study did not measure PlGF in their study cohort. 
However, this study quantified PlGF in low risk women in late pregnancy to explore the potential 
association with intrapartum and neonatal outcomes for the first time. Thus, sample size calculation 
based on PlGF was not possible prior to study commencement as there was no appropriate data for 
PlGF at term relevant to the outcomes presented in this study.  
Recruitment of participants was performed primarily by a research midwife familiar with the hospital 
staff and systems. Recruitment methods evolved during the course of the study in response to 
recruitment rate and feedback from the research midwife, participants and hospital staff. Although 
selection bias was minimised through study design, women who participated were volunteers from a 
convenience sample and may therefore not necessarily represent all women who met the selection 
criteria. As stated by Junghans and Jones,252 people who voluntarily participate in research tend to 
have different baseline characteristics and outcomes compared to those who decline to participate, 
known as consent or volunteer bias. Thus, in chapter 3 study participants’ baseline characteristics and 
proportion with the CS-IFC outcome are compared with those of other women who delivered at the 
institution.  
The ultrasound parameters measured in this study were chosen because they have been shown to 
reflect fetal well-being and/or be predictive of adverse perinatal outcomes.138,139,150,247 In particular, 
the CPR has been shown to better predict perinatal outcomes than either of its components in 
isolation242,243,245,253,254 and is readily obtained, even in late pregnancy.131   
As discussed in chapter 1 of this Thesis, various biomarkers of placental function have been evaluated 
for their association with adverse peripartum outcomes. Of these, PlGF can be processed in a clinical 
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environment in as little as 15 minutes with the Alere Triage PlGF platform. As an objective of this 
study was to explore the potential for a readily accessible screening method, the study commenced 
with the Alere Triage PlGF platform. During the course of the study the Alere Triage assay 
consumables became unavailable and a larger scale, automated platform through a pathology provider 
became available. All subsequent PlGF assays were performed with the DELFIA Xpress PlGF 
platform. This change enabled a much higher throughput of participants. This is described further in 
chapter 4.   
The primary study outcomes of CS-IFC and CNO were selected for the following reasons. CS-IFC 
has a significant impact both on women and healthcare resources and also reflects the clinical 
intervention endpoint for IFC. Whilst it could be argued that instrumental delivery also represents a 
clinically significant manifestation of IFC, it is likely to be less severe, and also requires fewer 
resources to perform than CS-IFC. A pragmatic approach was used for the classification of CS-IFC, 
being that contemporaneously recorded in the patient records by the treating obstetric team on the 
labour ward. As an observational study, this approach to classification was chosen to accurately 
reflect the clinical environment. The CNO utilised parameters that have been shown to reflect poor 
neonatal condition at birth and/or risk of neurological injury. The neonatal acidosis cut-offs were 
selected following a literature review of umbilical cord gases thresholds associated with acute 
intrapartum hypoxia and subsequent results and recommendations. For acidosis, the International 
Cerebral Palsy Taskforce advocates the use of pH <7.00 and base deficit ≤-12mmol/L,223 which have 
been substantiated by data more recently from over one million pregnancies as reported by Iliodromiti 
et al.224 Although pH has been the most widely reported of the cord gases, lactate has recently been 
shown225 to be more sensitive than pH in detecting fetal metabolic acidosis and prediction of 
subsequent neonatal morbidities, with sensitivity and specificity of 46.4% and 94.9% for lactate vs. 
8.9% and 99.8% for pH, respectively. As such, lactate >6 mmol/L was also incorporated into the 
acidosis outcome.226 
Data was collected from the hospital’s electronic maternity and pathology records, and participant’s 
case notes. In all cases of operative delivery (both CS and instrumental), the participant’s paper 
records were reviewed in conjunction with their electronic health record by a single experienced 
obstetrician (SK). Additionally, electronic intrapartum FHR recordings were also reviewed by SK in 
a blinded fashion and coded as either reassuring, suspicious or pathological according to the Royal 
Australian and New Zealand College of Obstetricians and Gynaecologists.207  
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The next chapter (chapter 3) reports the results from the ultrasound component of the study, including 
associations with perinatal outcomes. 
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Chapter 3: Ultrasound data and outcomes 
The material detailed in this chapter has been: 
a) Presented at the 2014 and 2016 UQ International Postgraduate Student Symposium, Brisbane 
b) Presented at the 2015 RCOG World Congress, Brisbane 
c) Presented at the 2016 PSANZ Annual Congress, Townsville 
d) Published in the journal, Ultrasound in Obstetrics and Gynecology137 
3.1 Introduction 
Fetal hemodynamics, as measured by spectral Doppler ultrasound, have been shown to be associated 
with adverse intrapartum and neonatal outcomes. Specifically, abnormal pulsatility indices (UA, 
MCA, UtA), CPR, UVf and EFW have been associated with FGR, maternal hypertension, PET, 
adverse neonatal outcomes and stillbirth. These results have primarily been reported from 
retrospective studies in at-risk populations, such as SGA fetuses or women with suspected PET. 
However, low risk pregnancies represent the majority of pregnancies in which the fetus becomes 
distressed in labour. Paradoxically, the low risk population does not receive routine ultrasound 
assessment after 20 weeks’ gestation to assess fetal well-being and Cochrane reviews do not support 
the use of either routine late pregnancy ultrasound or UA Doppler assessment in low risk 
populations.16,66 Consequently, very little data has been reported from prospective studies at term, yet 
fetal hemodynamics at this gestation are thought to most closely reflect the fetal condition at delivery. 
A recent prospective study at term showed that CS-IFC was associated with a higher proportion of 
fetuses with a CPR <10th centile within 72 hours of delivery than those with a CPR ≥10th centile.131 
Thus, the current study aimed to assess if a similar relationship was also present when measured up 
to two weeks prior to birth and to investigate whether the rate of change in Doppler parameters from 
36 weeks’ gestation was associated with CS-IFC, Op-IFC and/or CNO. 
Chapter 1 (Introduction) and chapter 2 (Methods) outline the background and overall methods for the 
study. The methods described in chapter 2 apply to this chapter. Briefly, a prospective, observational, 
panel study was undertaken on women with a singleton pregnancy and an uncomplicated antenatal 
course who were planning a vaginal delivery. As outlined in chapter 2, a sample size of 390 women 
was required to demonstrate a difference in the proportion of babies born by CS-IFC (n=39) vs. all 
other deliveries (n=351) with CPR <10th centile vs. those with CPR ≥10th centile (alpha=0.05, 
power=0.9). This chapter investigates the ultrasound parameters, maternal characteristics and their 
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associations with adverse intrapartum and neonatal outcomes. Ultrasound parameters assessed in this 
chapter are: 
1. UA-PI 
2. MCA-PI 
3. CPR 
4. Corrected umbilical vein flow (cUVf) (mL per kilogram per minute) 
5. UtA-PI 
6. EFWc 
It was hypothesised that hemodynamic parameters and EFWc would be different, and that the rate of 
change in these parameters would also be different, in fetuses born with and without the CS-IFC, Op-
IFC and/or CNO outcomes. 
3.1.1.1 Aims 
1. To describe the change in feto-placental Dopplers and EFW centile from 36 weeks to delivery 
in a cohort of low risk women 
2. To describe the difference between the rate of change in feto-placental Dopplers and EFW 
from 36 weeks to delivery for CS-IFC vs. all other deliveries, operative delivery for Op-IFC 
vs. all other deliveries and CNO vs. no CNO in low risk women. 
3. To determine if there is any difference between feto-placental Dopplers and EFW measured 
within 2 weeks of delivery for CS-IFC vs. all other deliveries, Op-IFC vs. all other deliveries 
and CNO vs. no CNO in low risk women. 
3.2 Methods 
Participants were recruited, assessed fortnightly and had outcome data collected according to the 
methods described in chapter 2 of this Thesis.   
The outcomes investigated in this chapter are: 
1. CS-IFC vs. all other deliveries 
2. Op-IFC vs. all other deliveries 
3. CNO vs. all other deliveries  
Exclusions were made in accordance with those stated in chapter 2. Additionally, pregnancies 
complicated by severe urosepsis, shoulder dystocia and those with missing data (ultrasound or CTG) 
were excluded. As this study was designed to explore the association between IFC and placental 
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dysfunction, rather than maternal medical conditions or birth trauma, these women were excluded 
from the final analysis. Additionally, women without complete CPR or intrapartum monitoring data 
were excluded as these represented a key predictor and outcome for the study. 
Intra-observer and inter-observer variability for UA-PI, MCA-PI and CPR were assessed by AS and 
LB. For 20 women, umbilical artery and middle cerebral artery spectral Doppler waveforms were 
recorded in triplicate, which was then repeated after a delay of at least 15 minutes. Measurement of 
the UA-PI and MCA-PI for each recorded waveform was performed by AS and LB, in a blinded 
fashion, over a minimum of three cardiac cycles. The intra- and inter-observer variability was 
expressed as the coefficient of variation for UA-PI, MCA-PI and CPR, with <25%255 and <10%,256 
respectively, considered clinically acceptable.  
For descriptive statistical testing, methods were used as described in chapter 2. Longitudinal statistical 
analysis was performed by calculating the change in the measured parameter per day. This accounts 
for differences in assessment intervals between women participating in the study. Secondly, the rate 
of change between the first and second assessment, first and third assessment, second and third 
assessment and first and last assessment (irrespective of gestation) for each participant was calculated 
and reported. 
3.3 Results 
Study recruitment commenced on 6th May, 2014, and continued until the final assessment was 
completed in August 2016. The last participant birthed in September 2016. A total of 483 women 
were recruited to the study. Of these, 46 (9.5%) women were excluded as per the study protocol as 
follows. Eighteen women (18/46, 39.1%) were excluded due to a late decision to deliver electively 
by CS, of which the majority (11/18, 61%) were performed for malpresentation. Three (3/46, 6.5%) 
women did not have an MCA-PI recorded at assessment, of which two (2/46, 4.4%) were due to 
technical difficulty (very low fetal head position) and one (1/46, 2.2%) was due to operator error. A 
further 21 (21/46, 45.7%) women were excluded because continuous intrapartum FHR monitoring 
was not performed. Finally, one (1/46, 2.2%) woman was excluded due to maternal urosepsis that 
required intensive care unit admission and three (3/46, 6.5%) women were excluded as birth was 
complicated by shoulder dystocia. This was to support the study’s primary aim to assess the 
association between operative delivery for IFC precipitated by placental dysfunction rather than 
maternal conditions or birth trauma. Thus, the final study cohort was comprised of 437 women. 
(Figure 24)  
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3.3.1 Maternal characteristics 
Overall, most women who participated in the study were Caucasian, nulliparous, non-smokers, 
approximately 30 years of age who had conceived spontaneously and had a normal BMI. The baseline 
characteristics of women recruited to the study closely reflect those of the institution’s population, 
when similar inclusion criteria were applied, with respect to age257 (30.0 vs. 30.3 years), BMI257 (22.6 
vs. 22.7 kg/m2) and gestation at delivery8 (40.0 vs. 40.0 weeks), respectively. A greater proportion of 
women in the study were Caucasian compared to the institutional population (62.9% vs. 53.4%, 
respectively). The proportion of women with the CS-IFC outcome was similar between the study 
cohort and institutional population8 (3.9%, 19/483 vs. 3.8%, 1179/30719, respectively). 
Figure 24 Participant flow diagram 
 
3.3.2 Inclusion and exclusion 
There were no major differences in maternal characteristics between women included and excluded 
from the final analysis with respect to nulliparity, age, BMI, ethnicity, presence of diabetes or chronic 
hypertension, cigarette smoking, assisted conception and interval between last assessment and labour, 
regardless of whether labour was spontaneous or induced. However, women who were excluded were 
less advanced in gestation at last assessment and at delivery (Error! Reference source not found.), 
compared to women who were included in the final analysis.  
3.3.3 Final study cohort 
After exclusions, the final study cohort was analysed by CS-IFC, Op-IFC and CNO outcomes. (Table 
4). There were no differences in maternal characteristics for women with the CS-IFC, Op-IFC and 
483 women 
recruited
437 women 
included
419 non CS‐
IFC 18 CS‐IFC
46 
exclusions
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CNO outcomes with respect to age, BMI, ethnicity, chronic hypertension, smoking status, ART and 
interval between last assessment and either spontaneous or induced labour. However, of the neonates 
in the Op-IFC and/or CNO cohorts, a higher proportion were born to nulliparous women and those 
without diabetes. Additionally, they underwent final assessment and were delivered later in gestation. 
For Doppler outcome groups (MCA-PI <5th centile, CPR <5th centile and CPR <10th centile), a 
significantly higher proportion of babies with abnormal Doppler results had the adverse outcome (CS-
IFC, Op-IFC and/or CNO) than those with normal Doppler results. 
Table 2 Maternal characteristics by inclusion and exclusion 
Characteristic  Total  Included  Excluded  p 
 (n=483) (n=437) (n=46)  
Nulliparous  420 (87.0) 382 (87.4) 38 (82.6) 0.36*
Maternal age (years) 29.8 (4.5) 29.8 (4.5) 30.0 (5.0) 0.52#
BMI 22.6 (20.9-
25.8) 
22.6 (20.9-
25.8) 
22.5 (20.3-
25.2) 
0.72^ 
Ethnicity                          Caucasian 304 (62.9) 269 (61.6) 35 (76.1) 0.12~ 
East Asian 85 (17.6) 77 (17.6) 8 (17.4) - 
Central Asian 48 (9.9) 46 (10.5) 2 (4.4) - 
Other 46 (9.5) 45 (10.3) 1 (2.2) - 
Diabetes mellitus 35 (7.3) 35 (8.0) 0 (0.0) - 
Chronic hypertension 1 (0.2) 1 (0.2) 0 (0.0) - 
Cigarette smoker 42 (8.7) 41 (9.4) 1 (2.2) 0.08~ 
ART 14 (3.0) 11 (2.6) 3 (6.7) 0.14~
Gestation at last assessment 38.4 (37.9-
39.9) 
38.4 (37.9-
39.9) 
38.0 (36.1-
39.4) 
0.003^ 
Interval to labour from last 
assessment 
8.0 (5.0-
13.0) 
8.0 (5.0-12.0) 9.5 (5.0-14.5) 0.33^ 
Interval to spontaneous labour from 
last assessment 
8.0 (5.0-
12.0) 
8.0 (5.0-12.0) 6.5 (4.0-13.0) 0.63^ 
Gestation at delivery 40.0 (39.1-
40.9) 
40.0 (39.2-
40.9) 
39.4 (38.7-
40.1) 
<0.001^
Dopplers at last assessment     
UA-PI >95th centile 45 (9.3) 36 (8.2) 9 (19.6) 0.42* 
MCA-PI <5th centile 49 (10.3) 45 (10.3) 4 (9.8) 0.91* 
CPR <5th centile 38 (8.0) 33 (7.6) 5 (12.5) 0.24~ 
CPR <10th centile 72 (15.1) 65 (14.9) 7 (17.5) 0.66* 
Data presented as n (%), mean (SD) and median (IQR), as appropriate. * = Pearson’s chi squared test. 
# = Student’s t-test. ^ = Kruskall-Wallis equality-of-populations rank test. ~ = Fisher’s exact test.
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3.3.4 Dopplers and estimated fetal weight  
3.3.4.1 Variability 
Inter-observer and intra-observer variability results are presented in Table 3Error! Reference source 
not found.. All variability results were <10%, including their 95% CIs. 
Table 3 Variability (inter- and intra-observer) for umbilical and middle cerebral artery pulsatility 
indices and cerebroplacental ratio 
Parameter Inter-observer, % (95% CI) Intra-observer, % (95% CI) 
UA-PI 6.13 (4.52-7.39) 6.19 (3.44-7.97) 
MCA-PI 5.35 (2.30-7.20) 3.17 (2.12-3.95) 
CPR 7.81 (5.56-9.52) 7.55 (5.20-9.30) 
Data presented as median (IQR). 
3.3.4.2 Umbilical artery pulsatility index 
3.3.4.2.1 Distribution by gestation 
The UA-PI was skewed at each fortnightly assessment (Figure 25) and at the last assessment 
preceding delivery. Therefore, all cross-sectional analyses performed for UA-PI were performed with 
non-parametric tests. However, the rate of change in UA-PI showed a normal distribution and was 
therefore assessed with parametric tests, with one exception. The rate of change in UA-PI between 
38 and 40 weeks’ gestation showed a skewed distribution and was assessed using the Kruskall-Wallis 
equality-of-populations rank test 
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Table 4 Maternal characteristics by outcomes 
Characteristic Overall  CS-IFC Op-IFC CNO 
        
(n=437) 
Absent 
(n=419) 
Present 
(n=18) 
p Absent 
(n=355) 
Present 
(n=82) 
p Absent 
(n=352) 
Present 
(n=85) 
p 
Nulliparous  382 (87.4) 365 (87.1) 17 (94.4) 0.71~ 304 (85.6) 78 (95.1) 0.02 301 (85.5) 81 (95.3) 0.02~ 
Maternal age 29.8 (4.5) 30.0 (27.0-
33.0) 
29.5 (27-
33) 
0.52# 30.0 (26.0-
33.0) 
30 (27.0-
33.0) 
0.80 30.0 (26.0-
33.0) 
30.0 (27.0-
33.0) 
0.35# 
BMI 22.6 (20.9-
25.8) 
22.6 (20.9-
25.8) 
22.7 (20.5-
26.7) 
0.86^ 22.6 (20.9-
25.8) 
22.8 (20.8-
25.8) 
0.82 22.8 (20.9-
25.9) 
22.4 (20.8-
25.3) 
0.56^ 
Ethnicity                   Caucasian 269 (61.6) 258 (61.6) 11 (61.1) 0.28~ 219 (61.7) 50 (61.0) 0.57 215 (61.1) 54 (63.5) 0.39* 
East Asian 77 (17.6) 76 (18.1) 1 (5.6) - 64 (18.0) 13 (15.9) - 67 (19.0) 810(11.8) - 
Central Asian 46 (10.5) 43 (10.3) 3 (16.7) - 34 (9.6) 12 (14.6) - 36 (10.2) 10 (11.8) - 
Other 45 (10.3) 42 (10.0) 3 (16.7) - 38 (10.7) 7 (8.5) - 34 (9.7) 11 (12.9) - 
Diabetes mellitus 35 (8.0) 35 (8.4) 0 (0.0) - 33 (9.3) 2 (2.4) 0.04 33 (9.4) 2 (2.4) 0.04~ 
Chronic hypertension 1 (0.2) 1 (0.2) 0 (0.0) - 1 (0.3) 0 (0.0) - 1 (0.3) 0 (0.0) - 
Cigarette smoker 41 (9.4) 40 (9.6) 1 (5.6) 1.0~ 35 (9.9) 6 (7.3) 0.67 34 (9.7) 7 (8.2) 0.69* 
ART 11 (2.6) 11 (2.7) 0 (0.0) - 11 (3.2) 0 (0.0) 0.13 10 (2.9) 1 (1.2) 0.70~ 
Gestation at last assessment 38.4 (37.9-
39.9) 
38.4 (37.9-
39.9) 
39.1 (38.3-
40.1) 
0.07^ 38.4 (37.7-
39.9) 
39.3 (38.3-
40) 
<0.001 38.4 (37.7-
39.9) 
39.3 (38.3-
40.1) 
<0.001^ 
Interval to labour from last 
assessment 
8.0 (5.0-
12.0) 
8.0 (5.0-
12.0) 
6.5 (2.0-
15.0) 
0.11^ 8.0 (5.0-
13.0) 
8.0 (5.0-
11.0) 
0.16 8.0 (5.0-
13.0) 
8.0 (5.0-
11.0) 
0.32^ 
Interval to spontaneous labour 
from last assessment 
8.0 (5.0-
12.0) 
8.0 (5.0-
12.0) 
6.0 (4.0-
11.0) 
0.53^ 8.0 (5.0-
13.0) 
8.0 (5.0-
11.0) 
0.25 8.0 (4.5-
12.5) 
9.0 (5.0-
11.0) 
0.66^ 
Gestation at delivery 40.0 (39.2-
40.9) 
40.0 (39.1-
40.9) 
40.4 (39.6-
40.9) 
0.32^ 40.0 (39.1-
40.9) 
40.4 (39.6-
41.1) 
0.01 40.0 (39.1-
40.7) 
40.6 (39.6-
41.1) 
<0.001^ 
Birth weight <10th centile 18 (3.0) 12 (2.9) 1 (5.6) 0.43~ 8 (2.3) 5 (6.1) 0.08~ 8 (2.3) 5 (5.9) 0.09~ 
UA-PI >95th centile 36 (8.2) 35 (8.4) 1 (5.6) 0.67~ 28 (7.9) 8 (9.8) 0.58* 28 (8.0) 8 (9.4) 0.66* 
MCA-PI <5th centile 45 (10.3) 38 (9.1) 7 (38.9) <0.001* 25 (7.0) 20 (24.4) <0.001* 29 (8.2) 16 (18.8) 0.004* 
CPR <5th centile 33 (7.8) 27 (6.4) 6 (33.3) <0.001* 18 (5.1) 15 (18.3) <0.001* 20 (5.7) 13 (15.3) 0.003* 
CPR <10th centile 65 (14.9) 55 (13.1) 10 (55.6) <0.001* 38 (10.7) 27 (32.9) <0.001* 42 (11.9) 23 (27.1) <0.001* 
Data presented as n (%), mean (SD) and median (IQR), as appropriate. * = Pearson’s chi squared test. # = Student’s t-test. ^ = Kruskall-Wallis equality-of-populations 
rank test. ~ = Fisher’s exact test. 
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Figure 25 Umbilical artery pulsatility index by gestation 
 
3.3.4.2.2 Centiles by gestation 
The UA-PI centiles for each assessment are presented in Table 5. UA-PI values decreased for each 
given centile with advancing gestation. 
3.3.4.2.3 Association with outcomes 
The median UA-PI at each fortnightly assessment, grouped by CS-IFC and CNO outcome groups, 
are presented in Table 6. The median UA-PI was not significantly different at any gestation when 
CS-IFC and CNO outcome groups were compared. In babies born with Op-IFC, the median UA-PI 
was lower at 36 weeks’ gestation and higher at 38 and 40 weeks’ gestation and at last assessment 
preceding delivery, compared to those without Op-IFC. However, the median UA-PI was 
significantly higher only at 40 weeks’ gestation.  
Table 5 Umbilical artery pulsatility index centiles by gestation 
Gestation n Centiles 
  5th 10th  25th  50th  75th  90th  95th  
36 weeks 413 0.64 0.69 0.75 0.83 0.92 1.00 1.10 
38 weeks 365 0.61 0.65 0.71 0.80 0.88 0.98 1.00 
40 weeks 170 0.60 0.64 0.69 0.79 0.86 0.94 1.00 
Last assessment 437 0.61 0.65 0.70 0.80 0.89 0.97 1.01 
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3.3.4.2.4 Rate of change from 36 weeks to delivery 
The UA-PI decreased in the study cohort from 36 weeks to delivery. The mean rate of change between 
36, 38 and 40 weeks’ gestation, and all possible gestation interval comparisons, varied from -0.017 
to -0.020 per day (Table 7).  
3.3.4.2.4.1 CS-IFC 
The UA-PI decreased in babies not delivered by CS-IFC across all gestation combinations from 36 
to 40 weeks (Table 7). The mean rate of change of UA-PI in this non CS-IFC group varied from -
0.018 to -0.020 per day. Similarly, for babies delivered with CS-IFC, the UA-PI decreased from first 
to last assessment, 36 to 40 weeks’ and from 36 to 38 weeks’ gestation, ranging from -0.019 to -0.003 
per day. Interestingly, in the CS-IFC group, the UA-PI increased from 38 to 40 weeks’ gestation by 
0.010 per day. Additionally, the UA-PI from 36 to 40 weeks’ gestation decreased 6.7 times slower in 
fetuses born by CS-IFC compared to all other deliveries. However, no significant difference in the 
rate of change in UA-PI between babies born with or without CS-IFC was demonstrated. 
3.3.4.2.4.2 Op-IFC  
The UA-PI in babies delivered for Op-IFC decreased across all gestation interval combinations 
between 36 and 40 weeks. The mean rate of change in UA-PI for babies born without Op-IFC varied 
from -0.020 to -0.019 per day. In babies born with Op-IFC, the mean rate of change in UA-PI varied 
from -0.088 to -0.008. The greatest difference in the rate of change for gestation interval comparisons 
was between first and last assessment, where the rate of decrease in UA-PI was 2.5 times lower for 
babies born with Op-IFC compared to those without Op-IFC, although this was not significant. 
3.3.4.2.4.3 CNO  
The UA-PI in babies delivered with CNO decreased across all assessment combinations from 36 to 
40 weeks (Table 7). The mean rate of change in UA-PI for babies born without CNO varied from -
0.020 to -0.018, whilst for babies born with CNO it varied from -0.020 to -0.010. The rate of decrease 
in UA-PI was 1.9 times lower for babies born with CNO compared to those without CNO between 
38 and 40 weeks’ gestation. There were no significant differences found in the rate of change in UA-
PI between the CNO groups for any of the gestation interval comparisons. 
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Table 6 Umbilical artery pulsatility index by gestation and outcomes 
Gestation  CS-IFC Op-IFC CNO 
 Absent Present p^ Absent Present p^ Absent Present p^ 
36 weeks 0.84 (0.76-0.92) 0.79 (0.75-0.88) 0.25 0.84 (0.76-0.92) 0.80 (0.75-0.93) 0.57 0.83 (0.75-0.92) 0.85 (0.78-0.94) 0.12 
38 weeks 0.80 (0.71-0.88) 0.78 (0.71-0.86) 0.79 0.80 (0.70-0.88) 0.81 (0.71-0.90) 0.26 0.80 (0.70-0.88) 0.81 (0.75-0.90) 0.13 
40 weeks 0.78 (0.69-0.87) 0.84 (0.82-0.85) 0.17 0.77 (0.67-0.86) 0.84 (0.75-0.90) 0.01 0.77 (0.69-0.86) 0.84 (0.72-0.87) 0.09 
Last assessment 0.80 (0.70-0.89) 0.83 (0.75-0.85) 0.69 0.79 (0.70-0.88) 0.82 (0.70-0.90) 0.23 0.79 (0.70-0.89) 0.81 (0.73-0.88) 0.21 
Data presented as median (IQR). ^ = Kruskall-Wallis equality-of-populations rank test. 
 
 
Table 7 Rate of change in umbilical artery pulsatility index 
Gestation Overall CS-IFC Op-IFC CNO 
 n (PI/day) Absent Present p Absent Present p Absent Present p 
First to last  363 -0.017 -0.018 (0.057) -0.010 (0.034) 0.60# -0.020 (0.056) -0.008 (0.054) 0.11# -0.018 (0.055) -0.017 (0.057) 0.91# 
36 to 40 weeks 157 -0.020 -0.020 (0.036) -0.003 (0.028) 0.22# -0.020 (0.035) -0.018 (0.040) 0.82# -0.020 (0.035) -0.019 (0.040) 0.85# 
36 to 38 weeks 340 -0.019 -0.019 (0.067) -0.019 (0.040) 0.99# -0.020 (0.066) -0.014 (0.069) 0.45# -0.019 (0.065) -0.020 (0.070) 0.90# 
38 to 40 weeks 160 -0.017 -0.018 (0.060) 0.010 (0.074) 0.18^ -0.019 (0.062) -0.011 (0.059) 0.50^ -0.019 (0.066) -0.010 (0.046) 0.44^ 
First to last = first assessment to last assessment. Data presented as mean (SD). # = Student’s t-test. ^ = Kruskall-Wallis equality-of-populations rank test.  
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3.3.4.3 Middle cerebral artery pulsatility index 
3.3.4.3.1 Distribution by gestation 
The MCA-PI was skewed at each fortnightly assessment (Figure 26) and at the last assessment 
preceding delivery. Consequently, the Kruskall-Wallis equality-of-populations non-parametric test 
was performed for all cross-sectional analyses of the MCA-PI (Table 9). The distribution of the 
change over time for MCA-PI was normally distributed and, thus, parametric testing (Student’s t-
test) was used for analysis (Table 10). 
Figure 26 Middle cerebral artery pulsatility index by gestation 
 
3.3.4.3.2 Centiles by gestation 
The MCA-PI centiles for each assessment are presented in Table 8. MCA-PI values decreased for 
each given centile with advancing gestation. 
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Table 8 Middle cerebral artery pulsatility index centiles by gestation 
Gestation n Centile  
  5th  10th  25th  50th  75th  90th  95th  
36 weeks 412 1.22 1.34 1.51 1.70 1.90 2.10 2.20 
38 weeks 365 1.02 1.13 1.30 1.50 1.70 1.88 2.00 
40 weeks 169 0.93 1.00 1.14 1.30 1.52 1.75 1.90 
Last assessment 437 0.98 1.06 1.24 1.45 1.69 1.90 2.10 
3.3.4.3.3 Association with outcomes 
The MCA-PI was lower at all gestations amongst fetuses who were born by CS-IFC compared to all 
other deliveries (Table 9). 
The MCA-PI at last assessment was significantly lower in CS-IFC deliveries. In babies born Op-IFC 
compared to those without Op-IFC, the median MCA-PI was significantly lower at all assessments 
and for the last assessment preceding delivery Amongst babies born with CNO compared to babies 
without CNO, the MCA-PI was also lower at 36 and 40 weeks’ gestation and at the last assessment 
prior to delivery, irrespective of gestation. The MCA-PI was also significantly lower in babies with 
CNO at last assessment prior to delivery. 
3.3.4.3.4 Rate of change from 36 weeks 
The MCA-PI decreased in the study cohort from 36 weeks to delivery. The mean rate of change 
between 36, 38 and 40 weeks’ gestation, and all possible gestation interval comparisons, varied from 
-0.090 to -0.100 per day.  
3.3.4.3.4.1 CS-IFC 
The MCA-PI in babies delivered by CS-IFC, or not, decreased for all gestation combinations from 
36 weeks to delivery (Table 10). The mean rate of change of MCA-PI in the group with absent CS-
IFC varied from -0.088 to -0.099 per day. For babies delivered with CS-IFC the mean rate of change 
of MCA-PI varied from -0.106 to -0.134 per day, which was greater than the change observed for 
babies without CS-IFC. However, no significant difference in the rate of change in MCA-PI between 
babies born with or without CS-IFC was found. 
3.3.4.3.4.2 Op-IFC 
Babies born with Op-IFC had a greater decrease in MCA-PI compared to babies without Op-IFC for 
all gestation interval comparisons (Table 10). The variation in mean rate of change in MCA-PI for 
this cohort was -0.104 to -0.115 per day, whilst for those without Op-IFC it was -0.085 to -0.097 per 
day. The rate of change in MCA-PI was not significantly different for any gestation interval 
comparison.  
 63 
 
Table 9 Middle cerebral artery pulsatility index by outcomes 
 CS-IFC Op-IFC CNO 
 Absent Present p^ Absent Present p^ Absent Present p^ 
36 weeks 1.70 (1.51-1.90) 1.58 (1.35-1.88) 0.31 1.72 (1.53-1.90) 1.63 (1.43-1.85) 0.03 1.70 (1.51-1.89) 1.67 (1.49-1.90) 0.83 
38 weeks 1.51 (1.30-1.70) 1.34 (1.19-1.54) 0.09 1.54 (1.34-1.71) 1.36 (1.19-1.65) <0.001 1.50 (1.30-1.70) 1.52 (1.28-1.70) 0.72 
40 weeks 1.32 (1.16-1.53) 1.04 (1.00-1.15) 0.009 1.34 (1.17-1.54) 1.20 (1.02-1.49) 0.02 1.34 (1.16-1.53) 1.24 (1.04-1.44) 0.08 
Last assessment 1.46 (1.25-1.70) 1.17 (1.02-1.34) 0.001 1.49 (1.30-1.70) 1.25 (1.10-1.51) 0.001 1.47 (1.29-1.70) 1.34 (1.18-1.61) 0.01 
Data presented as median (IQR). ^ = Kruskall-Wallis equality-of-populations rank test. 
 
 
Table 10 Rate of change in middle cerebral artery pulsatility index by gestation and outcomes 
Gestation Overall CS-IFC Op-IFC CNO 
 n PI/day Absent Present p# Absent  Present p# Absent Present p# 
First to last  362 -0.095 -0.094 (0.125) -0.113 (0.197) 0.55 -0.091 (0.128) -0.107 (0.134) 0.35 -0.092 (0.132) -0.105 (0.120) 0.44 
36 to 40 weeks 156 -0.100 -0.099 (0.080) -0.127 (0.087) 0.37 -0.097 (0.076) -0.109 (0.091) 0.42 -0.099 (0.084) -0.103 (0.067) 0.78 
36 to 38 weeks 342 -0.990 -0.099 (0.158) -0.106 (0.218) 0.86 -0.095 (0.153) -0.114 (0.184) 0.36 -0.098 (0.162) -0.101 (0.154) 0.90 
38 to 40 weeks 162 -0.090 -0.088 (0.158) -0.134 (0.134) 0.39 -0.085 (0.149) -0.104 (0.178) 0.51 -0.081 (0.150) -0.117 (0.174) 0.19 
Data presented as mean (SD). # = Student’s t-test. 
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3.3.4.3.4.3 CNO 
A similar pattern was observed for babies delivered with CNO (Table 10). The mean rate of change 
in MCA-PI in babies without CNO varied from -0.081 to -0.099 per day, whilst those with CNO had 
MCA-PI decreases from -0.101 to -0.117 per day. For babies with CNO, the rate of decrease in MCA-
PI was greater than those born with CNO. 
3.3.4.4 Cerebroplacental ratio 
3.3.4.4.1 Distribution by gestation 
The CPR by gestation in weeks is displayed in Figure 27 and the CPR centiles are presented in Table 
11 by fortnightly assessment. The CPR at the first assessment was normally distributed. However, as 
women advanced in gestation, including the last assessment preceding delivery, the CPR became 
skewed. Consequently, the Kruskall-Wallis equality-of-populations non-parametric test was 
performed for all cross-sectional analyses of the CPR (Table 12). The distribution of the change in 
CPR over time was normally distributed and, thus, parametric testing (Student’s t-test) was used for 
analysis (Table 13). 
Figure 27 Cerebroplacental ratio by gestation 
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3.3.4.4.2 Centiles by gestation 
The CPR centiles for each assessment are presented in Table 11. CPR values decreased for each given 
centile with advancing gestation. 
Table 11 Cerebroplacental ratio centiles by gestation 
Gestation n Centile  
  5th  10th  25th  50th  75th  90th  95th  
36 weeks 412 1.43 1.53 1.76 2.03 2.31 2.57 2.74 
38 weeks 365 1.23 1.33 1.61 1.90 2.18 2.50 2.63 
40 weeks 169 1.06 1.18 1.43 1.71 2.06 2.37 2.63 
Last assessment 437 1.16 1.32 1.55 1.84 2.18 2.50 2.65 
 
3.3.4.4.3 Association with outcomes 
The median CPRs at each fortnightly assessment, grouped by CS-IFC, Op-IFC and CNO outcome 
groups, are presented in (Table 12). 
3.3.4.4.3.1 CS-IFC 
The median CPR at 38 and 40 weeks’ gestation and at last visit preceding delivery were lower for 
fetuses who were delivered by CS-IFC compared to all other deliveries (Table 12). The median CPR 
was significantly lower for these CS-IFC fetuses at 40 weeks’ gestation and at last visit preceding 
delivery. However, at 36 weeks’ gestation the median CPR was higher amongst fetuses delivered by 
CS-IFC compared to other deliveries, although this difference was not significant. 
3.3.4.4.3.2 Op-IFC  
The median CPR was lower amongst babies born with Op-IFC compared to those without Op-IFC at 
all assessments, including the last assessment preceding delivery. At 36 weeks’ gestation the 
difference between those with and without Op-IFC was not significant. However, the CPR was 
significantly lower amongst babies born with Op-IFC at 38 and 40 weeks’ gestation and at last 
assessment preceding delivery. 
3.3.4.4.3.3 CNO 
The median CPR amongst babies born with CNO compared to those without CNO was lower at all 
assessments from 36 weeks’ gestation, including the last assessment preceding delivery (Table 12). 
The difference between those with and without CNO was significant at 40 weeks’ gestation and at 
last assessment preceding delivery.  
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Table 12 Cerebroplacental ratio by gestation and outcomes 
Gestation CS-IFC Op-IFC CNO 
 Absent Present p^ Absent Present p^ Absent Present p^ 
36 weeks 2.03 (1.77-2.31) 2.10 (1.63-2.36) 0.84 2.04 (1.79-2.33) 1.96 (1.64-2.29) 0.07 2.05 (1.80-2.31) 1.94 (1.70-2.29) 0.13 
38 weeks 1.90 (1.62-2.18) 1.80 (1.43-2.22) 0.33 1.93 (1.65-2.21) 1.78 (1.40-2.11) 0.002 1.90 (1.62-2.20) 1.89 (1.51-2.14) 0.22 
40 weeks 1.73 (1.46-2.06) 1.24 (1.18-1.40) 0.003 1.75 (1.53-2.12) 1.44 (1.26-1.77) 0.001 1.74 (1.51-2.07) 1.6 (1.33-1.89) 0.01 
Last assessment 1.86 (1.57-2.18) 1.41 (1.23-1.80) 0.002 1.90 (1.61-2.23) 1.50 (1.33-1.89) 0.001 1.88 (1.60-2.19) 1.66 (1.40-2.05) 0.001
Data presented as median (IQR). ^ = Kruskall-Wallis equality-of-populations rank test. 
 
 
Table 13 Rate of change in cerebroplacental ratio by gestation and outcomes 
Gestation Overall CS-IFC Op-IFC CNO 
 n (PI/day) Absent Present p# Absent Present p# Absent Present p# 
First to last  360 -0.073 (0.198) -0.071 (0.195) -0.120 (0.258) 0.32 -0.062 (0.201) -0.117 (0.183) 0.03 -0.070 (0.205) -0.085 (0.173) 0.53 
36 to 40 weeks 156 -0.077 (0.119) -0.073 (0.119) -0.157 (0.093) 0.07 -0.070 (0.120) -0.097 (0.117) 0.23 -0.074 (0.125) -0.087 (0.101) 0.56 
36 to 38 weeks 338 -0.072 (0.238) -0.071 (0.234) -0.076 (0.311) 0.95 -0.063 (0.233) -0.108 (0.252) 0.16 -0.073 (0.242) -0.070 (0.224) 0.94 
38 to 40 weeks 160 -0.075 (0.238) -0.067 (0.235) -0.221 (0.257) 0.06 -0.060 (0.236) -0.121 (0.243) 0.16 -0.057 (0.244) -0.124 (0.217) 0.12 
Data presented as mean (SD). # = Student’s t-test. 
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3.3.4.4.4 Rate of change from 36 weeks  
The CPR decreased for all gestation comparison combinations between 36 weeks’ gestation and 
delivery (Table 13). 
3.3.4.4.4.1 CS-IFC 
The CPR decreased faster in babies delivered by CS-IFC, compared to all other deliveries, for all 
gestation interval combinations (Table 13). This did not reach significance. 
3.3.4.4.4.2 Op-IFC  
Babies born with Op-IFC had a faster decrease in CPR compared to babies without Op-IFC for all 
gestation interval combinations. The rate of change in the first vs. last CPR preceding delivery was 
significantly greater for babies born with Op-IFC compared to those without Op-IFC.  
3.3.4.4.4.3 CNO 
The CPR decreased faster in babies delivered with CNO, compared to babies without CNO. This was 
true for all gestation interval combinations except the interval from 36 to 38 weeks’ gestation, where 
the CPR decreased faster among babies born without CNO. Nevertheless, the rate of change in CPR 
for all interval combinations was not significant. 
3.3.4.5 Umbilical vein flow 
3.3.4.5.1 Distribution by gestation 
The cUVf distribution by gestation is displayed in Figure 28 and the centiles by gestation are 
displayed in Table 14. The cUVf was skewed at each gestation and at last assessment preceding 
delivery. As such, the Kruskall-Wallis equality-of-populations non-parametric test was performed for 
all cross-sectional analyses of cUVf (Table 15). The distribution of the change in cUVf over time was 
normally distributed and therefore was analysed using parametric testing (Student’s t-test). (Table 
16). 
3.3.4.5.2 Centiles by gestation 
The cUVf centiles by gestation are presented in Table 14. For each reported centile, the cUVf 
decreased with advancing gestation. 
3.3.4.5.3 Association with outcomes 
The median cUVf at each fortnightly assessment, grouped by CS-IFC, CNO and Op-IFC outcome 
groups, are presented in Table 15. Median cUVf decreased with advancing gestation for all outcome 
groups. At each gestation, the median cUVf was lower in pregnancies complicated by CS-IFC, Op- 
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IFC and/or CNO were compared to uncomplicated pregnancies. Corrected UVf at 36 weeks’ in 
women delivered by CS-IFC compared to those who were not was the only exception, with CS-IFC 
deliveries recording a median cUVf 1mL/kg/min greater than other deliveries. At 38 weeks’ gestation 
and at last assessment preceding delivery babies who were delivered by CS-IFC or Op-IFC had 
significantly lower cUVf than their uncomplicated counterparts. 
Figure 28 Corrected umbilical vein flow by gestation 
 
Table 14 Corrected umbilical vein flow centiles by gestation 
Gestation n Centile 
  5th  10th 25th 50th  75th 90th 95th 
36 weeks 403 65 70 81 95 112 127 141 
38 weeks 353 57 63 74 85 97 112 123 
40 weeks 158 52 57 67 76 87 97 109 
Last assessment 433 54 61 72 82 96 113 127 
 
3.3.4.5.4 Rate of change from 36 weeks 
The rate of change in cUVf in the study cohort from 36 weeks’ to delivery is presented in (Table 16). 
The rate of change in cUVf was most rapid when 36 weeks’ gestation was compared to 40 weeks’ 
gestation and slowest from first to last assessment.  
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Table 15 Corrected umbilical vein flow by gestation and outcomes 
Gestation CS-IFC Op-IFC CNO 
 Absent Present p^ Absent Present p^ Absent Present p^ 
36 weeks 95 (81-112) 96 (80-111) 0.94 97 (81-113) 92 (81-105) 0.19 96 (81-113) 92 (82-106) 0.33 
38 weeks 85 (74-98) 78 (61-87) 0.04 95 (74-100) 82 (71-92) 0.04 85 (74-98) 82 (72-93) 0.13 
40 weeks 76 (67-87) 71 (61-96) 0.84 76 (67-86) 75 (68-89) 0.61 76 (67-89) 75 (70-83) 0.99 
Last assessment 82 (73-96) 71 (61-83) 0.009 82 (73-99) 77 (68-90) 0.001 84 (73-98) 77 (71-89) 0.004
Data presented as median (IQR). ^ = Kruskall-Wallis equality-of-populations rank test. 
 
 
Table 16 Rate of change in corrected umbilical vein flow by gestation and outcomes 
Gestation Overall CS-IFC Op-IFC CNO 
 n (mL/kg/min/day) Absent Present p# Absent Present p# Absent Present p# 
First to last assessment 348 -4.5 (12.3) -4.2 (12.3) -10.3 (12.3) 0.05 -4.1 (12.9) -5.7 (9.7) 0.32 -4.2 (13.2) -5.4 (8.8) 0.47 
36 to 40 weeks 143 -4.8 (6.9) -4.7 (7.0) -7.0 (-4.1) 0.46 -4.6 (7.1) -5.5 (6.3) 0.51 -4.8 (7.5) -4.9 (5.2) 0.91 
36 to 38 weeks 325 -4.7 (13.9) -4.3 (13.9) -11.8 (13.7) 0.04 -4.2 (14.4) -6.5 (12.2) 0.21 -4.4 (14.6) -5.7 (11.3) 0.47 
38 to 40 weeks 146 -4.6 (11.8) -4.6 (11.8) -4.5 (13.2) 0.98 -5.0 (12.5) -3.6 (9.7) 0.55 -4.8 (12.2) -4.1 )10.9) 0.76 
Data presented as mean (SD). # = Student’s t-test 
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3.3.4.5.4.1 CS-IFC, Op-IFC and CNO  
The mean cUVf decreased at a faster rate in babies delivered by CS-IFC compared to those without 
CS-IFC when all gestational periods were compared, except from 38 to 40 weeks’ gestation (Table 
16). This gestational pattern of cUVf decreasing at a faster rate in pregnancies with complications 
also occurred for babies delivered with the Op-IFC and/or CNO outcome(s). However, the difference 
was only significant for CS-IFC vs. all other deliveries when the rate of change in cUVf was assessed 
from 36 to 38 weeks’ gestation.  
3.3.4.6 Uterine artery pulsatility index 
3.3.4.6.1 Distribution by gestation 
The UtA-PI was skewed at each fortnightly assessment (Figure 29) and at last assessment preceding 
delivery. Consequently, the Kruskall-Wallis equality-of-populations non-parametric test was 
performed for all cross-sectional analyses of the UtA-PI (Table 18). The distribution of the change 
over time for MCA-PI was normally distributed and, thus, Student’s t-test was used for analysis 
(Table 19). 
Figure 29 Uterine artery pulsatility index by gestation 
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3.3.4.6.2 Centiles by gestation 
The centile values for UtA-PI are presented in Table 17. For each centile, the overall trend was for 
UtA-PI to decrease or remain almost stable with advancing gestation from first assessment. 
Table 17 Uterine artery pulsatility index centiles by gestation 
Gestation n Centiles  
  5th  10th  25th  50th  75th  90th  95th  
36 weeks 389 0.47 0.50 0.56 0.64 0.75 0.89 0.98 
38 weeks 350 0.44 0.48 0.54 0.62 0.75 0.89 1.01 
40 weeks 159 0.44 0.49 0.55 0.62 0.73 0.85 0.92 
Last assessment 428 0.44 0.48 0.55 0.62 0.75 0.90 1.03 
 
3.3.4.6.3 Association with outcomes 
The median UtA-PI, grouped by CS-IFC, Op-IFC and CNO outcome groups, are presented in Table 
18. 
3.3.4.6.3.1 CS-IFC 
The median UtA-PI was higher in pregnancies delivered by CS-IFC from 38 weeks, and at last 
assessment preceding delivery, compared to all other deliveries (Table 18), although this only reached 
statistical significance at 40 weeks and at last assessment preceding delivery. Conversely, the median 
UtA-PI was lower in women with CS-IFC deliveries at 36 weeks, although this difference was not 
statistically significant. 
3.3.4.6.3.2 Op-IFC 
The median UtA-PI amongst babies delivered with Op-IFC was lower at 36 weeks’ gestation and 
higher from 38 weeks’ gestation compared to those delivered without Op-IFC (Table 18). The 
differences were significant at 38 weeks’ gestation and at last assessment preceding delivery. 
3.3.4.6.3.3 CNO 
The median UtA-PI amongst babies born with CNO was higher at assessments from 38 weeks’ 
gestation (Table 18). Nevertheless, the difference between those with and without CNO was 
significant at 38 weeks’ gestation and at last assessment preceding delivery. 
3.3.4.6.4 Rate of change from 36 weeks 
Overall, the UtA-PI decreased between each gestation from 36 weeks (Table 19). 
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Table 18 Association of uterine artery pulsatility index by gestation and outcomes 
Gestation CS-IFC Op-IFC CNO 
 Absent Present p^  Absent Present p^  Absent Present p^  
36 weeks 0.64 (0.56-0.76) 0.62 (0.56-0.73) 0.59 0.64 (0.56-0.76) 0.63 (0.56-0.73) 0.55 0.64 (0.56-0.76) 0.63 (0.56-0.73) 0.81 
38 weeks 0.62 (0.54-0.74) 0.69 (0.57-0.79) 0.15 0.61 (0.53-0.74) 0.69 (0.58-0.79) 0.01 0.62 (0.53-0.74) 0.68 (0.59-0.79) 0.02 
40 weeks 0.62 (0.55-0.72) 0.74 (0.64-0.89) 0.02 0.62 (0.55-0.71) 0.65 (0.57-0.75) 0.13 0.62 (0.54-0.71) 0.64 (0.58-0.75) 0.13 
Last assessment 0.62 (0.55-0.74) 0.72 (0.62-0.87) 0.01 0.62 (0.54-0.74) 0.69 (0.58-0.78) 0.01 0.62 (0.54-0.73) 0.68 (0.59-0.80) 0.007 
Data presented as median (IQR). ^ = Kruskall-Wallis equality-of-populations rank test. 
 
 
Table 19 Rate of change in uterine artery pulsatility index by gestation and outcomes 
Gestation Overall CS-IFC Op-IFC CNO 
 n (PI/day) Absent Present p#  Absent Present p# Absent Present p# 
First to last  339 -0.003 (0.107) -0.006 (0.106) 0.057 (0.117) 0.02 -0.011 (0.113) 0.023 (0.080) 0.01 -0.006 (0.102) 0.005 (0.124) 0.43 
36 to 40 weeks 139 -0.002 (0.038) -0.002 (0.038) -0.002 (0.025) 0.98 -0.004 (0.039) 0.003 (0.034) 0.32 -0.004 (0.038) 0.006 (0.038) 0.19 
36 to 38 weeks 309 -0.005 (0.116) -0.006 (0.117) 0.026 (0.083) 0.33 -0.010 (0.123) 0.015 (0.082) 0.13 -0.007 (0.109) 0.004 (0.137) 0.49 
38 to 40 weeks 147 -0.001 (0.096) -0.005 (0.092) 0.070 (0.149) 0.03 -0.008 (0.097) 0.021 (.092) 0.11 -0.005 (0.101) 0.010 (0.081) 0.40 
Data presented as mean (SD). # = Student’s t-test. 
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3.3.4.6.4.1 CS-IFC 
The UtA-PI decreased faster in babies who were not delivered by CS-IFC, compared to CS-IFC 
deliveries, for all gestation interval combinations (Table 19). This difference was significant for two 
comparisons (first vs. last assessment and 38 weeks vs. 40 weeks). Of note, for babies delivered by 
CS-IFC, the UtA-PI increased or was stable between the different gestation comparisons whilst in all 
other deliveries it decreased or remained stable. 
3.3.4.6.4.2 Op-IFC 
The rate of increase in the UtA-PI was more rapid with advancing gestation in babies who had Op-
IFC compared to those who did not. In babies who did not experience Op-IFC, the UtA-PI decreased 
more rapidly with advancing gestation (Table 19). Those born with Op-IFC underwent an increase in 
UtA-PI more rapidly than the decrease in UtA-PI observed in pregnancies without Op-IFC for all 
gestation ranges. 
3.3.4.6.4.3 CNO 
For babies delivered with CNO, UtA-PI increased between all of the different gestation comparisons 
(Table 19) whilst it decreased for babies delivered without CNO. The mean magnitude of change in 
the UtA-PI for babies with and without CNO for the different gestation comparisons varied from 
0.004/day to 0.010/day. The greatest difference in the rate of change in UtA-PI between those with 
and without CNO occurred from 38 and 40 weeks’ gestation. 
3.3.4.7 Estimated fetal weight 
3.3.4.7.1 Distribution by gestation 
The distribution of EFW centile by gestation is displayed in Figure 30 and centiles of the study group 
by gestation are listed in Table 20. The distribution of EFW centile was skewed at each fortnightly 
assessment and at last assessment preceding delivery. Thus, the Kruskall-Wallis equality-of-
populations non-parametric test was performed for all cross-sectional analyses (Table 21). The rate 
of change in EFW centile was normally distributed and, thus, the Student’s t-test was used for these 
analyses (Table 22). 
3.3.4.7.2 Centiles by gestation 
The EFW centiles of the study group at all gestations were higher than those of the reference, 
particularly for centiles below the median (Table 20). With advancing gestation, the EFW centiles in 
the study group remained relatively stable until assessment at 40 weeks’ gestation. 
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Figure 30 Estimated fetal weight centile by gestation 
 
Table 20 Estimated fetal weight centiles by gestation 
Gestation n Centiles 
  5th  10th  25th  50th  75th  90th  95th  
36 weeks 403 15.1 22.0 35.0 53.8 75.0 89.0 94.0 
38 weeks 360 15.5 22.0 37.0 52.0 72.4 88.0 93.0 
40 weeks 138 9.6 17.0 28.0 43.0 69.0 84.0 91.0 
Last assessment 436 13.8 20.1 34.1 52.0 73.0 88.0 92.1 
 
3.3.4.7.3 Association with outcomes 
The median EFWc at each fortnightly assessment, grouped by CS-IFC, Op-IFC and CNO outcome 
groups, are presented in Table 21. EFWc were similar for the deliveries with complications present 
vs. those without complications at each gestation. However, at 40 weeks’ gestation babies delivered 
by CS-IFC and/or Op-IFC had higher EFW centiles than their uncomplicated equivalents. For babies 
with Op-IFC, their median EFW centile at 38 weeks’ gestation and last assessment preceding delivery 
was significantly lower than babies without Op-IFC. 
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Table 21 Estimated fetal weight centile by gestation and outcomes 
Gestation CS-IFC Op-IFC CNO 
 Absent Present p^  Absent Present p^  Absent Present p^  
36 weeks 53.8 (35.0-75.2) 53.0 (43.5-65.3) 0.85 54.0 (34.5-77.0) 50.0 (36.0-65.0 ) 0.11 53.9 (34.0-75.6) 53.0 (39.0-74.0) 0.97 
38 weeks 52.0 (37.0-74.5) 52.0 (39.0-63.2) 0.32 54.0 (38.0-75.0) 48.0 (33.0-66.0) 0.04 53.5 (37.0-75.0) 50.0 (37.0-66.0) 0.16 
40 weeks 42.0 (30.0-70.0) 66.0 (17.0-69.0) 0.76 41.0 (30.0-70.0) 47.4 (22.0-68.0) 0.69 45.0 (30.0-72.0) 39.2 (24.0-66.0) 0.15 
Last assessment 52.0 (34.2-75.0) 56.0 (27.0-66.0) 0.47 52.7 (36.0-75.0) 49.5 (30.5-68.0) 0.04 53.0 (35.9-75.0) 48.0 (32.0-68.0) 0.11 
Data presented as median (IQR). ^ = Kruskall-Wallis equality-of-populations rank test. 
 
 
Table 22 Rate of change in estimated fetal weight centile by gestation and outcomes 
Gestation Overall CS-IFC Op-IFC CNO 
 n (EFWc/day) Absent Present p#  Absent Present p#  Absent Present p# 
First to last  348 -0.2 (6.8) -0.2 (6.9) -0.2 (6.0) 1.00 -0.1 (7.2) -0.6 (5.2) 0.61 0.2 (7.0) -1.7 (5.9) 0.03 
36 to 40 weeks 125 -1.4 (4.2) -1.3 (4.2) -2.5 (3.5) 0.48 -1.6 (4.2) -0.6 (4.1) 0.22 -1.1 (4.2) -2.0 (4.2) 0.33 
36 to 38 weeks 326 -0.3 (7.7) -0.3 (7.8) -1.3 (7.2) 0.62 -0.3 (7.9) -0.3 (7.0) 0.98 0.1 (8.0) -1.8 (6.4) 0.07 
38 to 40 weeks 127 -1.2 (7.6) -1.3 (7.5) 0.0 (9.0) 0.66 -1.2 (8.1) -1.1 (6.2) 0.93 -1.0 (7.5) -1.8 (7.7) 0.58 
Data presented as mean (SD). # = Student’s t-test. 
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3.3.4.7.4 Rate of change from 36 weeks 
The rate of change in EFW centile for different gestation intervals by CS-IFC, Op-IFC and CNO 
outcomes is presented in Table 22. The rate of change in the overall study group was highest for the 
interval from 36 to 40 weeks’ gestation and lowest from first to last assessment preceding delivery. 
3.3.4.7.4.1 CS-IFC, Op-IFC and CNO  
The decline in EFW centile was more rapid for babies delivered by CS-IFC compared to all other 
deliveries for the interval from 36 to 40 weeks’ gestation and 36 to 38 weeks’ gestation (Table 22). 
The decline in EFW centile was more rapid for babies delivered with Op-IFC compared to all other 
deliveries for the interval between first and last assessment (Table 22). No other gestation intervals 
investigated showed this pattern for babies delivered with Op-IFC. 
The decline in EFW centile was more rapid for babies delivered with CNO compared to all other 
deliveries for the interval between first and last assessment (Table 22). 
3.4 Discussion 
This chapter shows that the MCA-PI, CPR, cUVf and EFWc all decrease, whilst the UA-PI and UtA-
PI increase, from 36 weeks to delivery in a low risk group of women. Furthermore, MCA-PI, CPR, 
cUVf and UtA-PI were significantly different at the last assessment preceding delivery for babies in 
the adverse outcome groups (CS-IFC, Op-IFC and CNO), whilst EFWc was significantly different 
only for babies with Op-IFC at 38 weeks and last assessment compared to those without Op-IFC. 
Conversely, the rate of change in cUVf, UtA-PI and EFWc between the outcomes showed inconsistent 
but significant difference between babies in some of the adverse outcome groups compared to those 
without adverse outcomes. 
3.4.1 Association with outcomes 
The association between raised UA resistance and early onset FGR is well documented.32 However, 
the pattern of increased UA resistance has not been evident in late onset growth restriction, even 
within an SGA population.258 The findings of this study show that in a low risk population at term 
the UA-PI is higher at 40 weeks’ gestation amongst babies born by Op-IFC compared to those without 
Op-IFC. Interestingly, this was not evident for any other outcome groups or at any other gestation, 
suggesting that increased UA resistance is subtle and may only be evident in a low risk population 
beyond 39 weeks’ gestation. This is in keeping with the survival time theory of pre-eclampsia 
proposed previously,259 whereby it is theorised that all pregnant women will develop pre-eclampsia 
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if they remain pregnant long enough, with some women developing it at an earlier gestation than 
others. There is, however, the possibility that this may be a spurious result or Type 1 error, given that 
no other gestation or adverse outcome group showed a significant difference in UA resistance values 
compared to those of normal outcomes. 
The association between reduced MCA-PI and adverse perinatal outcomes has been reported 
previously.46,122,131,258 The current study reports that MCA-PI was significantly lower for babies with 
the CS-IFC, Op-IFC or CNO outcomes. Although the populations in previous studies have largely 
been SGA or low birth weight (LBW), Prior et al.131 reported an association between reduced MCA-
PI and CS-IFC delivery in low risk women in early labour. The findings from the current study are 
consistent with these previous reports, demonstrating that cerebral redistribution occurs up to two 
weeks prior to delivery even amongst appropriately grown fetuses. 
The CPR has previously been shown to be associated with adverse perinatal outcomes,132,133,135,143,260-
262 as was demonstrated in this study. However, previous studies have been performed retrospectively 
or in populations with recognised risk factors, such as SGA. The current study demonstrates that the 
CPR is associated with CS-IFC, Op-IFC or CNO outcomes even when assessed up to 2 weeks prior 
to term birth. These results were published137 in conjunction with analysis comparing the screening 
performance of the CPR <10th centile against two other previously suggested thresholds,139 CPR ≤1 
and CPR <5th centile. This study demonstrated that the CPR <10th centile resulted in the best overall 
test performance for the CS-IFC and adverse neonatal outcomes, with sensitivity, specificity and 
AUROC curves of 55.6%, 87.9% and 0.72, and 55.6% and 87.9% and 0.58, respectively. However, 
the predictive utility of the CPR <10th centile would be considered fair for CS-IFC and poor for the 
adverse neonatal outcome, despite outperforming the other previously suggested CPR thresholds.  
The cUVf has been associated with growth restriction110,263 prior to changes in other fetal Dopplers. 
These studies have predominantly involved early rather than late onset growth restriction. The present 
study shows that babies with the adverse outcomes had significantly lower cUVf at last assessment 
preceding delivery than babies with normal outcomes, and babies born with Op-IFC also had lower 
cUVf at 38 weeks’ gestation than those without Op-IFC. Interestingly, the cUVf declined more 
rapidly in babies who were born by CS-IFC for the gestation intervals of first to last assessment and 
36 to 38 weeks’ gestation. Whilst the differences detected may represent a Type 1 error, this would 
appear less likely than a Type 2 error resulting from lower sample numbers at 36 to 40 weeks’ and 
38 to 40 weeks’ gestation. 
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A low EFWc or SGA classification is a recognised risk factor for adverse perinatal outcomes and 
placental insufficiency.50,264,265 Whilst these studies have studied at-risk populations, the current study 
shows that even in appropriately grown fetuses with normal UA-PI, a lower EFWc at 38 weeks’ 
gestation and last assessment preceding delivery is associated with Op-IFC. This is consistent with 
the suggestion that even amongst fetuses with EFW >10th centile there exists an at-risk cohort with 
failure to reach its growth potential, latent placental insufficiency and IFC. 
3.4.2 Rate of change 
The rate of change in UA-PI showed no significant difference between the CS-IFC, Op-IFC or CNO 
outcomes. This finding has not been reported previously. Nevertheless, this is consistent with reports 
from previous studies258,266 that have shown late onset growth restriction is not associated with 
differences in UA-PI compared to appropriately grown fetuses.  
The rate of change in MCA-PI and CPR was found to be no different between babies with or without 
the CS-IFC, Op-IFC or CNO outcomes. Although not previously reported, this finding challenges the 
assumption that late onset placental insufficiency results in progressive worsening of cerebral 
redistribution. Rather, it suggests that the fetus with latent placental insufficiency and subsequent CS-
IFC, Op-IFC or CNO outcomes already has a reduced MCA-PI and CPR prior to 36 weeks and 
maintains this reduced MCA-PI and CPR through to delivery. Compared to early onset FGR, where 
gradual deterioration in fetal Doppler indices occurs, this is a further point of difference between the 
two entities. 
The rate of change in cUVf at term in low risk fetuses and the association with adverse intrapartum 
and neonatal outcomes has not previously been reported. Previous reports of UV flow have 
demonstrated reduced flow prior to deterioration in UA indices in growth restricted fetuses.263 The 
cUVf results from this Thesis are consistent with the temporal pattern observed in FGR, as cUVf 
reduced faster in CS-IFC deliveries from 36 to 38 weeks compared to those without CS-IFC. 
Elevated uterine artery resistance in the first and second trimester is associated with conditions of 
placental insufficiency, including FGR and PET.267,268 The rate of change in UtA-PI from 36 weeks’ 
gestation in low risk pregnancies, however, has not been reported previously. This study shows that 
amongst women who deliver by CS-IFC or Op-IFC, the UtA-PI rises faster from 36 weeks’ gestation 
to last assessment and 38 to 40 weeks’ gestation than uncomplicated deliveries. This finding suggests 
that deterioration in maternal-placental vascular resistance can occur from 36 weeks’ gestation and 
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indicates late onset placental dysfunction that manifests in labour as fetal compromise when the feto-
placental unit is tested to the greatest degree. 
EFW growth velocity is widely used in modern obstetrics as a measure of fetal well-being. In addition 
to earlier reports from at-risk populations,269,270 a recent study in low risk women showed that reduced 
growth velocity from 28 to 36 weeks’ gestation was associated with increased odds of cerebral 
redistribution, neonatal acidosis and lower neonatal body fat percentage.97 The findings of this Thesis 
show that babies with CNO experienced a declining EFWc from first to last assessment whilst babies 
without CNO had an increasing EFWc, which is consistent with these previous reports. Additionally, 
the rate of decline in EFWc for babies with CNO exceeded the rate of increase in EFWc for those 
without CNO in the present study. Whilst differences in EFWc were demonstrated between those with 
and without CNO, this was not the case for CS-IFC and Op-IFC. This may be due to a maximum 
intervening period in gestation of 4 weeks, unlike other studies that have compared EFWc from 
second to third trimester or from early to late in the third trimester. 
An estimated sample size of 390 women was calculated to detect a difference in the proportion of 
babies with vs. without CS-IFC for CPR <10th centile compared to those with CPR ≥10th centile. 
However, a total recruitment group after exclusions resulted in 437 women included for analysis, of 
which 18 were delivered with CS-IFC. A post hoc power calculation was performed on the study 
group to determine the actual power achieved in the study. Given that 55.6% of babies delivered by 
CS-IFC and 13.1% of babies not delivered by CS-IFC had a CPR <10th centile, a final power of 1.00 
was achieved in the study with an alpha of 0.05. Thus, sample size was sufficient to detect a difference 
in proportions between the CS-IFC outcome groups. 
Additionally, a post hoc power calculation was performed to determine the actual power achieved in 
the study for babies with CPR <10th centile compared to those with CPR ≥10th centile for the 
secondary outcomes, Op-IFC and CNO. Given that 0.3% and 33% of babies delivered without and 
with Op-IFC had CPR <10th centile, respectively, a final power of 1.00 with an alpha of 0.05 was 
achieved in the study. For the CNO outcome, 12% and 27% of babies delivered without and with 
CNO had CPR <10th centile, respectively, achieving a final power of 0.90 with an alpha of 0.05 in 
the study. Therefore, the sample size was sufficient to detect a difference in the proportion of babies 
with CPR <10th centile for the secondary outcomes. 
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Strengths of the study include the prospective study design and low risk profile of women in the 
study. These aspects enhance the generalisability to other low risk populations in high income 
countries. 
Bias may be present from the following sources. Firstly, although participation was offered to eligible 
women, selection bias may have occurred due to recognised differences between women who 
volunteer to participate in research compared to those who decline.252 A higher proportion of 
Caucasian women were present in the study population vs. women who delivered at the institution 
when similar inclusion criteria were applied, which may be attributed to a lack of interpreter 
availability to support this research. Nevertheless, the baseline characteristics of the study population 
otherwise closely reflect those of the institutional population, suggesting that the results from the 
study population are translatable to women in the institution. Misclassification bias is also possible 
for the CS-IFC and Op-IFC outcome groups as variation in classification by treating obstetric teams 
is possible. In an attempt to minimise classification bias, hospital charts were reviewed by a single 
experienced obstetrician and any discrepancies between records were addressed with cross-checking 
with electronic medical records and, where necessary, the treating obstetric team. A confounder in 
the study is the difference in clinical management of diabetic pregnancies. Women with diabetes are 
routinely recommended induction of labour from 39 weeks’ gestation. Thus, distribution of EFWc of 
the study cohort at 40 weeks’ gestation may be artificially altered. 
3.5 Conclusion 
In this chapter it has been shown that in low risk women from 36 weeks to delivery: 
1. The UA-PI, MCA-PI, CPR, cUVf and EFW decrease with advancing gestation, whilst the 
UtA-PI is stable 
2. The rate of change in CPR and UtA-PI is different between those with and without CS-IFC, 
Op-IFC and/or CNO  
3.  The rate of change in cUVf is different from first to last visit and 36 to 38 weeks’ gestation 
between those with and without CS-IFC 
4. There is a difference between MCA-PI, CPR, cUVf, UtA-PI and EFWc at last assessment for 
those with and without CS-IFC, Op-IFC and/or CNO  
The next chapter of this Thesis will explore if there is any change in circulating PlGF concentrations 
and/or association with CS-IFC, Op-IFC and/or CNO from 36 weeks’ gestation to delivery. 
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Chapter 4: Placental growth factor 
The material detailed in this chapter has been: 
a) Presented at the 2014 and 2016 UQ International Postgraduate Student Symposium, Brisbane 
b) Presented at the 2015 RCOG World Congress, Brisbane 
c) Presented at the 2016 PSANZ Annual Congress, Townsville 
d) Published in Placenta271 
4.1 Introduction 
PlGF, a biomarker of placental function, has been shown to be associated with pregnancy 
complications, particularly PET and placentally derived FGR and stillbirth. Early clinical 
studies185,189,272 of PlGF demonstrated good screening performance for PET onset prior to 35 weeks’ 
gestation, with sensitivities over 90% in women with suspected PET. PlGF screening performance 
for PET after 35 or 37 weeks’ gestation, have reported189,272 lower sensitivity (57% - 70%) than earlier 
onset disease. These studies have predominantly been conducted in high risk populations, such as 
those with suspected or confirmed FGR or SGA and are thus likely to result in inflated screening 
performance results compared to those achievable in a low risk cohort. Additionally, study designs 
have varied with regard to gestation of PlGF sampling and thresholds for normality, ranging from 
early in the second trimester185,273 through to term,40,185,189,272 and PlGF threshold for defining 
abnormality (<5th centile, <12 pg/mL and <100 pg/mL). These studies therefore lack generalisability 
to low risk populations at term. 
PlGF has also been investigated in association with FGR, stillbirth and adverse pregnancy outcome. 
Amongst fetuses with suspected FGR (AC <10th centile) and histopathologically confirmed placental 
dysfunction, PlGF <5th centile from 20 weeks’ gestation had very good screening performance, with 
sensitivity of 98.2% for a 24.9% FPR.274 With respect to stillbirths from impaired placentation, PlGF 
measured at 19 to 24 weeks’ gestation has been shown to increase sensitivity for stillbirths occurring 
≥37 weeks’ gestation by 12.2% (from 33.3% to 45.5%) for a fixed 5% FPR when combined with 
maternal factors, biometry and UtA-PI.275 For adverse pregnancy outcome (non-reassuring fetal 
status during labour and neonatal acidosis) amongst SGA pregnancies, PlGF measured at 30 to 40 
weeks’ gestation is lower in the adverse pregnancy outcome group compared to the normal outcome 
group. 40 However, PlGF has not been shown to provide improvement in screening performance 
compared to Doppler indices alone, with AUROC curves of 0.652 vs. 0.656, respectively. However, 
the interval between sampling and delivery outcomes in this study ranged from 4 - 26 days, a period 
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in which PlGF concentration could change significantly. Again, these studies have shown PlGF to be 
associated with adverse perinatal outcomes but have not explored its role in low risk term pregnancies 
for IFC. 
Chapter 2 (Methods) outlines the methods utilised in this chapter and chapter 3 (ultrasound data and 
outcomes) presents the results from the ultrasound component of the study. Briefly, a prospective, 
observational, panel study was undertaken on women with a singleton pregnancy and an 
uncomplicated antenatal course who were planning a vaginal delivery. This chapter investigates 
maternal PlGF levels, maternal characteristics and their associations with adverse intrapartum and 
neonatal outcomes in this low risk cohort. During the course of the study two PlGF assay platforms 
were used: Alere Triage and DELFIA Xpress. At study commencement, maternal PlGF levels were 
measured on the Alere Triage platform, followed by the DELFIA Xpress platform from halfway 
through the study, when the Alere Triage assay consumables became unavailable. Interim analysis 
demonstrated significant associations between maternal PlGF levels and study outcomes and 
screening performance for the Alere Triage platform. However, it was noted that less significant 
associations and poorer screening performance were evident after the transition to the DELFIA 
Xpress platform despite correction of assay results to permit comparison between platforms. Thus, 
sub-group analysis was performed to report results from the Alere platform in isolation for this 
chapter and chapter 5. The outcomes investigated in this chapter are consistent with those of chapter 
3 (i.e. CS-IFC, Op-IFC and CNO). 
4.1.1 Aims 
The aims of this chapter are: 
1. To describe the change in maternal PlGF levels from 36 weeks to delivery.  
2. To describe any difference between the rate of change in PlGF from 36 weeks to delivery for 
CS-IFC vs. all other deliveries, Op-IFC vs. all other deliveries and CNO vs. no CNO. 
3. To determine if there is any difference between PlGF measured within 2 weeks of delivery 
(last assessment) for CS-IFC vs. all other deliveries, Op-IFC vs. all other deliveries and CNO 
vs. no CNO. 
4.2 Methods 
Participants were recruited, assessed fortnightly and had outcome data collected according to methods 
described in chapter 2 of this Thesis. Thus, all references to PlGF made in this chapter refer to 
maternal PlGF levels.  
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The outcomes investigated in this chapter are: 
1. CS-IFC vs. all other deliveries 
2. Op-IFC vs. all other deliveries 
3. CNO vs. all other deliveries  
Exclusions were made in accordance with the protocol, as stated in chapter 2. Additionally, 
pregnancies complicated by severe urosepsis, shoulder dystocia and those with missing data (PlGF 
or intrapartum FHR) were excluded, as stated and explained in chapter 2, Methods.  
Analysis was performed for two cohorts; the Alere cohort and Full cohort. The Alere cohort had all 
assays performed on the Alere platform and is a sub-group of the Full cohort. The Full cohort refers 
to all women who participated in the study, after exclusions for missing data and maternal 
complications. The full cohort had assays performed on either the Alere or DELFIA Xpress platform. 
To permit direct comparison of PlGF concentrations between the two platforms in the Full cohort, 
parallel testing on the two platforms was performed on 50 samples and a correction algorithm 
calculated. Parallel testing was based on paired samples from 50 individuals, whereby two venous 
blood samples were collected from the same blood draw, the first in an EDTA tube and the second in 
a serum separator tube, and assays performed on the respective platforms as described in Chapter 2 
(Methods).  The correction algorithm was applied to the assays of women from the Alere platform 
prior to analysis as part of the Full cohort.  
For descriptive statistical testing, the methods used are as described in chapter 2. Longitudinal 
statistical analysis was performed by calculating the change in PlGF per day, as described and 
explained in chapter 3, Methods section. The rate of change between assessments (36 to 38 weeks’ 
gestation, 36 to 40 weeks’ gestation, 38 to 40 weeks’ gestation; and first to last assessment, 
irrespective of gestation), for each participant was calculated and reported, mirroring the analysis of 
ultrasound parameters in chapter 3. 
4.3 Results 
4.3.1 Full cohort 
Identical recruitment and study period results as reported in chapter 3 (section 3.3) also apply to this 
chapter. The only difference between the Full cohort reported here and the study cohort in chapter 3 
(Error! Reference source not found.) relates to exclusions for missing data. Specifically, two (2/45, 
4.4%) women were excluded in this chapter for missing PlGF data, both due to participant 
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withdrawal. No exclusions were made in this chapter for missing ultrasound data. Thus, the Full 
cohort for analysis included 438 women whilst the Alere cohort included 207 women.  
4.3.1.1.1 Maternal characteristics 
Overall, women who participated in the study were predominantly Caucasian, nulliparous, non-
smokers of approximately 30 years of age who had conceived spontaneously and had a BMI within 
the healthy weight range (Table 23).  
4.3.1.1.2 Inclusion and exclusion 
Maternal characteristics between women included and excluded from the study did not differ for 
nulliparity, maternal age, BMI, ethnicity, diabetes mellitus, chronic hypertension, ART, interval 
between assessment and labour or proportion with PlGF <5th centile at last assessment (Table 23). 
Women excluded from the study underwent last assessment and delivery earlier in gestation than 
women who were included in the final analysis. 
4.3.1.2 Full cohort 
A correction algorithm was calculated by the Director of Clinical Pathology based on samples from 
50 individuals using the Passing and Bablock regression analysis method276 and applied to the Alere 
results that were included in the Full cohort analysis. The correction algorithm was: 
ܦܧܮܨܫܣ	݌݃/݉ܮ ൌ ሺ0.93	ݔ	ܶݎ݅ܽ݃݁	݌݃/݉ܮሻ ൅ 38.0  
4.3.1.2.1 Distribution by gestation  
PlGF concentration was skewed at each fortnightly assessment, as demonstrated by the scatterplot in 
(Figure 31). Likewise, PlGF at the last assessment preceding delivery showed a skewed distribution. 
Thus, all cross-sectional analyses of PlGF were performed with non-parametric tests. Additionally, 
the rate of change in PlGF was predominantly skewed for comparisons between gestations and was 
therefore assessed with a non-parametric (Kruskal-Wallis rank-sum) test of association for all 
outcomes.
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Figure 31 PlGF concentration by gestation 
 
4.3.1.3 Centiles by gestation 
The PlGF centiles for each assessment are presented in Table 25. PlGF values decreased for each 
given centile with advancing gestation. 
4.3.1.4 Association with outcomes 
The median PlGF concentration at each fortnightly assessment, grouped by CS-IFC, Op-IFC and 
CNO outcome groups, are presented in Table 26. Median PlGF was not significantly different at any 
gestation when normal and adverse outcomes for CS-IFC were compared. Similarly, median PlGF 
concentration was not significantly different between normal and adverse Op-IFC groups for 36, 38 
and 40 weeks’ gestation. PlGF concentration was significantly higher at last assessment for babies 
born without vs. those born with Op-IFC (133.8 vs. 93.5 pg/mL, p = 0.01).  
Babies born without CNO had higher median PlGF concentration, compared to those with CNO, at 
all gestations. For babies born without CNO compared to those with CNO, the median PlGF was 
higher at 36, 38 and weeks’ gestation (204.9 vs. 146.8 pg/mL, p = 0.02; 149.2 vs. 103.1 pg/mL, p = 
0.002; and 138.8 vs. 86.4 pg/mL, p <0.001, respectively) and at last assessment preceding delivery 
(140.0 vs. 93.8 pg/mL, p <0.001). 
4.3.1.5 Rate of change 
PlGF levels decreased from first assessment to delivery in the DELFIA cohort (Table 27). The mean 
rate of change between 36, 38 and 40 weeks’ gestation, and all possible interval comparisons, varied 
from -26.2 to -7.2 pg/mL/day. 
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4.3.1.5.1 CS-IFC 
For babies delivered with and without CS-IFC, PlGF levels decreased for all gestation interval 
combinations (Table 27). The mean rate of change in PlGF for babies born without CS-IFC varied 
from -23.8 to -17.1 pg/mL per day, whilst the mean rate of decrease in PlGF for babies born by CS-
IFC varied from -25.8 to -7.2 pg/mL per day. No significant difference in the rate of change in PlGF 
between babies born with or without CS-IFC was demonstrated for any gestation interval 
combination. 
4.3.1.5.2 Op-IFC 
For babies delivered with and without Op-IFC, PlGF decreased for all gestation interval combinations 
(Table 27). The mean rate of change in PlGF for babies born without Op-IFC varied from -23.5 to -
16.7 pg/mL per day, whilst the mean rate of decrease in PlGF for babies born by Op-IFC varied from 
-26.2 to -15.1 pg/mL per day. No significant difference in the rate of change in PlGF between babies 
born with or without Op-IFC was demonstrated for any gestation interval combination. 
4.3.1.5.3 CNO 
For babies delivered with and without CNO, PlGF decreased for all gestation interval combinations 
(Table 27). The mean rate of change in PlGF for babies born without CNO varied from -24.4 to -20.7 
pg/mL per day, whilst the mean rate of decrease in PlGF for babies born by CNO varied from -19.9 
to -10.7 pg/mL per day. No significant difference in the rate of change in PlGF between babies born 
with or without CNO was demonstrated for any gestation interval combination. 
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Table 23 Maternal characteristics by inclusion and exclusion 
Characteristic  Total  Included  Excluded  p 
 (n=483) (n=438) (n=45)  
Nulliparous  420 (87.0) 382 (87.2) 38 (84.4) 0.60*
Maternal age (years) 30.0 (4.5) 29.9 (4.5) 29.9 (5.0) 0.99#
BMI 22.6 (20.9-25.8) 22.6 (20.9-25.8) 22.6 (20.7-26.9) 0.75^ 
Ethnicity                                                  Caucasian 304 (62.9) 271 (61.9) 33 (73.3) 0.26~ 
East Asian 85 (17.6) 77 (17.6) 8 (17.8) - 
Central Asian 48 (9.9) 45 (10.3) 3 (6.7) - 
Other 46 (9.5) 45 (10.3) 1 (2.2) - 
Diabetes mellitus 35 (7.3) 35 (8.0) 0 (0.0) - 
Chronic hypertension 1 (0.2) 1 (0.2) 0 (0.0) - 
Cigarette smoker 42 (8.7) 41 (9.4) 1 (2.3) 0.16~ 
ART 14 (3.0) 11 (2.6) 3 (6.8) 0.13~
Gestation at last assessment 38.4 (37.9-39.9) 38.4 (37.9-39.9) 38.1 (36.1-39.6) 0.006^
Days from last assessment to labour 8.0 (5.0-13.0) 8.0 (5.0-12.0) 9.0 (5.0-15.0) 0.35^ 
Days from last assessment to spontaneous labour 8.0 (5.0-12.0) 8.0 (5.0-12.0) 6.0 (4.0-13.0) 0.59^ 
Gestation at delivery 40.0 (39.1-40.9) 40.0 (39.1-40.9) 39.4 (38.7-40.3) 0.005^
PlGF <5th centile at last assessment 22 (4.6) 21 (4.8) 1 (2.4) 0.71~ 
Data presented as n (%), mean (SD) or median (IQR), as appropriate. * = Pearson’s chi squared test. # = Student’s t-test. ^ = Kruskall-Wallis equality-of-
populations rank test. ~ = Fisher’s exact test. 
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Table 24 Maternal characteristics by outcomes (DELFIA cohort) 
Characteristic Overall  CS-IFC Op-IFC CNO 
             
(n=438) 
Absent 
(n=420) 
Present  
(n=18) 
p Absent 
(n=355) 
Present  
(n=83) 
p Absent 
(n=352) 
Present  
(n=86) 
p 
Nulliparous  382 (87.2) 365 (86.9) 17 (94.4) 0.49* 303 (85.4) 79 (95.2) 0.02* 301 (85.5) 81 (94.2) 0.03* 
Maternal age 29.9 (4.5) 29.9 (4.5) 29.2 (4.3) 0.49# 29.8 (4.6) 30 (4.0) 0.72# 29.8 (4.5) 30.3 (4.4) 0.34# 
BMI 22.6 (20.9-
25.8) 
22.6 (20.9-
25.7) 
22.7 (20.5-
26.7) 
0.89^ 22.6 (20.9-
25.8) 
22.6 (20.7-
25.8) 
0.85^ 22.7 (20.9-
25.8) 
22.4 (20.8-
25.3) 
0.69^ 
Ethnicity        Caucasian 271 (61.9) 260 (61.9) 11 (61.1) 0.28~ 220 (62.0) 51 (61.5) 0.53~ 216 (61.4) 55 (64.0) 0.38~ 
East Asian 77 (17.6) 76 (18.1) 1 (5.6) - 64 (18.0) 13 (15.7) - 67 (19.0) 10 (11.6) - 
Central Asian 45 (10.3) 42 (10.0) 3 (16.7) - 33 (9.3) 12 (14.5) - 35 (9.9) 10 (11.6) - 
Other 45 (10.3) 42 (10.0) 3 (16.7) - 38 (10.7) 7 (8.4) - 34 (9.7) 11 (12.8) - 
Diabetes mellitus 35 (8.0) 35 (8.3) 0 (0.0) - 33 (9.3) 2 (2.4) 0.04~ 33 (9.4) 2 (2.3) 0.03~ 
Chronic hypertension 1 (0.2) 1 (0.2) 0 (0.0) - 1 (0.3) 0 (0.0) - 1 (0.3) 0 (0.0) - 
Cigarette smoker 41 (9.4) 40 (9.5) 1 (5.6) 1.0~ 35 (9.9) 6 (7.2) 0.54* 34 (9.7) 7 (8.1) 0.67* 
ART 11 (2.6) 11 (2.7) 0 (0.0) - 11 (3.2) 0 (0.0) - 10 (2.9) 1 (1.2) 0.70~ 
Gestation at assessment 38.4 (37.9-
39.9) 
38.4 (37.9-
39.9) 
39.1 (38.3-
40.1) 
0.07^ 38.4 (37.7-
39.9) 
39.3 (38.1-
40.0) 
0.002^ 38.4 (37.7-
39.9) 
39.2 (38.3-
40.1) 
<0.001^ 
Interval to labour 8.0 (5.0-12.0) 8.0 (5.0-13.0) 6.5 (2.0-10.0) 0.11^ 8.0 (5.0-13.0) 8.0 (5.0-11.0) 0.19^ 8.0 (5.0-13.0) 8.0 (5.0-11.0) 0.39^ 
Interval to labour 
(spont) 
8.0 (5.0-12.0) 8.0 (5.0-12.0) 6.0 (4.0-11.0) 0.52^ 8.0 (5.0-13.0) 8.0 (5.0-11.0) 0.34^ 8.0 (4.5-12.5) 9.0 (5.0-12.0) 0.52^ 
Gestation at delivery 40.0 (39.1-
40.9) 
40.0 (39.1-
40.9) 
40.4 (39.6-
40.9) 
0.31^ 40.0 (39.1-
40.9) 
40.3 (39.4-
41.1) 
0.01^ 40.0 (39.1-
40.7) 
40.5 (39.6-
41.1) 
<0.001^ 
BW <10th centile 13 (3.0) 12 (2.9) 1 (5.6) 0.43~ 8 (2.3) 5 (6.0) 0.08~ 8 (2.3) 5 (5.8) 0.15~ 
PlGF ≤5th centile 21 (4.8) 19 (4.5) 2 (11.1) 0.21~ 14 (3.9) 7 (8.4) 0.09~ 17 (4.8) 4 (4.7) 1.00~ 
Gestation at assessment = weeks’ gestation at last assessment preceding delivery. Interval to labour = days from last PlGF assessment to labour. Interval to labour (spont) = days from 
last PlGF assessment to spontaneous labour. Gestation at delivery = weeks’ gestation at delivery. Data presented as n (%), mean (SD) or median (IQR), as appropriate. * = Pearson’s 
chi squared test. # = Student’s t-test. ^ = Kruskall-Wallis equality-of-populations rank test. ~ = Fisher’s exact test.  
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Table 25 PlGF centiles by gestation (DELFIA cohort) 
Gestation n Centile 
  5th 10th 25th 50th 75th 90th 95th 
36 weeks 416 62.6 70.2 101.0 195.2 409.4 803.4 1340.0 
38 weeks 363 50.0 60.2 84.7 139.4 258.4 527.2 899.2 
40 weeks 162 51.0 59.3 77.0 117.6 212.1 351.4 503.9 
Last assessment 438 49.8 57.5 78.2 125.8 241.7 477.0 790.4 
PlGF concentration presented as pg/mL. 
 
Table 26 PlGF by gestation and outcomes (DELFIA cohort) 
Gestation CS-IFC Op-IFC CNO 
 Absent Present p^ Absent Present p^ Absent Present p^ 
36 weeks 195.2 (101.0-410.9) 190.8 (101.7-389.0) 0.84 195.7 (106.6-408.7) 190.0 (83.9-478.1) 0.41 204.9 (106.8-455.3) 146.8 (88.6-292.8) 0.02 
38 weeks 139.4 (85.8-266.2) 118.3 (82.5-152.9) 0.23 141.2 (89.2-264.9) 113.1 (74.5-249.1) 0.13 149.2 (90.6-283.4) 103.1 (75.9-181.2) 0.002 
40 weeks 119.8 (78.0-221.0) 86.6 (61.9-128.1) 0.11 125.0 (77.0-212.1) 95.7 (73.3-262.7) 0.30 138.7 (83.0-241.1) 86.4 (63.7-124.1) <0.001 
Last assessment 127.2 (78.3-248.6) 99.4 (71.5-152.9) 0.10 133.8 (82.6-243.5) 93.5 (67.4-207.0) 0.01 140.0 (83.2-264.3) 93.8 (65.6-128.1) <0.001 
Data presented as median (IQR), pg/mL. ^ = Kruskall-Wallis equality-of-populations rank test. 
 
Table 27 Rate of change in PlGF by outcomes (DELFIA cohort) 
Gestation Overall CS-IFC Op-IFC CNO 
 n pg/mL/day Absent Present p^ Absent Present p^ Absent Present p^ 
First to last  361 -21.0 (-66.1- -3.6) -21.0 (-67.8- -3.8) -20.8 (-60.7- -2.5) 0.98 -21.4 (-66.1- -4.0) -18.5 (-74.6- -3.6) 0.92 -23.9 (-75.1- -3.5) -17.4 (-44.3- -4.3) 0.17 
36 - 40 weeks 146 -23.8 (-62.3- -7.0) -23.8 (-62.7- -7.0) -24.6 (-50.2- -4.0) 0.75 -23.5 (-59.8- -7.6) -26.2 (-68.2- -4.9) 0.84 -24.4 (-67.8- -6.9) -19.9 (-45.8- -7.2) 0.42 
36 - 38 weeks 340 -20.2 (-79.1- -1.3) -20.0 (-78.1- -1.5) -25.8 (-110.1- 1.1) 0.75 -20.2 (-77.4- -0.7) -21.6 (-93.2- -3.1) 0.81 -20.7 (-86.7- -1.2) -19.6 (-56.5- -2.6) 0.39 
38 - 40 weeks 151 -16.0 (-47.8- -2.5) -17.1 (-47.8- -2.7) -7.2 (-41.8- -2.5) 0.60 -16.7 (-45.4- 0.1) -15.1 (-60.0- -2.6) 0.75 -23.0 (-62.0- -2.5) -10.7 (-31.8- -1.7) 0.14 
Rate of change presented in pg/mL/day, median (IQR). ^ = Kruskall-Wallis equality-of-populations rank test.
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4.3.2 Alere cohort 
4.3.2.1 Maternal characteristics 
The maternal characteristics of the Alere study population, overall and by outcome group, are 
presented in Table 28. For women who delivered by CS-IFC, the interval in days between last 
assessment and delivery was shorter than for those who did not deliver by CS-IFC, although this 
difference no longer existed when women who underwent induction were excluded from the analysis.  
For women who delivered by Op-IFC, a higher proportion were nulliparous than those without Op-
IFC (Table 28). Additionally, women who delivered by Op-IFC had a shorter interval between last 
assessment and labour, and delivered a higher proportion of SGA infants compared to those delivered 
without Op-IFC. 
A higher proportion of babies born with CNO were born to nulliparous women than those without 
CNO (Table 28). Additionally, babies born with CNO underwent final assessment and were delivered 
later in gestation than those babies delivered without CNO. 
4.3.2.2 Distribution by gestation 
PlGF concentration was skewed at each fortnightly assessment (Figure 32), and at the last assessment 
preceding delivery. Additionally, the rate of change in PlGF was skewed for each gestation interval 
comparison and was therefore assessed with a non-parametric (Kruskal-Wallis rank-sum) test of 
association for all outcomes (Table 31). 
4.3.2.3 Centiles by gestation 
The PlGF concentration for each assessment from the 5th to 95th centiles are presented in Table 29. 
PlGF values decreased for each given centile with advancing gestation. 
4.3.2.4 Association with outcomes 
The median PlGF concentration at each assessment, grouped by CS-IFC, Op-IFC and CNO outcome 
groups, are presented in Table 30. For babies born with CS-IFC, PlGF was significantly lower at 38, 
40 weeks’ gestation and at last assessment preceding delivery compared to those without CS-IFC 
(Table 30). For babies born with Op-IFC, PlGF was significantly lower at 38 weeks’ gestation and at 
last assessment preceding delivery compared to those without Op-IFC (Table 30). For babies born 
with CNO, PlGF levels were lower at 38 weeks’ gestation and at last assessment preceding delivery 
compared to those without CNO (Table 30). 
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Table 28 Maternal characteristics by outcomes (Alere cohort) 
Characteristic Overall CS-IFC Op-IFC CNO 
  Absent  Present  p Absent  Present  p Absent  Present  p 
 (n=207) (n=207) (n=7)  (n=168) (n=39)  (n=166) (n=41)  
Nulliparous  164 (79.2) 158 (79.0) 6 (85.7) 1.0* 128 (76.2) 36 (92.3) 0.03* 126 (75.9) 38 (92.7) 0.02* 
Maternal age 30.0 (4.5) 29.6 (4.2) 29.7 (4.4) 0.93# 29.5 (4.3) 29.8 (3.7) 0.70# 29.4 (4.2) 30.3 (4.4) 0.23# 
BMI 22.7 (21.1-
26.0) 
22.7 (21.2-
26.0) 
20.7 (18.7-
23.9) 
0.15^ 22.7 (21.1-
26.0) 
23.7 (21.4-
26.5) 
0.79^ 22.7 (21.1-
26.0) 
22.4 (21.5-
25.3) 
0.69^ 
Ethnicity         Caucasian 133 (64.3) 129 (64.5) 4 (57.1) 0.72~ 111 (66.1) 22 (56.4) 0.31* 109 (65.7) 24 (58.5) 0.16~ 
East Asian 33 (15.9) 32 (16.0) 1 (14.3) - 27 (16.1) 6 (15.4) - 29 (17.5) 4 (9.8) - 
Central Asian 17 (8.2) 16 (8.0) 1 (14.3) - 11 (6.6) 6 (15.4) - 12 (7.2) 5 (12.2) - 
Other 24 (11.6) 23 (11.5) 1 (14.3) - 19 (11.3) 5 (12.8) - 16 (9.6) 8 (19.5) - 
Diabetes mellitus 0 (0.0) 0 (0.0) 0 (0.0) - 0 (0.0) 0 (0.0) - 0 (0.0) 0 (0.0) - 
Chronic hypertension 0 (0.0) 0 (0.0) 0 (0.0) - 0 (0.0) 0 (0.0) - 0 (0.0) 0 (0.0) - 
Cigarette smoker 19 (9.2) 19 (9.5) 0 (0.0) - 17 (10.1) 2 (5.1) 0.54~ 18 (10.8) 1 (2.4) 0.10~ 
ART 6 (3.0) 6 (3.1) 0 (0.0) - 6 (3.7) 0 (0.0) - 6 (3.7) 0 (0.0) - 
Gestation at assessment 38.7 (38.0-
40.0) 
38.7 (37.9-
40.0) 
39.4 (38.3-
40.0) 
0.38^ 38.6 (37.9-
40.0) 
39.3 (38.1-
40.1) 
0.08^ 38.6 (37.9-
40.0) 
39.7 (38.1-
40.1) 
<0.03^ 
Interval to labour 9.0 (5.0-13.0) 8.0 (5.0-13.0) 6.5 (2.0-10.0) 0.02^ 9.0 (5.0-14.0) 7.0 (5.0-10.0) 0.04^ 9.0 (5.0-14.0) 9.0 (5.0-11.0) 0.55^ 
Interval to labour 
(spont) 
8.0 (5.0-12.0) 8.0 (5.0-13.0) 5.5 (4.5 -8.0) 0.27^ 8.0 (5.0-13.0) 8.0 (5.0-10.0) 0.76^ 8.0 (5.0-13.0) 9.0 (5.0-11.0) 0.69^ 
Gestation at delivery 40.3 (39.4-
41.1) 
40.2 (39.4-
41.1) 
40.3 (39.4-
40.4) 
0.50^ 40.2 (39.4-
41.1) 
40.3 (39.4-
41.3) 
0.57^ 40.1 (39.3-
41.0) 
40.6 (39.6-
41.3) 
<0.02^ 
BW <10th centile 10 (4.8) 9 (4.5) 1 (14.3) 0.30~ 5 (3.0) 5 (12.8) 0.02~ 7 (4.2) 3 (7.3) 0.42~ 
PlGF ≤5th centile 7 (3.4) 6 (3.0) 1 (14.3) 0.22~ 4 (2.4) 3 (7.7) 0.12~ 6 (3.6) 1 (2.4) 1.00~ 
Gestation at assessment = weeks’ gestation at last assessment preceding delivery. Interval to labour = days from last PlGF assessment to labour. Interval to labour 
(spont) = days from last PlGF assessment to spontaneous labour. Gestation at delivery = weeks’ gestation at delivery. Data presented as n (%), mean (SD) or median 
(IQR), as appropriate. * = Pearson’s chi squared test. # = Student’s t-test. ^ = Kruskall-Wallis equality-of-populations rank test. ~ = Fisher’s exact test. 
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Figure 32 PlGF concentration by gestation (Alere cohort) 
 
 
4.3.2.5 Rate of change 
PlGF decreased with advancing gestation in the Alere cohort (Table 31). The mean rate of change 
varied from -32.6 to -4.0 pg/mL per day across the DELFIA cohort for all possible gestation interval 
combinations. 
4.3.2.5.1 CS-IFC 
For babies delivered with and without CS-IFC, PlGF decreased for all gestation interval combinations 
(Table 31). The mean rate of change in PlGF for babies born without CS-IFC varied from -32.6 to -
25.5 pg/mL per day, whilst the mean rate of change in PlGF for babies born by CS-IFC varied from 
-13.4 to -4.0 pg/mL per day. No significant difference was demonstrated in the rate of change in PlGF 
between babies born with or without CS-IFC for any gestation interval combination. 
4.3.2.5.2 Op-IFC 
For babies delivered with and without Op-IFC, PlGF decreased with advancing gestation (Table 31). 
The mean rate of change in PlGF for babies born without Op-IFC varied from -29.7 to -25.2 pg/mL 
per day, whilst the mean rate of change in babies born with Op-IFC varied from -31.7 to -5.4 pg/mL 
per day. No significant difference in the rate of change in PlGF between babies born with or without 
Op-IFC was demonstrated for any gestation interval combination. 
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4.3.2.5.3 CNO 
For babies delivered with and without CNO, PlGF concentration decreased with advancing gestation 
(Table 31). For babies born without CNO, the mean rate of change varied from -31.9 to -21.7 pg/mL 
per day, whilst the mean rate of change for those born with CNO varied from -31.8 to -5.4 pg/mL per 
day. The rate of change in PlGF was not significantly different for those with and without CNO for 
any gestation interval combination.  
Table 29 Centiles for PlGF concentration by gestation (Alere cohort) 
Gestation n Centiles 
  5th 10th 25th 50th 75th 90th 95th 
36 weeks 192 27.9 37.2 74.2 186.5 576.0  1200.0 1750.0 
38 weeks 173 15.8 24.8 46.4 117.0 345.0 860.0 1370.0 
40 weeks 86 18.6 27.2 44.0 82.3 158.0 468.0   697.0 
Last assessment 207 15.8 23.9 44.0 94.8 266.0 697.0 1090.0 
PlGF concentration presented in pg/mL. 
4.4 Discussion 
The results presented in this chapter show that in otherwise low-risk pregnancies, PlGF levels are 
lower in women whose infants experience CNO (acidosis, low Apgar score or NICU admission). 
Additionally, the rate of change in PlGF does not differ in low risk women who deliver infants with 
CS-IFC, Op-IFC or CNO from those women without these complications. 
Published results from this study271 (n=342) showed that PlGF concentrations were lower amongst 
pregnancies that resulted in adverse intrapartum or neonatal outcomes. The outcomes reported 
included Op-IFC, suspicious or pathological intrapartum fetal heart rate pattern, abnormal umbilical 
artery cord gases (pH ≤7.1 and/or lactate ≥6mmol/L), Apgar score ≤7 at 5 minutes and a composite 
adverse neonatal outcome. Further analysis of this cohort with SGA babies excluded (BW <10th 
centile) demonstrated that these associations persisted in the AGA cohort. 
The results presented from this study support the theory that subtle placental dysfunction, reflected 
by lower PlGF, is associated with poorer intrapartum and neonatal outcomes in low risk women up 
to two weeks prior to labour. These are novel findings that have not previously been reported. 
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Table 30 PlGF by gestation and outcomes (Alere cohort) 
Gestation CS-IFC Op-IFC CNO 
 Absent Present p^ Absent Present p^ Absent Present p^ 
36 weeks 191 (78-588) 44 (43-152) 0.12 192 (102-587) 121 (43-456) 0.08 194 (83-648) 161 (58-378) 0.24 
38 weeks 121 (47-357) 48 (25-81) 0.02 125 (60-351)   55 (39-185) 0.03 127 (57-373)   80 (39-172) 0.02 
40 weeks   89 (44-159) 35 (19-54) 0.03   94 (47-158)   51 (43-93) 0.07   94 (45-190)   62 (28-99) 0.08 
Last assessment 101 (44-270) 45 (25-62) 0.01 114 (52-278)   51 (28-93) 0.002 116 (47-283)   60 (28-93) 0.004 
PlGF concentration presented in pg/mL, median (IQR). ^ =Kruskall-Wallis equality-of-populations rank test. 
 
 
Table 31 Rate of change in PlGF (Alere cohort) 
Gestation Overall CS-IFC Op-IFC CNO 
 n pg/mL/day Absent Present p^ Absent Present p^ Absent Present p^ 
First to last  173 -26.1 (-85.1- -3.7) -28.1 (-85.2- -3.8) -4.4 (-22.4- 0.0) 0.14 -27.5 (-88.4- -3.7) -13.2 (-80.6- -3.4) 0.38 -26.8 (-85.2- -3.3) -24.0 (-82.8- -5.4) 0.80 
36 to 40 weeks 76 -31.0 (-75.4- -8.0) -32.6 (-76.1- -8.2) -13.4 (-22.4- -4.4) 0.31 -29 .7 (-74.8- -10.3) -31.7 (-80.6- -4.4) 0.82 -31.9 (-74.8- -7.8) -30.0 (-80.6- -8.2) 0.98 
36 to 38 weeks 158 -26.0 (-112- -2.7) -26.8 (-112.0- -2.7) -4.9 (-27.7- -3.3) 0.55 -25.2 (-112.0- -1.3) -27.7 (-107.5- -3.4) 1.0 -21.7 (-115.0- -1.1) -31.8 (-90.2- -4.3) 0.70 
38 to 40 weeks 81 -20.7 (-59.0- -0.5) -25.5 (-71.0- -0.45) -4.0 (-11.3- -1.3) 0.22 -25.9 (-73.3- -3.0) -5.4 (-39.0- -0.0) 0.44 -26.4 (-75.7- -3.0) -5.4 (-38.6- 0.1) 0.17 
Rate of change presented in pg/mL/day, median (IQR). ^ = Kruskall-Wallis equality-of-populations rank test. 
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Interestingly, PlGF was not significantly lower when pregnancies with CS-IFC and Op-IFC were 
compared to those without CS-IFC and Op-IFC at each fortnightly interval when assessed cross-
sectionally in isolation. However, PlGF was lower amongst Op-IFC deliveries when only the last 
PlGF concentration prior to delivery was evaluated. The pattern of difference in these results may be 
attributable to several influences. Firstly, the sample size at the fortnightly assessments, when 
analysed cross-sectionally in isolation, is insufficient to demonstrate a difference in PlGF between 
women with and without CS-IFC. Post hoc power calculations (alpha 0.05, power 0.8) indicated 
prohibitive sample sizes (>100 000 women) for assessment at 36 and 38 weeks’ gestation, and 1274 
and 2668 women at 40 weeks’ gestation to demonstrate a difference for the CS-IFC and Op-IFC 
outcomes, respectively. Secondly, placental function in the period between assessment and labour is 
unknown and may deteriorate without detection by the assessment schedule used in this study. Lastly, 
it is possible that no difference in PlGF exists between pregnancies complicated by CS-IFC and Op-
IFC compared to those without in cross-sectional analyses. 
Although PlGF has been previously shown to be predictive of pre-term PET and FGR, the association 
with adverse intrapartum and neonatal outcomes has not been reported from low risk populations at 
term. In the only other study of PlGF in late pregnancy and its association with intrapartum 
outcomes,40 SGA pregnancies from 30 to 40 week’s gestation had PlGF prospectively measured and 
showed that PlGF was associated with Op-IFC and PET. Whilst Lobmaier’s study demonstrated an 
association between PlGF and Op-IFC, the assessment of an at-risk cohort and earlier gestation at 
assessment are significant points of difference with the current study. A study population with a 
higher disease prevalence is likely to demonstrate a stronger screening performance than a population 
with a low prevalence.277 
In a multicentre study of PlGF and placental FGR by Benton et al.,274 pregnancies from 20 to 40 
weeks’ gestation with suspected FGR and an absence of PET or hypertension had PlGF assessed at 
enrolment and histological placental assessment at delivery to confirm cases of placentally derived 
FGR. This study showed that low PlGF (<5th centile) was associated with placental FGR and 
performed favourably as a screening test (AUROC 0.96). Benton’s study overlaps with the current 
study with regard to gestation at assessment but differs substantially in terms of risk profile and 
gestation. Nevertheless, results reported in this chapter are broadly in keeping with Lobmaier’s and 
Benton’s studies which show that lower PlGF is associated with impaired placental function and 
adverse clinical outcomes. Significantly, this study associates low maternal PlGF with intrapartum 
and neonatal complications, even in a low risk population at term. 
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The rate of change in PlGF from 36 week’s gestation in low risk pregnancies has not been reported 
previously. This chapter reports that the rate of change in PlGF is not significantly different between 
those with and without CS-IFC, Op-IFC or CNO, regardless of gestation interval used for assessment. 
This finding, coupled with the cross-sectional results, suggests that levels of PlGF in those with the 
adverse outcomes (Op-IFC and CNO) are lower and this is evident from 36 weeks’ gestation through 
to delivery for CNO and at final assessment preceding delivery for Op-IFC. This pattern of difference 
is in keeping with that observed with PlGF in other studies of PET,185,189 where PlGF has been 
demonstrated to be lower throughout pregnancy. 
The results obtained on the two different PlGF assay platforms presented in this chapter raise 
discussion points. The Alere Triage and DELFIA platforms both measure isoform 1 of PlGF via use 
of an antibody and use of fluoroimmunometric technology. However, the Alere platform uses a single 
antibody, plasma from an anticoagulated blood sample and a manual system for delivery of the 
plasma to the test cartridge. In contrast, the DELFIA platform uses two antibodies, serum from a 
clotted blood sample and an automated system to measure and deliver the serum in the test procedure. 
The results between the two systems are not directly comparable. Although a correction algorithm 
was created to allow direct comparison of these adjusted results, variation between the actual result 
and the adjusted result were evident. Lastly, the smaller sample size in the Alere cohort analysis 
compared to the DELFIA cohort analysis (207 vs. 438 women) raises the possibility of a Type 1 
statistical error. That is, the Alere cohort analysis demonstrated difference in PlGF concentration 
between the three outcome groups (CS-IFC, Op-IFC and CNO), whilst the DELFIA cohort analysis 
showed difference only for the CNO outcome groups. Thus, rejecting the null hypothesis for the Alere 
group analysis, that no difference exists between CS-IFC and Op-IFC outcome groups, may represent 
a Type 1 error, perhaps due to insufficient sample size in that cohort. Conversely, the DELFIA cohort 
may be falsely supporting the null hypothesis due to the dilution effect of using two different PlGF 
assay platforms, despite applying a correction algorithm to standardise the results. 
4.5 Conclusion 
In this chapter it has been shown that in low risk women from 36 weeks’ gestation to delivery: 
1. PlGF concentration decreases with advancing gestation 
2. The rate of change in PlGF concentration does not differ in pregnancies with and without CS-
IFC, Op-IFC and/or CNO 
3. In the Full cohort: 
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a. PlGF concentration is lower at last assessment for babies delivered by Op-IFC 
compared to those without Op-IFC 
b. PlGF concentration is lower at all gestations for babies born with CNO compared to 
those without CNO 
4. In the Alere cohort: 
a. PlGF concentration is lower at 38 weeks’ and 40 weeks’ gestation and at last 
assessment in those with CS-IFC compared to those without CS-IFC 
b. PlGF concentration is lower at 38 weeks’ gestation and at last assessment in those with 
Op-IFC and/or CNO compared to those without Op-IFC and/or CNO 
The following chapter will assess the screening performance of ultrasound parameters and PlGF that 
have shown association with CS-IFC, Op-IFC and CNO in chapter 3 and this chapter.  
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Chapter 5: Screening performance of ultrasound parameters 
and placental growth factor 
The material detailed in this chapter has been: 
a) Presented at the 2016 ISUOG World Congress, Rome 
b) Presented at the 2016 UQ International Postgraduate Student Symposium, Brisbane 
c) Presented at the 2017 QPaCT Conference, Brisbane 
d) Published in the Journal of Ultrasound in Obstetrics and Gynecology137 
e) Published in the Journal of Fetal Diagnosis and Therapy136 
f) Published in the Journal of Maternal-Fetal and Neonatal Medicine278 
g) Published in the Journal of Fetal Diagnosis and Therapy279 
5.1 Introduction 
Spectral Doppler ultrasound indices and PlGF have been shown to be associated with adverse 
intrapartum and neonatal outcomes arising from placental dysfunction. Chapter 3 of this Thesis also 
demonstrated association between various Doppler parameters (MCA-PI, CPR, cUVf and UtA-PI) 
and perinatal outcomes (CS-IFC, Op-IFC and CNO). Other studies have investigated the screening 
potential of ultrasound parameters for the detection of placentally mediated conditions, such as pre-
eclampsia,280 gestational hypertension186 and/or growth restriction.150 However, these previous 
studies have investigated at-risk populations in the first or second trimester of pregnancy.  
Additionally, chapter 4 of this Thesis demonstrated association between PlGF and Op-IFC (last 
assessment) and CNO in the DELFIA cohort, and with CS-IFC, Op-IFC and CNO outcomes for the 
Alere cohort. As the results from the PlGF assay platforms differed, screening performance was 
investigated for both cohorts in this chapter. For both the ultrasound and PlGF parameters reported 
in this Thesis, irrespective of assay platform, associations with outcomes were most frequent at the 
last assessment preceding delivery. Thus, this chapter investigates these associations at last 
assessment preceding delivery further, testing the screening performance of the associated parameters 
identified in chapters 3 and 4 of this Thesis. 
Fetal and maternal Doppler parameters and PlGF concentration are known to change over the course 
of gestation.102,109,185,237,281 As the women in the study underwent last assessment preceding delivery 
at a range of gestations, direct comparison of unadjusted variables between women may falsely report 
associations, or lack thereof. Thus, two gestation adjustment methods were used, regression and 
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centile adjustment, in addition to raw values for investigation of relationships between parameters 
and outcomes. 
5.1.1 Aims 
The aims of this chapter are: 
1. To describe the screening performance of different combinations of ultrasound parameters 
associated with CS-IFC, Op-IFC and CNO identified in chapter 3 of this Thesis 
2. To describe the screening performance of PlGF in the DELFIA cohort study and Alere cohorts 
to detect CS-IFC, Op-IFC and CNO 
3. To describe the combined screening performance of ultrasound parameters and PlGF for the 
detection of CS-IFC, Op-IFC and CNO. 
5.2 Methods 
The Alere cohort is a sub-group of the DELFIA cohort study. The methods described in chapter 2 
detail the measurement, collection and analysis of ultrasound and PlGF data used in this chapter. This 
chapter utilises results from chapters 3 (ultrasound) and 4 (PlGF) that demonstrated significant 
associations of the predictor at last assessment preceding delivery with CS-IFC, Op-IFC and CNO. 
The analysis was performed in parallel for the study and Alere cohorts, as described in chapter 4, 
section 4.2.  
Correlation between predictors was assessed with Spearman’s rank correlation test to identify 
potentially confounding influences between predictors. Spearman’s rho exceeding 0.5 was selected 
as a useful threshold for identification of moderate, or higher, correlation.282 The screening 
performance was then tested and reported using logistic regression (odds ratio, 95% confidence 
interval, p value) for each predictor in isolation and in combined models. The reference groups for 
odds ratio reporting were those pregnancies with the absence of the adverse outcomes (CS-IFC, Op-
IFC and CNO).  Multiple logistic regression models, for variables with p≤0.20, were tested with 
backwards stepwise regression analysis in order to add back significant variables if they were later 
identified as significant. Comparison between AUROC curve models was performed using Stata’s 
“roccomp” command. Consistent with previous statistical analysis in this Thesis, a significance level 
of 0.05 was selected for both inclusion and exclusion for the backwards stepwise regression models. 
Gestation adjustment was applied by two methods; logistic regression using gestation at assessment 
as a covariate, and centiles created internally from data for uncomplicated pregnancies in the study 
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as described in Section 2.10, Methods, using the absolute residuals method. The term ‘gestation 
adjustment’ is used to distinguish between the raw values (unadjusted for gestational change) and 
those which account for gestation related change (regression or percentile adjustment). 
Additionally, the relationship between predictors that demonstrated significant associations on 
univariate analysis with CS-IFC, Op-IFC and/or CNO were then assessed at commonly applied 
thresholds (UA-PI >95th centile, MCA-PI <5th centile, CPR <5th and <10th centiles, UtA-PI >95th 
centile, PlGF <5th centile and EFW <10th centile). Instances where analysis was performed using 
thresholds is stated as such. All other analysis was performed with continuous data. 
5.3 Results 
Of the 483 women recruited to the study, 378 were eligible for inclusion in the final analysis for the 
DELFIA cohort study and 185 in the Alere cohort. Exclusions were made for missing data as per the 
results in chapters 3 and 4. Additionally, for the DELFIA cohort study 5 women were excluded due 
to missing ultrasound (CPR, cUVf, UtA-PI) and/or PlGF data (n=3 and n=2, respectively). For the 
Alere cohort reported in this chapter compared to that reported in chapter 4, 22 additional women 
were excluded due to missing Doppler and centile data (n=7 and n=15, respectively). The participant 
flow diagram for the study and Alere cohorts are presented in Figure 33 and Figure 34, respectively. 
 
Figure 33 Participant flow diagram (DELFIA cohort) 
 
483 women 
recruited
378 women 
included
363 non CS‐
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exclusions
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Figure 34 Participant flow diagram (Alere cohort) 
 
 
5.3.1 Maternal characteristics 
The study and Alere cohorts in this chapter were derived from the same group of women as reported 
in chapters 3 and 4, and therefore closely reflect maternal characteristics reported in those chapters. 
Minor differences in the cohorts arise from missing data. Specifically, missing data for CPR (3/483, 
0.6%) and PlGF (2/483, 0.4%) in the DELFIA cohort study, and missing Doppler and centile data 
(7/483, 1.4% and 15/483, 3.1%, respectively) in the Alere cohort.  
Associations between commonly used clinical thresholds for ultrasound parameters, PlGF, EFW, BW 
and study outcomes for the study and Alere cohorts are presented in Table 32 and Table 33, 
respectively. For the CS-IFC outcome, there were associations with MCA-PI <5th centile, CPR <5th 
and <10th centiles in both cohorts. For Op-IFC, both cohorts again demonstrated association with 
MCA-PI <5th centile, CPR <5th and <10th centiles, and also with UtA-PI >95th centile. Additionally, 
the Alere cohort demonstrated an association between Op-IFC and BW <10th centile. For the CNO 
outcome, both cohorts showed association with MCA-PI <5th and CPR <5th centiles, whilst the 
DELFIA cohort also showed association with CPR <10th centile and UtA-PI >95th centile. 
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Table 32 Maternal characteristics and screening parameters by outcomes (DELFIA cohort) 
Characteristic Overall  CS-IFC Op-IFC CNO 
  Absent  Present  p Absent  Present  p Absent  Present  p 
 (n=378) (n=363) (n=15)  (n=303) (n=75)  (n=303) (n=75)  
Nulliparous  330 (87.3) 316 (87.1) 14 (93.3) 0.70* 259 (85.5) 71 (94.7) 0.03* 259 (85.5) 71 (94.7) 0.03* 
Maternal age 30.0 (4.4) 29.9 (4.4) 29.5 (4.6) 0.72# 29.8 (4.6) 30.1 (3.8) 0.63# 29.7 (4.4) 30.5 (4.3) 0.21# 
BMI 22.6 (20.9-
25.7) 
22.6 (20.9-
25.7) 
23.0 (20.3-
26.7) 
0.92^ 22.5 (20.9-
25.7) 
23.5 (20.8-
26.1) 
0.34^ 22.7 (20.9-
25.8) 
22.2 (20.8-
25.2) 
0.44^ 
Ethnicity      Caucasian 233 (61.6) 224 (61.7) 9 (60.0) 0.35~ 187 (61.7) 46 (61.3) 0.53* 184 (60.7) 49 (65.3) 0.64* 
East Asian 70 (18.5) 69 (19.0) 1 (6.7) - 57 (18.8) 13 (17.3) - 60 (19.8) 10 (13.3) - 
Central Asian 41 (10.9) 38 (10.5) 3 (20.0) - 31 (10.2) 10 (13.3) - 32 (10.6) 9 (12.0) - 
Other 34 (9.0) 32 (8.8) 2 (13.3) - 28 (9.2) 6 (8.0) - 27 (8.9) 7 (9.3) - 
Diabetes mellitus 30 (7.9) 30 (8.3) 0 (0.0) - 28 (9.2) 2 (2.7) 0.06~ 28 (9.2) 2 (2.7) 0.06~ 
Chronic hypertension 1 (0.3) 1 (0.3) 0 (0.0) - 1 (0.3) 0 (0.0) - 1 (0.3) 0 (0.0) - 
Cigarette smoker 30 (7.9) 30 (8.3) 0 (0.0) - 26 (8.6) 4 (5.3) 0.35~ 24 (7.9) 6 (8.0) 0.98* 
ART 11 (3.0) 11 (3.1) 0 (0.0) - 11 (3.8) 0 (0.0) - 10 (3.4) 1 (1.4) 0.70~ 
Gestation at assessment 38.4 (37.9-
39.9) 
38.4 (37.9-
39.9) 
38.7 (38.3-
40.0) 
0.35^ 38.4 (37.7-
39.9) 
39.1 (38.1-
40.0) 
0.003^ 38.4 (37.7-
39.9) 
38.7 (38.3-
40.0) 
0.002^ 
Interval to labour 8.0 (5.0-12.0) 8.0 (5.0-12.0) 7.0 (4.0-11.0) 0.41^ 8.0 (5.0-12.0) 8.0 (5.0-11.0) 0.26^ 8.0 (5.0-12.0) 8.0 (5.0-11.0) 0.98^ 
Interval to labour 
(spont) 
8.0 (5.0-12.0) 8.0 (5.0-12.0) 7.5 (4.0-11.0) 0.68^ 8.0 (5.0-12.0) 8.0 (5.0-11.0) 0.49^ 8.0 (4.0-12.0) 9.0 (5.5-12.0) 0.22^ 
Gestation at delivery 40.0 (39.1-
40.9) 
40.0 (39.1-
40.9) 
40.3 (39.4-
40.7) 
0.58^ 39.9 (39.1-
40.7) 
40.1 (39.4-
41.1) 
0.02^ 39.9 (39.0-
40.7) 
40.3 (39.6-
41.3) 
0.002^ 
BW <10th centile 13 (3.4) 12 (3.3) 1 (6.7) 0.41~ 8 (2.6) 5 (6.7) 0.15~ 8 (2.6) 5 (6.7) 0.09~ 
UA-PI >95th centile 31 (8.2) 30 (8.3) 1 (6.7) 1.0~ 23 (7.6) 8 (10.7) 0.39* 23 (8.0) 8 (10.7) 0.39* 
MCA-PI <5th centile 38 (10.1) 34 (9.4) 4 (26.7) 0.03~ 22 (7.3) 16 (21.3) <0.001* 25 (8.3) 13 (17.3) 0.02* 
CPR <5th centile 30 (7.9) 25 (6.9) 5 (33.3) <0.001~ 16 (5.3) 14 (18.7) <0.001* 18 (5.9) 12 (16.0) 0.004* 
CPR <10th centile 59 (15.6) 52 (14.3) 7 (46.7) 0.001* 35 (11.6) 24 (32.0) <0.001* 38 (12.5) 21 (28.0) 0.001* 
UtA-PI >95th centile 28 (7.4) 25 (6.9) 3 (20.0) 0.09~ 16 (5.3) 12 (16.0) 0.002* 18 (5.9) 10 (13.3) 0.03* 
PlGF <5th centile 18 (4.8) 17 (4.7) 1 (6.7) 0.21~ 12 (4.0) 6 (8.0) 0.14* 16 (5.3) 2 (2.7) 0.55~ 
EFW <10th centile 13 (3.4) 12 (3.3) 1 (6.7) 0.31~ 9 (3.0) 4 (5.3) 0.30~ 11 (3.6) 2 (2.7) 1.0~ 
Gestation at assessment = weeks’ gestation at last assessment preceding delivery. Interval to labour = days from last PlGF assessment to labour. Interval 
to labour (spont) = days from last PlGF assessment to spontaneous labour. Gestation at delivery = weeks’ gestation at delivery. Data presented as n (%), 
mean (SD) or median (IQR), as appropriate. * = Pearson’s chi squared test. # = Student’s t-test. ^ = Kruskall-Wallis equality-of-populations rank test. ~ = 
Fisher’s exact test. 
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Table 33 Maternal characteristics and screening parameters by outcomes (Alere cohort) 
Characteristic Overall  CS-IFC Op-IFC CNO 
  Absent  Present  p Absent  Present  p Absent  Present  p 
 (n=185) (n=179) (n=6)  (n=147) (n=38)  (n=147) (n=38)  
Nulliparous  148 (80.0) 143 (79.9) 5 (83.3) 1.0~ 113 (76.9) 35 (92.1) 0.04~ 113 (76.9) 35 (92.1) 0.04~ 
Maternal age 30.0 (4.2) 29.5 (4.2) 29.8 (4.8) 0.84# 29.4 (4.3) 29.8 (3.8) 0.57# 29.3 (4.1) 30.2 (4.4) 0.22# 
BMI 22.6 (21.1-
25.7) 
22.6 (21.1-
25.7) 
21.5 (18.7-
23.9) 
0.30^ 22.5 (21.0-
25.4) 
23.8 (21.5-
26.5) 
0.43^ 22.6 (21.1-
25.7) 
22.5 (21.5-
25.3) 
0.92^ 
Ethnicity        Caucasian 117 (63.2) 113 (63.1) 4 (66.7) 0.80~ 95 (64.6) 22 (57.9) 0.46* 93 (63.3) 24 (63.2) 0.46~ 
East Asian 32 (17.3) 31 (17.3) 1 (16.7) - 26 (17.7) 6 (15.8) - 28 (19.1) 4 (10.5) - 
Central Asian 17 (9.2) 16 (8.9) 1 (16.7) - 11 (7.5) 6 (15.8) - 12 (8.2) 5 (13.2) - 
Other 19 (10.3) 19 (10.6) 0 (0.0) - 15 (10.2) 4 (10.5) - 14 (9.5) 5 (13.2) - 
Diabetes mellitus 0 (0.0) 0 (0.0) 0 (0.0) - 0 (0.0) 0 (0.0) - 0 (0.0) 0 (0.0) - 
Chronic hypertension 0 (0.0) 0 (0.0) 0 (0.0) - 0 (0.0) 0 (0.0) - 0 (0.0) 0 (0.0) - 
Cigarette smoker 15 (8.1) 15 (8.4) 0 (0.0) - 13 (8.8) 2 (5.3) 0.74~ 14 (9.5) 1 (2.6) 0.31~ 
ART 6 (3.3) 6 (3.5) 0 (0.0) - 6 (4.2) 0 (0.0) - 6 (4.2) 0 (0.0) - 
Interval to labour 38.7 (37.9-
40.0) 
38.6 (37.9-
40.0) 
39.1 (38.3-
39.7) 
0.53^ 38.6 (37.7-
40.0) 
39.1 (38.1-
40.1) 
0.09^ 38.6 (37.9-
40.0) 
39.0 (38.1-
40.1) 
0.08^ 
Interval to labour 
(spont) 
9.0 (5.0-13.0) 9.0 (5.0-13.0) 4.5 (1.0-7.0) 0.03^ 9.0 (5.0-13.0) 7.0 (5.0-10.0) 0.05^ 9.0 (5.0-13.0) 9.0 (5.0-12.0) 0.96^ 
Gestation at delivery 8.0 (5.0-13.0) 8.0 (5.0-13.0) 5.0 (4.0 -10.0) 0.34^ 8.0 (5.0-13.0) 8.0 (5.0-10.5) 0.76^ 8.0 (5.0-13.0) 10.0 (5.0-12.0) 0.48^ 
Interval to labour 40.1 (39.4-
41.1) 
40.1 (39.3-
41.1) 
39.9 (39.4-
40.4) 
0.40^ 40.1 (39.3-
41.1) 
40.2 (39.4-
41.3) 
0.53^ 40.1 (39.1-
41.1) 
40.4 (39.6-
41.4) 
0.02^ 
BW <10th centile 10 (5.4) 9 (5.0) 1 (16.7) 0.29~ 5 (3.4) 5 (13.2) 0.03~ 7 (4.8) 3 (7.9) 0.43~ 
UA-PI >95th centile 15 (8.1) 14 (7.8) 1 (16.7) 0.40~ 9 (6.1) 6 (15.8) 0.05* 13 (8.8) 2 (5.3) 0.74 ~ 
MCA-PI <5th centile 29 (15.7) 26 (14.5) 3 (50.0) 0.05~ 17 (11.6) 12 (31.6) 0.002* 19 (12.9) 10 (26.3) 0.04* 
CPR <5th centile 18 (9.7) 14 (7.8) 4 (66.7) 0.001~ 8 (5.4) 10 (26.3) <0.001* 11 (7.5) 7 (18.4) 0.04* 
CPR <10th centile 35 (18.9) 31 (17.3) 4 (66.7) 0.01 21 (14.3) 14 (36.8) 0.002* 25 (17.0) 10 (26.3) 0.19* 
UtA-PI >95th centile 12 (6.5) 10 (5.6) 2 (33.3) 0.05~ 6 (4.1) 6 (15.8) 0.009* 8 (5.4) 4 (10.5) 0.27~ 
PlGF <5th centile 6 (3.2) 5 (2.8) 1 (16.7) 0.18~ 3 (2.0) 3 (7.9) 0.10~ 5 (3.4) 1 (2.6) 1.0~ 
EFW <10th centile 9 (4.9) 8 (4.5) 1 (16.7) 0.26~ 5 (3.4) 4 (10.5) 0.09~ 8 (5.4) 1 (2.6) 0.69~ 
Gestation at assessment = weeks’ gestation at last assessment preceding delivery. Interval to labour = days from last PlGF assessment to labour. Interval to labour (spont) = days from 
last PlGF assessment to spontaneous labour. Gestation at delivery = weeks’ gestation at delivery. Data presented as n (%), mean (SD) or median (IQR), as appropriate. *Pearson’s chi 
squared test. # = Student’s t-test. ^ = Kruskall-Wallis equality-of-populations rank test. ~ = Fisher’s exact test.   
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5.3.2 Correlation 
5.3.2.1 DELFIA cohort 
Correlation between unadjusted and adjusted ultrasound and PlGF predictors are reported in Table 
34 and Table 35. In the DELFIA cohort, unadjusted variables with Spearman’s rho exceeding 0.5 
were CPR with MCA-PI and EFW centile with birthweight centile. Similarly, the centile adjusted 
variables showed Spearman’s rho above 0.5 for CPR centile with UA-PI centile and MCA-PI centile, 
and EFW centile with birthweight centile. 
Table 34 Correlation between unadjusted variables (DELFIA cohort) 
 CPR PlGF UA-PI MCA-PI UtA-PI cUVf BWc
PlGF 0.2397 *             
UA-PI -0.4823 * -0.1100 *           
MCA-PI 0.7714 * 0.1909 * 0.1328 *         
UtA-PI -0.0352  -0.0573  0.0802  0.0284        
cUVf 0.2538 * 0.2187 * -0.0500  0.2425 * -0.0425      
BWc 0.2434 * 0.1960 * -0.2014 * 0.1344 * -0.0490  0.1826 *   
EFWc 0.2408 * 0.1077 * -0.1516 * 0.1783 * -0.0515  0.1127 * 0.7457 * 
Data presented are Spearman’s Rho; c = centile; * = p <0.05. 
Table 35 Correlation between gestation-adjusted variables (centiles, DELFIA cohort) 
 UA-PIc MCA-PIc CPRc cUVfc UtA-PIc PlGFc EFWc 
MCA-PIc 0.1305              
CPRc -0.5503 * 0.7528 *           
cUVfc -0.1095 * 0.1320 * 0.1792 *         
UtA-PIc 0.0797  0.0267  -0.0410  -0.0301        
PlGFc -0.1488 * 0.1331 * 0.2033 * -0.0422  -0.0638      
EFWc -0.1740 * 0.1588 * 0.2388 * 0.0722  -0.0549  0.1001 ~   
BWc -0.2091 * 0.1284 * 0.2442 * 0.1800 * -0.0510  0.1929 * 0.7457 * 
Data presented are Spearman’s Rho; c = centile; * = p ≤0.05; ~ p = 0.05. 
5.3.2.2 Alere cohort 
Correlation between unadjusted and adjusted ultrasound and PlGF variables are reported in Table 36 
and Table 37, respectively. Spearman’s rho was ≥0.5 for CPR with UA-PI and MCA-PI and EFWc 
with birthweight centile. All other variable combinations resulted in rho <0.5. Centile adjusted 
variables showed the same pattern of correlation as the unadjusted variables. These patterns of 
correlation were consistent across the study and Alere cohorts. 
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Table 36 Correlation between unadjusted variables (Alere cohort) 
 UA-PI MCA-PI CPR cUVf UtA-PI PlGF  EFWc 
MCA-PI 0.0866              
CPR -0.4999 * 0.7866 *           
cUVf 0.0721  0.2330 * 0.2437 *         
UtA-PI 0.1080  -0.0805  -0.1297  -0.0448        
PlGF -0.1394  0.1730 * 0.2356 * 0.2412 * -0.1374      
EFWc -0.2270 * 0.0703  0.1739 * 0.1230  -0.0533  0.1153    
BWc -0.2318 * 0.1061  0.2164 * 0.2047 * 0.0039  0.2159 * 0.7489 * 
c = centile; * = p <0.05. 
Table 37 Correlation between gestation-adjusted variables (centiles, Alere cohort) 
 UA-PIc MCA-PIc CPRc cUVfc UtA-PIc PlGFc EFWc 
MCA-PIc 0.0511              
CPRc -0.5581 * 0.7613 *           
cUVfc -0.1531 * 0.0970  0.1587 *         
UtA-PIc 0.0970  -0.0644  -0.1342  -0.0204        
PlGFc -0.1803 * 0.1249  0.2102 * 0.1750  -0.1387      
EFWc -0.2370 * 0.0468  0.1672 * 0.0928  -0.0559  0.1151    
BWc -0.2661  0.0348 * 0.1904 * 0.1363 * -0.0013  0.1932 * 0.7489 * 
c = centile; * = p <0.05. 
5.3.3 Screening performance 
5.3.3.1 DELFIA cohort 
5.3.3.1.1 Unadjusted variables 
5.3.3.1.1.1 Single variables 
The screening performance of unadjusted, single predictors for the DELFIA cohort is presented in 
Table 38. For CS-IFC, predictive variables were MCA-PI, CPR, cUVf and UtA-PI. In this cohort, 
UA-PI, PlGF and EFW centile were not predictive. 
In screening for Op-IFC, MCA-PI, CPR, cUVf, UtA-PI and EFW centile were predictive (Table 38). 
However, UA-PI and PlGF were not predictive. 
For CNO, predictive variables were MCA-PI, CPR and cUVf (Table 38). Unadjusted variables 
without predictive performance were UA-PI, UtA-PI, PlGF and EFW centile. 
5.3.3.1.1.2 Multiple, unadjusted variables 
The combined screening performance of unadjusted ultrasound and PlGF variables is presented in 
Table 39. In screening for CS-IFC, the combination of MCA-PI and UtA-PI and CPR and UtA-PI 
were predictive, with AUROC curves of 0.75 and 0.72, respectively. In screening for Op-IFC, two 
models were predictive; the combination of MCA-PI, cUVf, UtA-PI and nulliparity and the 
combination of CPR, cUVf and UtA-PI produced AUROC curves of 0.72 and 0.69, respectively. For 
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the prediction of CNO, the combination of UtA-PI and gestation at delivery and CPR, UtA-PI and 
gestation at delivery produced AUROC curves of 0.65 and 0.66, respectively. 
5.3.3.1.2 Gestation adjusted variables 
5.3.3.1.2.1 Regression adjusted variables 
5.3.3.1.2.1.1 Single variables 
After adjusting for gestation at delivery, MCA-PI, CPR, cUVf and UtA-PI were individually 
predictive of CS-IFC (Table 40). MCA-PI and UtA-PI produced the equal highest AUROC curve.  
5.3.3.1.2.1.2 Multiple variables 
When the individually predictive variables were combined in a multivariable model, the highest 
AUROC curve (0.75) was generated by the combination of MCA-PI and UtA-PI, whilst the model 
with CPR and UtA-PI produced the second highest AUROC (0.72), after adjusting for gestation at 
delivery and maternal characteristics. However, the AUROC curves for these models did not differ 
significantly (p = 0.45). 
In screening for Op-IFC, UA-PI, MCA-PI, CPR, cUVf, UtA-PI and EFW centile were individually 
predictive of Op-IFC. In a multivariable model, after adjusting for confounders (gestation at delivery, 
nulliparity and diabetes mellitus), cUVf, UtA-PI, nulliparity and either MCA-PI or CPR was 
predictive of Op-IFC (Table 41). These two models produced similar AUROC curves (0.72 vs. 0.69, 
95% CI 0.66-0.79 vs 0.62-0.76, respectively; p = 0.18). 
In screening for CNO, only UA-PI, MCA-PI, CPR and cUVf were individually predictive (Table 40). 
A multivariable model containing either UA-PI and MCA-PI or CPR, and cUVf, UtA-PI, PlGF, 
gestation at delivery, nulliparity and maternal diabetes showed that the combination of CPR, UtA-PI 
and gestation at delivery were predictive of CNO (Table 41), as were UtA-PI and gestation at delivery. 
The highest AUROC curve for the prediction of CNO was achieved by the combination of CPR, UtA-
PI and gestation at delivery (0.66, 95% CI 0.59-0.73), although this was not significantly higher than 
the combination of UtA-PI and gestation at delivery (0.65, 95% CI 0.58-0.71; p = 0.42). 
5.3.3.1.2.2 Centile adjusted variables 
5.3.3.1.2.2.1 Single variables 
5.3.3.1.2.2.1.1 Associations 
The relationships between individual ultrasound and PlGF variables (centile adjusted) with CS-IFC, 
Op-IFC and CNO are presented in Table 42. For CS-IFC, MCA-PI centile (MCAc), CPR centile 
(CPRc) and UtA-PI centile (UtA-PIc) were different between those with and without CS-IFC. For 
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pregnancies with and without Op-IFC, UA-PI centiles (UA-PIc), MCA-PIc, CPRc, UtA-PIc, PlGF 
centiles (PlGFc) and EFW centiles were significantly different. For babies born with and without 
CNO, UA-PIc, CPRc, UtA-PIc and PlGFc were significantly different between the CNO groups. 
5.3.3.1.2.2.1.2 Screening  
The screening performance of centile adjusted ultrasound and PlGF variables, individually and 
combined, for the prediction of CS-IFC, Op-IFC and CNO are presented in Table 43 and Table 44. 
For CS-IFC, individual predictors were MCA-PIc, CPRc, UtA-PIc, with AUROC curves ranging from 
0.68 to 0.70 (p = 0.94).  
5.3.3.1.2.2.2 Multiple variables 
A multivariable model that included either MCA-PIc or CPRc with UtA-PIc demonstrated AUROC 
curves of 0.78 and 0.74, respectively (p = 0.37). 
In screening for Op-IFC, UA-PIc, MCA-PIc, CPRc, UtA-PIc, PlGFc and EFWc were individually 
predictive, with AUROC curves ranging from 0.57 to 0.66 (p = 0.02) (Table 43). Comparison of UA-
PIc and CPRc demonstrated significantly higher AUROC curve for CPRc. A multivariable model that 
included either UA-PIc and MCA-PIc or CPRc, in combination with UtA-PIc, PlGFc and EFWc 
resulted in AUROC curves of 0.71 and 0.70, respectively (p = 0.70) (Table 44). 
In screening for CNO, UA-PIc, CPRc and UtA-PIc and PlGFc were individually predictive, with 
AUROC curves ranging from 0.55 to 0.62 (p = 0.06) (Table 43). A multivariable model that included 
UA-PIc or CPRc, combined with UtA-PIc and PlGFc produced the same AUROC curve (0.67, p = 
0.90) (Table 44). 
5.3.3.1.3 Comparison of combined models (DELFIA cohort) 
Comparison of the combined models for the prediction of CS-IFC, unadjusted and adjusted for 
gestation at assessment, is presented in Table 45 and Figure 35. When the various models were 
compared, none resulted in a significantly higher AUROC curve than another (p = 0.87). 
Comparisons of the unadjusted and adjusted, combined models for the prediction of Op-IFC are 
presented in Table 45 and Figure 36. When the various models’ AUROC curves were compared, none 
was superior to another (p = 0.52). 
Comparisons of the screening performance for the various unadjusted and adjusted, combined models 
for the prediction of CNO are presented in Table 45 and Figure 37. When the various models were 
compared, none had significantly higher AUROC curve than another (p = 0.72). 
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Table 38 Outcomes by single, unadjusted ultrasound and PlGF predictors (DELFIA cohort) 
Predictor CS-IFC Op-IFC CNO 
 OR p AUROC OR p AUROC OR p AUROC
UA-PI 11.06 
(0.37-
326.20) 
0.16 0.55 5.24 
(0.84-
32.58) 
0.08 0.55 4.72 
(0.76-
29.36) 
0.10 0.56 
MCA-PI 0.14 (0.02-
0.86) 
0.03 0.69 0.13 
(0.05-
0.32) 
<0.001 0.67 0.42 
(0.19-
0.95) 
0.04 0.59 
CPR 0.23 (0.07-
0.81) 
0.02 0.68 0.24 
(0.13-
0.44) 
<0.001 0.68 0.45 
(0.25-
0.80) 
0.006 0.61 
cUVf 0.97 (0.94-
1.00) 
0.04 0.65 0.98 
(0.96-
0.99) 
0.001 0.61 0.98 
(0.97-
1.00) 
0.02 0.58 
UtA-PI 10.83 
(1.78-
66.04) 
0.01 0.69 3.89 
(1.18-
12.77) 
0.025 0.59 2.91 
(0.88-
9.64) 
0.08 0.58 
EFWc 0.99 (0.97-
1.02) 
0.58 0.53 0.99 
(0.98-
1.00) 
0.04 0.57 0.99 
(0.98-
1.00) 
0.25 0.54 
PlGF 1.00 (0.99-
1.00) 
0.12 0.60 1.00 
(1.00-
1.00) 
0.16 0.60 1.00 
(1.00-
1.00) 
0.13 0.64 
 
Table 39 Outcomes by combined ultrasound and PlGF predictors (DELFIA cohort) 
Outcome  Predictor OR 95% CI p AUROC
CS-IFC MCA-PI 0.10 0.01-0.67 0.02  
 UtA-PI 17.61 2.52-123.02 0.004 0.75 
 CPR 0.23 0.07-0.81 0.02  
 UtA-PI 12.47 1.81-86.10 0.01 0.72 
Op-IFC MCA-PI 0.14 0.05-0.36 <0.001  
 cUVf 0.98 0.97-1.00 0.04  
 UtA-PI 6.01 1.64-21.99 0.007  
 Nulliparity 0.32 0.11-0.95 0.04 0.72 
 CPR 0.28 0.14-0.53 <0.001  
 cUVf 0.98 0.97-1.00 0.03  
 UtA-PI 4.35 1.20-15.74 0.03 0.69 
CNO Gestation at delivery 1.47 1.16-1.87 0.001  
 UtA-PI 3.58 1.05-12.21 0.04 0.65 
 CPR 0.51 0.29-0.91 0.02  
 Gestation at delivery 1.42 1.11-1.81 0.005  
 UtA-PI 3.52 1.01-12.25 0.05 0.66 
 
Table 40 Single variables, adjusted for gestation (DELFIA cohort) 
Predictor CS-IFC Op-IFC CNO 
 OR p AUROC OR p AUROC OR p AUROC
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UA-PI 12.89 
(0.45-
369.61) 
0.14 0.59 8.30 
(1.27-
54.34) 
0.03 0.64 7.40 
(1.12-
48.29) 
0.04 0.64 
MCA-PI 0.12 (0.02-
0.94) 
0.04 0.70 0.17 
(0.06-
0.44) 
<0.001 0.68 0.63 
(0.26-
1.49) 
0.29 0.62 
CPR 0.23 (0.06-
0.86) 
0.03 0.68 0.28 
(0.15-
0.52) 
<0.001 0.69 0.53 
(0.30-
0.95) 
0.03 0.64 
cUVf 0.97 (0.94-
1.00) 
0.04 0.65 0.98 
(0.97-
1.00) 
0.02 0.64 0.99 
(0.98-
1.00) 
0.16 0.62 
UtA-PI 12.07 
(1.91-
76.20) 
0.01 0.68 4.56 
(1.35-
15.39) 
0.01 0.65 3.36 
(0.99-
11.46) 
0.05 0.64 
PlGF 1.00 (0.99-
1.00) 
0.13 0.62 1.00 
(1.00-
1.00) 
0.27 0.63 1.00 
(1.00-
1.00) 
0.23 0.63 
EFWc 0.99 (0.97-
1.02) 
0.58 0.53 0.99 
(0.98-
1.00) 
0.04 0.57 0.99 
(0.98-
1.00) 
0.25 0.54 
 
Table 41 Multiple variables, adjusted for gestation (DELFIA cohort) 
Outcome  Predictor OR 95% CI p AUROC
CS-IFC MCA-PI 0.10 0.01-0.67 0.02  
 UtA-PI 17.61 2.52-123.02 0.004 0.75 
 CPR 0.23 0.07-0.81 0.02  
 UtA-PI 12.47 1.81-86.10 0.01 0.72 
Op-IFC MCA-PI 0.14 0.05-0.36 <0.001  
 cUVf 0.98 0.97-1.00 0.04  
 UtA-PI 6.01 1.64-21.99 0.007  
 Nulliparity 0.32 0.11-0.95 0.04 0.72 
 CPR 0.28 0.14-0.53 <0.001  
 cUVf 0.98 0.97-1.00 0.03  
 UtA-PI 4.35 1.20-15.74 0.03 0.69 
CNO Gestation at delivery 1.47 1.16-1.87 0.001  
 UtA-PI 3.58 1.05-12.21 0.04 0.65 
 CPR 0.51 0.29-0.91 0.02  
 Gestation at delivery 1.42 1.11-1.81 0.005  
 UtA-PI 3.52 1.01-12.25 0.048 0.66 
 
Table 42 Associations between individual, centile adjusted variables and outcomes (DELFIA 
cohort) 
Variable CS-IFC Op-IFC CNO 
 Absent Present p Absent Present p Absent Present p
UA-PIc 51 (23-77) 69 (32-77) 0.31 50 (22-75) 64 (27-87) 0.03 49 (22-75) 56 (32-83) 0.02
MCA-PIc 42 (22-69) 14 (10-38) 0.01 46 (24-71) 25 (10-61) <0.001 43 (22-70) 36 (18-67) 0.19
CPRc 42 (21-72) 15 (7-47) 0.02 46 (23-74) 23 (10-48) <0.001 43 (22-74) 32 (14-60) 0.02
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cUVfc 44 (25-70) 28 (9-63) 0.08 44 (25-72) 40 (19-62) 0.11 44 (24-72) 42 (21-57) 0.39
UtA-PIc 47 (26-74) 74 (48-93) 0.01 46 (25-74) 64 (35-84) 0.01 47 (25-74) 61 (37-83) 0.02
PlGFc 47 (22-75) 34 (15-54) 0.18 49 (25-75) 32 (12-66) 0.02 50 (25-76) 31 (14-52) <0.00
EFWc 52 (34-75) 58 (27-66) 0.65 53 (36-75) 48 (31-68) 0.047 53 (35-75) 50 (30-70) 0.24
c = centile 
Table 43 Screening performance of single, centile adjusted variables for outcomes (DELFIA 
cohort) 
Predictor CS-IFC Op-IFC CNO 
 OR p AUROC OR p AUROC OR p AUROC
UA-PIc 2.35 
(0.40-
13.878) 
0.35 0.58 2.51 
(1.05-
5.99) 
0.04 0.58 2.68 
(1.12-
6.40) 
0.03 0.58 
MCA-PIc 0.08 
(0.01-
0.73) 
0.03 0.70 0.18 
(0.07-
0.47) 
<0.001 0.64 0.57 
(0.24-
1.37) 
0.21 0.55 
CPRc 0.11 
(0.01-
0.90) 
0.04 0.68 0.14 
(0.05-
0.38) 
<0.001 0.66 0.37 
(0.15-
0.89) 
0.03 0.59 
cUVfc 0.16 
(0.02-
1.32) 
0.09 0.63 0.45 
(0.17-
1.17) 
0.10 0.56 0.62 
(0.24-
1.57) 
0.31 0.53 
UtA-PIc 12.70 
(1.67-
96.75) 
0.01 0.69 3.27 
(1.32-
8.13) 
0.01 0.59 2.87 
(1.16-
7.10) 
0.02 0.59 
PlGFc 0.26 
(0.04-
1.72) 
0.16 0.60 0.34 
(0.14-
0.83) 
0.02 0.59 0.21 
(0.08-
0.52) 
0.001 0.62 
EFWc 0.99 
(0.97-
1.02) 
0.58 0.53 0.99 
(0.98-
1.00) 
0.04 0.57 0.99 
(0.98-
1.00) 
0.25 0.54 
c = centile 
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Table 44 Screening performance of multiple, centile adjusted variables for outcomes (DELFIA 
cohort) 
Outcome  Predictor OR 95% CI p AUROC 
CS-IFC MCA-PIc 0.07 0.01-0.65 0.02 0.77 
 UtA-PIc 14.87 1.87-118.32 0.01  
 CPRc 0.12 0.01-0.98 0.047 0.74 
 UtA-PIc 12.10 1.58-92.83 0.02  
Op-IFC MCA-PIc 0.15 0.06-0.41 <0.001 0.71 
 UtA-PIc 4.13 1.61-10.63 0.003  
 GAd 1.37 1.08-1.75 0.01  
 Nulliparity 0.34 0.11-0.99 0.048  
 CPRc 0.15 0.06-0.39 <0.001 0.70 
 UtA-PIc 3.55 1.38-9.15 0.009  
 GAd 1.38 1.09-1.75 0.008  
CNO UtA-PIc 2.86 1.13-7.22 0.03 0.70 
 PlGFc 0.19 0.07-0.49 0.001  
 GAd 2.86 1.13-7.22 0.03  
c = centile, GAd = gestation at delivery.  
5.3.3.1.3.1 Adjusted and unadjusted variables 
Comparison of unadjusted and adjusted combined models for the prediction of CS-IFC, Op-IFC and 
CNO for the DELFIA cohort are presented in Table 45. 
In screening for CS-IFC, the model combining centile-adjusted MCA-PI and UtA-PI produced the 
highest AUROC curve (0.78), although this was not significantly different to the other models (p = 
0.87). For the prediction of Op-IFC, unadjusted MCA-PI, cUVf, UtA-PI and parity produced the 
highest AUROC curve (0.76), although this was not significantly different to the other models (p = 
0.52). In screening for CNO, the models combining unadjusted CPR, UtA-PI and gestation at 
delivery, and centile-adjusted UtA-PI, PlGF and gestation at delivery produced the highest AUROC 
curve (0.76), although this was not significantly different to the other models (p = 0.72).
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Table 45 Comparison of combined models, unadjusted and adjusted (DELFIA cohort) 
Outcome  Predictor n AUROC 95% CI p 
CS-IFC MCA + UtA 378 0.77 0.66-0.88 0.87 
 CPR + UtA 378 0.75 0.63-0.86  
 MCA + UtA + GAa 378 0.77 0.66-0.89  
 CPR + UtA + GAa 378 0.75 0.64-0.86  
 MCAc + UtAc 378 0.78 0.66-0.89  
 CPRc + UtAc 378 0.75 0.64-0.87  
Op-IFC MCA + UV + UtA + parity 378 0.76 0.65-0.88 0.52 
 CPR + UV + UtA 378 0.73 0.60-0.86  
 MCA + UV + UtA + parity + GAa 378 0.75 0.64-0.86  
 CPR + UV + UtA + GAa 378 0.72 0.58-0.85  
 MCAc + UtAc + GAd + parity 378 0.75 0.62-0.88  
 CPRc + UtAc + GAd 378 0.72 0.58-0.85  
CNO UtA + GAd 378 0.63 0.49-0.77 0.72 
 CPR + UtA + GAd 378 0.67 0.54-0.80  
 UtA + GAd + GAa 378 0.62 0.48-0.76  
 CPRc + UtAc + GAd + GAa 378 0.66 0.53-0.80  
 UtAc + PlGFc + GAd 378 0.67 0.54-0.80  
GAa = gestation at assessment, c = centile, GAd = gestation at delivery.  
Figure 35 Screening performance for CS-IFC (DELFIA cohort) 
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Figure 36 Screening performance for Op-IFC (DELFIA cohort) 
 
Figure 37 Screening performance for CNO (DELFIA cohort) 
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5.3.3.2 Alere cohort 
5.3.3.2.1 Unadjusted variables (single and multiple) 
Screening performance for single and multiple variables, unadjusted for gestation, are presented in 
Table 46 and Table 47, respectively. In screening for CS-IFC, UA-PI, MCA-PI, CPR and UtA-PI 
were individually predictive, with AUROC curves ranging from 0.69 to 0.89 (p <0.001). The AUROC 
produced by CPR was significantly higher than that produced by both UA-PI and UtA-PI, but not 
MCA-PI. Comparison of all other individual predictor models produced differences that were not 
significantly different. Multivariable models with either UA-PI and MCA-PI or CPR, in combination 
with UtA-PI produced AUROC curves of 0.88 and 0.89, respectively (p = 0.95). 
In screening for Op-IFC, UA-PI, MCA-PI, CPR and cUVf, unadjusted for gestation, were 
individually predictive (Table 46). Comparison of the AUROC curves for the individual variables 
demonstrated that only CPR AUROC curve was significantly higher than that for UtA-PI (p = 0.04). 
Multivariable models composed of either UA-PI or MCA-PI or CPR, in combination with cUVf 
produced the same AUROC curves (0.74, p = 0.30). 
In screening for CNO, no individual, unadjusted variables were predictive, thus no multivariable 
model could be tested for CNO (Table 46). 
Table 46 Screening performance of single variables, unadjusted for gestation for outcomes (Alere 
cohort) 
Predictor CS-IFC Op-IFC CNO 
 OR p AUROC OR p AUROC OR p AUROC 
UA-PI 244.3 (2.6-
22559.7) 
0.02 0.69 39.2 (2.7-
564.3) 
0.01 0.62 1.19 (0.09-
15.54) 
0.89 0.52 
MCA-PI 0.01 (0.00-
0.21) 
0.02 0.84 0.11 (0.03-
0.40) 
0.001 0.68 0.30 (0.09-
1.00) 
0.05 0.61 
CPR 0.17 (0.00-
0.25) 
0.003 0.89 0.14 (0.06-
0.37) 
<0.001 0.72 0.46 (0.21-
1.02) 
0.06 0.62 
cUVf 0.98 (0.94-
1.03) 
0.42 0.58 0.97 (0.96-
0.99) 
0.01 0.63 0.98 (0.96-
1.00) 
0.06 0.60 
UtA-PI 43.5 (2.50-
757.29) 
0.01 0.74 6.18 (0.97-
39.39) 
0.05 0.60 3.08 (0.47-
20.07) 
0.24 0.58 
PlGF 0.98 (0.95-
1.00) 
0.10 0.80 1.00 (1.0-
1.0) 
0.25 0.66 1.00 (1.00-
1.00) 
0.23 0.64 
EFWc 0.98 (0.94-
1.01) 
0.18 0.66 0.99 (0.97-
1.00) 
0.10 0.58 1.00 (0.98-
1.01) 
0.62 0.53 
c = centile. 
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Table 47 Screening performance of multiple variables, unadjusted for gestation for outcomes 
(Alere cohort) 
Outcome  Predictor OR 95% CI p AUROC
CS-IFC MCA-PI 0.003 0.00-0.36 0.02  
 UtA-PI 93.72 2.79-3151.89 0.01 0.88 
 CPR 0.02 0.00-0.25 0.003 0.89 
Op-IFC UA-PI 72.91 3.94-1350.68 0.004  
 MCA-PI 0.09 0.02-0.35 <0.001 0.73 
 CPR 0.14 0.06-0.37 <0.001 0.72 
CNO GAd 1.51 1.07-2.14 0.02 0.62 
GAd = gestation at delivery 
5.3.3.2.2 Adjusted variables 
5.3.3.2.2.1 GA regression adjusted (single and multiple) 
Screening performance for single and multiple variables, adjusted for gestation by regression, are 
presented in Table 48 and Table 49. In screening for CS-IFC, UA-PI, MCA-PI, CPR and UtA-PI 
were individually predictive, with AUROC curves ranging from 0.70 to 0.89 (p = 0.91). Multivariable 
models with either UA-PI and MCA-PI or CPR, in combination with UtA-PI produced AUROC 
curves of 0.89, (p = 0.91). 
In screening for Op-IFC, UA-PI, MCA-PI, CPR and cUVf, unadjusted for gestation, were 
individually predictive (Table 48). Comparison of the AUROC curves for the individual variables 
demonstrated no difference in AUROC curves (p = 0.13). Multivariable models composed of either 
UA-PI or MCA-PI or CPR, in combination with cUVf produced the same AUROC curves (0.75, p = 
0.70). 
In screening for CNO, no individual, unadjusted variables were predictive, and therefore no 
multivariable model could be tested for CNO (Table 48). 
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Table 48 Screening performance of single variables, adjusted by regression for gestation, for 
outcomes (Alere cohort) 
Predictor CS-IFC Op-IFC CNO 
 OR p AUROC OR p AUROC OR p AUROC
UA-PIa 273.9 (2.7-
27390.0) 
0.02 0.70 72.1 (4.1-
1258.2) 
0.003 0.67 1.69 
(0.13-
22.29) 
0.69 0.61 
MCA-PIa 0.01 (0.00-
0.45) 
0.02 0.84 0.13 
(0.03-
0.51) 
0.004 0.68 0.41 
(0.11-
1.43) 
0.16 0.61 
CPRa 0.02 (0.00-
0.26) 
0.004 0.89 0.16 
(0.06-
0.42) 
<0.001 0.73 0.53 
(0.24-
1.18) 
0.12 0.63 
cUVfa 0.99 (0.94-
1.03) 
0.57 0.61 0.98 
(0.96-
1.00) 
0.046 0.64 0.99 
(0.97-
1.01) 
0.19 0.62 
UtA-PIa 47.6 (2.5-
890.3) 
0.01 0.72 6.49 
(0.98-
42.76) 
0.05 0.64 3.16 
(0.47-
21.2) 
0.24 0.62 
PlGFa 0.98 (0.95-
1.00) 
0.10 0.81 1.00 
(1.00-
1.00) 
0.32 0.62 1.00 
(1.00-
1.00) 
0.30 0.62 
EFWc 0.98 (0.94-
1.01) 
0.18 0.66 0.99 
(0.97-
1.00) 
0.10 0.58 1.00 
(0.98-
1.01) 
0.62 0.53 
a = adjusted by regression for gestation at assessment. 
Table 49 Screening performance of multiple variables, adjusted by regression for gestation, for 
outcomes 
Outcome  Predictor OR 95% CI p AUROC
CS-IFC MCA-PI 0.003 0.00-0.36 0.01 0.88 
 UtA-PI 93.72 2.79-3151.89 0.004  
 CPR 0.17 0.001-0.252 0.003 0.89 
Op-IFC UA-PI 72.91 3.93-1350.68 0.004 0.73 
 MCA-PI 0.09 0.02-0.35 <0.001  
 CPR 0.14 0.06-0.37 <0.001 0.72 
CNO GAd  1.51 1.07-2.14 0.02 0.62 
GAd = gestation at delivery. 
 118 
 
5.3.3.2.2.2 Centile adjusted (single and multiple) 
The associations between, and screening performance of, individual ultrasound and PlGF variables 
for prediction of CS-IFC, Op-IFC and CNO, corrected for gestation by centiles, are presented in Table 
50 and Table 51, respectively. For CS-IFC, UA-PIc, MCA-PIc, CPRc and UtA-PIc and PlGFc were 
individually predictive, with AUROC curves ranging from 0.70 to 0.88 (p <0.001). The AUROC 
curve for CPRc was greater than UA-PIc (p = 0.01). Multivariable models with either UA-PIc and 
MCA-PIc or CPRc, and UtA-PIc produced AUROC curves of 0.88 and 0.89 (p = 0.01) (Table 52). 
In screening for Op-IFC, UA-PIc, MCA-PIc, CPRc, UtA-PIc, PlGFc and EFWc were individually 
predictive, with AUROC curves ranging from 0.60 to 0.71 (p = 0.09) (Table 51). Multivariable 
models with either UA-PIc and MCA-PIc or CPRc, combined with UtA-PIc, PlGFc and EFWc 
produced AUROC curves of 0.70 and 0.71, respectively (p = 0.29) (Table 52).  
In screening for CNO, only PlGFc was predictive, with AUROC curve of 0.63. Therefore, no 
multivariable model was tested for CNO. 
Table 50 Association of single variables, adjusted for gestation (centile), for outcomes (Alere 
cohort) 
Variable CS-IFC Op-IFC CNO 
 Absent Present p Absent Present p Absent Present p 
UA-PIc 0.46 
(0.22-
0.75) 
0.75 
(0.52-
0.78) 
0.09 0.46 
(0.21-
0.71) 
0.68 
(0.32-
0.92) 
0.01 0.46 
(0.22-
0.71) 
0.52 
(0.27-
0.82) 
0.33 
MCA-
PIc 
0.39 
(0.18-
0.67) 
0.11 
(0.08-
0.18) 
0.01 0.41 
(0.20-
0.70) 
0.20 
(0.09-
0.46) 
0.01 0.40 
(0.19-
0.69) 
0.29 
(0.10-
0.54) 
0.16 
CPRc 0.43 
(0.18-
0.73) 
0.07 
(0.03-
0.13) 
0.001 0.46 
(0.24-
0.76) 
0.19 
(0.07-
0.39) 
0.001 0.43 
(0.18-
0.75) 
0.23 
(0.10-
0.51) 
0.054
cUVfc 0.46 
(0.25-
0.70) 
0.41 
(0.13-
0.63) 
0.60 0.46 
(0.25-
0.73) 
0.44 
(0.22-
0.57) 
0.21 0.46 
(0.25-
0.73) 
0.44 
(0.21-
0.57) 
0.47 
UtA-PIc 0.48 
(0.29-
0.73) 
0.75 
(0.65-
0.96) 
0.04 0.48 
(0.25-
0.73) 
0.64 
(0.37-
0.80) 
0.049 0.48 
(0.25-
0.72) 
0.58 
(0.37-
0.80) 
0.12 
PlGFc 0.43 
(0.20-
0.72) 
0.14 
(0.08-
0.21) 
0.01 0.45 
(0.22-
0.72) 
0.22 
(0.10-
0.47) 
0.005 0.45 
(0.22-
0.72) 
0.26 
(0.12-
0.47) 
0.02 
EFWc 53 (37-
74) 
41 (20-
63) 
0.17 54 (37-
75) 
50 (20-
70) 
0.13 52 (36-
75) 
56 (32-
72) 
0.63 
c = centile. 
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Table 51 Screening performance of single variables, adjusted for gestation (centile), for outcomes 
(Alere cohort) 
Predictor CS-IFC Op-IFC CNO 
 OR p AUROC OR p AUROC OR p AUROC
UA-PIc 11.37 
(0.52-
249.29) 
0.12 0.70 5.57 
(1.58-
19.59) 
0.01 0.65 1.87 
(0.56-
6.21) 
0.31 0.55 
MCA-PIc 0.001 
(0.00-
0.65) 
0.04 0.83 0.16 
(0.04-
0.63) 
0.01 0.66 0.40 
(0.11-
1.43) 
0.21 0.57 
CPRc <0.001 
(0.00-
0.43) 
0.03 0.89 0.07 
(0.02-
0.29) 
<0.001 0.71 0.30 
(0.08-
1.05) 
0.06 0.60 
cUVfc 0.45 
(0.02-
10.20) 
0.62 0.56 0.37 
(0.10-
1.47) 
0.16 0.57 0.56 
(0.15-
2.17) 
0.41 0.54 
UtA-PIc 39.64 
(1.00-
1576.11) 
0.05 0.75 4.04 
(1.06-
15.51) 
0.04 0.60 2.84 
(0.75-
10.68) 
0.12 0.58 
PlGFc 0.002 
(0.00-
0.74) 
0.04 0.80 0.18 
(0.05-
0.71) 
0.01 0.65 0.22 
(0.06-
0.83) 
0.03 0.63 
EFWc 0.98 
(0.94-
1.01) 
0.18 0.66 0.99 
(0.97-
1.00) 
0.10 0.58 0.99 
(0.98-
1.01) 
0.62 0.53 
c = centile. 
Table 52 Screening performance of multiple variables, adjusted for gestation (centile), for 
outcomes (Alere cohort) 
Outcome  Predictor OR 95% CI p AUROC 
CS-IFC MCA-PIc 0.001 0.00-0.65 0.04 0.83 
 CPRc 0.00001 0.00-0.43 0.03 0.89 
Op-IFC UA-PIc 6.36 1.77-22.84 0.005 0.70 
 MCA-PIc 0.13 0.03-0.56 0.006  
 CPRc 0.07 0.02-0.29 <0.001 0.71 
CNO PlGFc 0.16 0.04-0.68 0.01 0.69 
 GAd 1.61 1.12-2.31 0.009  
c = centile, GAd = gestation at delivery. 
5.3.3.2.3 Comparison of models (Alere cohort) 
5.3.3.2.3.1 Comparison of combined models (Alere cohort) 
Comparison of the combined models for the prediction of CS-IFC, Op-IFC and CNO in the Alere 
cohort, unadjusted and adjusted for gestation at assessment, is presented in Table 53. In screening for 
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CS-IFC the AUROC curves ranged from 0.88 to 0.95, with the highest AUROC curve produced by 
the combination of MCA-PIc, UtA-PIc and PlGF 
In screening for Op-IFC, the AUROC curves ranged from 0.73 to 0.75, with the highest AUROC 
curve produced by CPRc, UtA-PIc and PlGFc. 
In screening for CNO, the AUROC curves ranged from 0.61 to 0.63. The highest AUROC curve was 
produced by PlGFc, although this was not statistically different from MCA, the only other variable 
predictive of CNO. 
Table 53 Comparison of combined models (unadjusted and adjusted, Alere cohort) 
Outcome  Predictor n AUROC 95% CI p 
CS-IFC UA + MCA + UtA 185 0.89 0.78-0.99 0.42 
 CPR + UtA 185 0.89 0.77-1.00  
 UA + MCA + UtA + GAa 185 0.89 0.79-0.99  
 CPR + UtA + GAa 185 0.88 0.77-1.00  
 MCAc + UtAc + PlGFc 185 0.95 0.90-0.99  
 CPRc + UtAc+ PlGFc 185 0.94 0.88-1.00  
Op-IFC UA + MCA + UV + UtA 185 0.74 0.64-0.83 0.93 
 CPR + UV + UV + UtA 185 0.73 0.64-0.83  
 UA + MCA + UV + UtA + GAd 185 0.73 0.64-0.83  
 CPR + UV + UtA + GAd 185 0.73 0.64-0.83  
 UAc + MCAc + UtAc + PlGFc 185 0.74 0.64-0.84  
 CPRc + UtAc + PlGFc 185 0.75 0.65-0.85  
CNO MCA 185 0.61 0.50-0.71 0.77 
 PlGFc 185 0.63 0.52-0.73  
GAa = gestation at assessment, GAd = gestation at delivery, c = centile. 
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Figure 38 Screening for CS-IFC (Alere cohort) 
 
Figure 39 Screening for Op-IFC (Alere cohort) 
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Figure 40 Screening for CNO (Alere cohort) 
 
 
5.4 Discussion 
The results presented in this chapter demonstrate that several Doppler variables and maternal PlGF 
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statistically different to the other (p = 0.77). For the Alere cohort, the highest AUROC curve was 
produced by PlGFc (0.63), although this was not statistically different to MCA-PI in isolation. 
For CS-IFC and Op-IFC, the combination of predictors provided significant improvement in 
screening performance. However, in screening for CNO, the variables tested in this study were of 
modest benefit, with AUROC curves reaching a maximum of 0.67. Interestingly, although the 
gestation-adjusted variables produced generally higher AUROC curves overall than their unadjusted 
counterparts, this was marginal and not statistically significant in the cohorts reported here. 
The screening performance from parameters investigated in this chapter have been 
published.136,278,279,283 These have shown136 that the CPR 10th centile offers better screening 
performance than the CPR 5th centile for detection of SGA, CS-IFC and composite adverse neonatal 
outcome, with sensitivities of 41.9%, 61.1% and 38.3%, respectively, for FPRs of 15.2% - 17.7%.  
However, these would be considered fair at best.  
Similarly, the screening performance of the CPR <10th centile, UtA-PI >95th centile and EFW <10th 
centile were assessed for the prediction of CS-IFC and composite adverse neonatal outcome.278 The 
CPR <10th centile and UtA-PI >95th centile had modest screening performance with sensitivities of 
33.3% and 28.4%, and FPRs of 15.8% and 17.0%, respectively. Interestingly, the EFW <10th centile, 
a common threshold applied to divide AGA and SGA fetuses in clinical practice, was the weakest of 
the three predictors. 
The screening performance of PlGF to detect SGA, CS-IFC and composite adverse neonatal outcome 
was reported from this study.279 Although low PlGF was associated with the adverse outcomes, 
sensitivities of 9.7% - 11.1% for CS-IFC and 22.2% - 26.8% for composite adverse neonatal outcome 
were achieved for FPRs of 10% – 20%, respectively. Whilst maternal PlGF concentration results 
showed lower PlGF levels amongst the adverse outcomes of Op-IFC and CNO for the full cohort, 
and all outcomes for the Alere cohort, PlGF proved poor as a screening tool and therefore has limited 
use in clinical practice for the prediction of CS-IFC, Op-IFC and CNO. 
The combined performance of the CPR and PlGF from this study were also reported.283 This 
publication explored the screening performance amongst the Alere cohort for the detection of CS-
IFC and adverse neonatal outcome. It found that CPR and PlGF centiles were lower amongst those 
with CS-IFC and composite adverse neonatal outcomes, achieving AUROC curves of 0.92 and 0.64, 
respectively. Additionally, threshold values were explored in order to achieve 100% sensitivity for 
the detection of CS-IFC. The thresholds of CPR 20th and PlGF 33rd centiles, when used in 
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combination, produced sensitivities, specificities and positive likelihood ratios of 100%, 86% and 
7.14, respectively, for CS-IFC and 34.2%, 87% and 2.63, respectively, for composite adverse neonatal 
outcome. Interestingly, the addition of PlGF to CPR did not significantly improve the screening 
performance for either CS-IFC or the composite adverse neonatal outcome. 
It is important to view all of these results in the context of the low risk cohort in which the study was 
undertaken. The proportion of SGA (<10th centile) babies in the study and Alere cohorts, 5.4% and 
3.4%, respectively, confirms the low risk profile of the study group. Unfortunately, the low number 
of these SGA babies precluded sub-analysis of test performance within this at-risk group. A higher 
risk group will naturally have a greater prevalence of the adverse event and thus the performance of 
any screening test will be higher.284 In pregnancy however, low risk women constitute by far the 
largest cohort from which the majority of cases of intrapartum fetal hypoxia occur,11 despite a 
relatively low prevalence of disease.  
In this chapter, sub-analysis of the Alere cohort produced higher AUROC curves, particularly in 
screening for CS-IFC. Although the two cohorts cannot be directly compared due to the different 
number of women in each, it does raise two questions. Firstly, are the Alere cohort results falsely 
reporting higher AUROC curves? Secondly, are the DELFIA cohort results falsely reporting poorer 
performance?  
The sample size was sufficient for assessment of CPR, although this is unknown for PlGF. The Alere 
cohort, after exclusions, included 185 women for analysis compared to 378 in the DELFIA cohort. 
In the Alere cohort the study population with CPR <10th centile compared to those with CPR ≥10th 
centile requiring CS-IFC was sufficient to achieve study power >0.8. However, it is not possible to 
perform a power calculation and draw conclusions for PlGF data due to the absence of an established 
cut-off for PlGF to define normality/abnormality in a low risk population at term. 
The Alere cohort used the Triage platform, as opposed to the DELFIA cohort which used the DELFIA 
Xpress assay results with a correction algorithm as previously described, for PlGF quantification. It 
is important to note that the Alere cohort contained a higher proportion of CS-IFC than the DELFIA 
cohort. The correction algorithm enabled comparison of results from the two platforms on a group 
basis but it is possible that the small number of CS-IFC events were disproportionately affected and 
results subsequently diluted by the correction algorithm applied to the Triage platform results. 
Although both platforms quantify isoform 1 of PlGF, their absolute concentration results differ when 
samples are tested in parallel, as has been noted previously between PlGF assay platforms.285 Possible 
 125 
 
explanations for this difference include the manual process of the Alere Triage versus the automated 
DELFIA Xpress platform, the possibility of the platforms measuring cross-reactive PlGF isoforms 
and bound verse unbound PlGF to different degrees.285 
Nevertheless, the findings add to the growing body of research which indicates that both pre-labour 
hemodynamic evidence of suboptimal fetal growth138,260,261 and subtle placental dysfunction271 are 
already evident in apparently low-risk pregnancies and that this predisposes these apparently 
normally grown babies to CS-IFC, Op-IFC and CNO. The key difference between this study and that 
of previous publications is its prospective nature combined with the low risk profile of the cohort. To 
date, much of the published data regarding ultrasound parameters and PlGF have been retrospective 
and undertaken in at-risk groups, such as women with pre-eclampsia, small for gestational age, and/or 
fetal growth restriction cohorts. However, because of the higher risk profile of these groups they 
naturally have higher rates of intrapartum intervention286 and adverse neonatal sequelae.287 
5.5 Conclusion 
In this chapter the screening performance of ultrasound variables and PlGF for the identification of 
CS-IFC, Op-IFC and CNO was assessed. A non-invasive screening method, as presented in this 
chapter, may provide benefit to pregnant women and their offspring through individualised risk 
stratification. Although cost analysis is clearly required, this may potentially provide the opportunity 
for timely discussion regarding timing, place and mode of birth, thereby improving obstetric care, 
neonatal outcomes and maternal satisfaction. The overall findings of this Thesis in context will be 
discussed in the final chapter. 
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Chapter 6: Discussion 
The population of women considered low risk at term is the group in which the majority of cases of 
fetal compromise and adverse neonatal outcomes occur. There is currently no screening test to 
identify the fetus at risk within this population. The results reported in this Thesis are unique in that 
they provide evidence that ultrasound parameters and PlGF provide a contribution towards addressing 
this clinical need.  
Intrapartum complications impact individuals, families and healthcare systems globally. Antepartum 
clinical risk classification and intrapartum monitoring systems have not reduced cerebral palsy rates, 
unnecessary intrapartum interventions or stillbirths in developed countries in over 40 years, thus 
representing an ongoing challenge in obstetric care worldwide. Late pregnancy complications, 
including CS-IFC, Op-IFC and CNO are associated with placental dysfunction. Studies of 
predominantly at-risk pregnancies have shown that ultrasound parameters and biomarkers are altered 
in pregnancies with SGA and/or IUGR fetuses, women with PET and babies requiring neonatal unit 
admission. Thus, the objective of this Thesis was to assess both the associations with and the potential 
value for, screening for CS-IFC, Op-IFC and CNO using hemodynamic ultrasound parameters and 
maternal PlGF levels in a low risk population from 36 weeks’ gestation.  
6.1 Principal findings 
The key findings from this study in a low risk population were: 
1. Decreased MCA-PI, CPR and cUVf, and increased UtA-PI are associated with and predictive 
of adverse intrapartum and neonatal outcomes. 
2. Lower PlGF levels are associated with and predictive of adverse intrapartum and neonatal 
outcomes. 
3. The highest combined screening performance for study outcomes was achieved by: 
a) MCA-PI (or CPR) + UtA-PI + PlGF (Alere) for CS-IFC 
b) MCA-PI + cUVf + UtA-PI + parity for Op-IFC 
c) PlGF (Alere) + GAd for CNO 
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6.2 Research findings 
The association between ultrasound parameters and CS-IFC, Op-IFC and CNO was reported in 
chapter 3. Overall, UA-PI, MCA-PI, CPR, cUVf and UtA-PI: 
 Decrease with advancing gestation;  
 Do not differ in their rate of change between those with and without the adverse outcomes 
(CS-IFC, Op-IFC or CNO);  
 Are associated with the adverse outcomes at last assessment preceding delivery, except UA-
PI, which is not associated. 
Median UA-PI was not associated with CS-IFC, Op-IFC or CNO, when assessed by gestation, with 
the exception of median UA-PI at 40 weeks’ gestation which was higher in babies delivered by Op-
IFC (0.84 vs. 0.70, p = 0.01) compared to those without Op-IFC. These findings are consistent with 
those of Oros et al.258 whose assessment amongst SGA term fetuses concluded that UA-PI frequently 
remained <95th centile despite fetal cerebral redistribution, and that of Figueras et al.264 who 
demonstrated that perinatal and neurodevelopmental outcomes amongst SGA fetuses with normal 
UA-PI were suboptimal. However, a study of term fetuses by Bolz et al.288 reported that an elevated 
UA-PI (>95th centile), compared to those with a normal UA-PI (≤95th centile), was associated with 
increased odds of CS-IFC compared to spontaneous vaginal delivery (OR 3.3). Interestingly, the 
mean gestation (39+2 weeks) of women in the study by Bolz et al. closely reflects that of the women 
presented in this Thesis, whilst the Doppler assessment occurred earlier in gestation for women 
examined in the studies by Oros et al. and Figueras et al. These findings suggest that an association 
between increased umbilical artery resistance and adverse perinatal outcomes may only be evident 
beyond 39 weeks’ gestation and may explain the seemingly conflicting results between authors. 
Nevertheless, despite a difference being evident at term gestation, the predictive value of UA-PI >95th 
centile was negligible.288 The analysis for rate of change in UA-PI showed no difference between the 
outcome groups. Despite the study by Oros et al.258 presenting results from a higher risk cohort, they 
also found that the UA-PI was virtually unchanged from 37 weeks’ gestation to delivery. Collectively, 
these UA Doppler findings support the theory that late onset placental dysfunction is a different entity 
to its early onset counterpart and therefore suggest that a different screening tool for the late onset 
cohort would be appropriate. 
Regarding MCA-PI, babies with the adverse CS-IFC, Op-IFC and CNO outcomes at last assessment 
preceding delivery had lower median values compared to those with normal outcomes. Additionally, 
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median MCA-PI was lower in the CS-IFC group at 40 weeks’ gestation and Op-IFC at all gestations. 
The MCA-PI findings presented in this Thesis are consistent with other studies in late pregnancy (34 
to 42 weeks’ gestation) generally from high risk populations, albeit with different study designs, that 
have shown associations between MCA-PI and poor intrapartum and neonatal outcomes.46,123,289 In 
these studies all authors used the MCA-PI <5th centile threshold value as a positive test result, except 
Ropacka-Lesiak et al., who used the MCA-PI 10th centile. Additionally, Kassanos et al. demonstrated 
in a study of antenatally low risk women, defined as those with an absence of maternal or fetal 
complications, at 38 to 41 weeks’ gestation with abnormal intrapartum CTG patterns that MCA 
resistance indices were temporally associated and positively correlated with oxygen saturation levels 
measured by fetal pulse oximetry.127 Interestingly, this study also showed that in fetuses with oxygen 
saturation levels decreasing below 37%, brain sparing was evident first by reduced MCA-PI, followed 
by MCA-RI, UA-PI and UA-RI changes. However, a systematic review290 of 35 studies in 2012 
showed poor predictive accuracy of MCA-PI for detection of perinatal compromise. There are two 
differences of note between this review and the current study. Firstly, the gestation of the studies 
reviewed290 ranged from 17 to 41 weeks’ gestation, which is significantly at variance with this study, 
which assessed women exclusively from 35 to 42 weeks’ gestation. Thus, early and late onset 
placental dysfunction, conditions that are now thought to be different conditions, were grouped 
together, diluting possible MCA-PI differences and predictive capacity within the late onset cases. 
Secondly, the risk profile of the studies in the review290 was predominantly high risk, whilst the 
current study was low risk. However, as late onset placental dysfunction is considered an under-
diagnosed late pregnancy complication,291 it is likely that women designated as high risk within these 
studies encountered early onset placental complications, and thus a different condition to the one 
reported here; one that is known to be better detected by changes in the UA-PI rather than the MCA-
PI.39  
Lastly, the rate of change in MCA-PI did not differ between the outcome groups. There is a scarcity 
of information in the literature regarding longitudinal changes in the MCA-PI, particularly in relation 
to adverse perinatal outcomes. In a study by Mari et al.,292 MCA-PI was recorded longitudinally in 
10 growth restricted fetuses from 23+0 to 32+4 weeks’ gestation and showed no longitudinal pattern 
as a group or when grouped according to neonatal outcome. A study of 40 IUGR fetuses at 28 to 36 
weeks’ gestation reported in 2017 by Gupta et al.,293 also concluded that longitudinal trends in MCA-
PI were inconsistent among neonatal outcome groups. The design differences, gestation at assessment 
and IUGR cohorts, between the study presented in this Thesis and these previous studies prevent 
direct comparison between studies. Again, MCA-PI in late onset growth restriction is known to be a 
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better indication of fetal compromise than in the early onset cohort and the cohort investigated for 
this Thesis was low risk.  
Median CPR was lower for babies with the adverse CS-IFC, Op-IFC and CNO outcomes at 40 weeks’ 
gestation and last assessment preceding delivery compared to those with normal outcomes. 
Additionally, for babies born by Op-IFC, median CPR was lower at 38 weeks’ gestation and these 
babies also displayed a significantly greater rate of decline in CPR from first to last assessment 
compared to those without Op-IFC. These cross-sectional results are similar to those of previous 
studies, although no other reported studies were directly comparable due to differing study design, 
particularly gestation at assessment, participant risk profile and outcomes assessed. A recent 
systematic review and meta-analysis294 also stated that heterogeneity between studies was a limitation 
in assessing the prognostic accuracy of the CPR for adverse perinatal outcomes, and recommended 
that clinical trials be conducted in sub-groups such as late fetal growth restriction to assess impact. 
Notwithstanding this, in a mixed risk cohort at 35 to 37 weeks’ gestation the CPR <5th centile has 
been shown to range in sensitivity from 6-15%, increasing to 14-50% when measured within two 
weeks of delivery for detection of adverse perinatal outcome (fetal distress, acidosis, Apgar <7 at 5 
minutes, neonatal or neonatal intensive care unit).142 Amongst SGA fetuses at 32 to 36 weeks’ 
gestation, observational studies have shown41,43 that the CPR <5th centile was not predictive of SGA 
at birth. Further studies of the utility of the CPR in term pregnancy for the prediction of adverse 
perinatal outcome in low risk131 or SGA289 populations showed that a low CPR (<10th and <5th centile, 
respectively) increased the odds of CS-IFC between six- and ten-fold, and was independently 
associated with Op-IFC regardless of fetal size. In regard to composite neonatal outcomes, a low CPR 
has been shown to be predictive, with greater than a two-fold increase in odds of an adverse 
outcome,295 higher sensitivity (87.8%) and negative predictive value than individual fetal Doppler 
indices,296 and better screening performance when compared to other common screening tests such 
as amniotic fluid index, biophysical profile, non-stress test, EFW or UVf.254,262 In contrast, in 
predominantly early onset IUGR cohorts the CPR threshold of 1.0 to 1.1 has been shown to be 
predictive of adverse perinatal outcomes, with estimated mean sensitivity and specificity for 
emergency delivery for IFC of 0.58 (95% CI 0.39 – 0.74) and 0.89 (95% CI 0.79 – 0.94), and 0.59 
(95% CI 0.44 – 0.73) and 0.91 (95% CI 0.82 – 0.96) for composite adverse neonatal outcome, 
respectively.294 These thresholds are well below the 5th centile according to published reference 
centiles.237,297 To summarise, the CPR as a stand-alone screening tool thus appears poor in low risk, 
pre-term populations but more promising at term, particularly when the interval between CPR 
measurement and delivery is no greater two weeks. 
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The association between rate of change in CPR in term pregnancies and adverse perinatal outcomes 
has not previously been reported. The findings from this study suggest that whilst longitudinal 
analysis showed significant association, it is not sufficiently strong to be predictive and is inferior as 
a screening tool compared to a single CPR measurement. 
Median cUVf was lower for babies with the adverse CS-IFC, Op-IFC and CNO outcomes at 40 
weeks’ gestation and last assessment preceding delivery compared to those with normal outcomes. 
Additionally, cUVf was also lower for babies born by CS-IFC and Op-IFC at 38 weeks’ gestation. 
These findings are consistent with other reports,107,247,266,298 which showed that cUVf was lower 
amongst fetuses with adverse perinatal outcomes, although were performed amongst cohorts of 
differing risk profile or gestation. Other authors43,299 have reported no association between cUVf and 
adverse perinatal outcomes, again from different gestations and cohorts, typically earlier in pregnancy 
and cohorts with higher risk profiles to those examined in this Thesis. The results reported in this 
Thesis are unique in that an association was shown between lower cUVf and adverse outcomes even 
amongst term fetuses up to two weeks prior to labour.  
Additionally, the rate of decline in cUVf was significantly greater amongst babies born by CS-IFC 
compared to those without CS-IFC deliveries when comparison was made from first to last 
assessment and 36 to 38 weeks’ gestation. Assessment of longitudinal change has not previously been 
reported in low risk, term pregnancies. This novel finding provides insight into fetal hemodynamic 
changes at term, suggesting that fetuses with IFC sufficient to require CS-IFC are not only supplied 
with less oxygen, nutrients and substrates from the placenta, but this occurs at a faster rate as term 
approaches.  
Median UtA-PI was higher for babies with the adverse CS-IFC, Op-IFC and CNO outcomes at last 
assessment preceding delivery compared to those with normal outcomes. Additionally, median UtA-
PI was higher for babies with Op-IFC and CNO at 38 weeks’ gestation compared to those without 
these complications. These findings are consistent with previous reports that have demonstrated an 
elevated UtA-PI is associated with adverse outcomes and produces promising diagnostic performance 
for SGA weight infants,146,288,300 CS-IFC,122 stillbirth132 and neonatal mortality.132,146 Although these 
studies suggest that the UtA-PI may be useful as a screening tool for placental dysfunction, they were 
predominantly retrospective in nature and performed in cohorts already at risk of placentally mediated 
complications or clinicians were not blinded to the ultrasound results. However, a large, un-blinded, 
prospective study301 of low risk women at 30-34 weeks of pregnancy reported marginal benefit 
conferred by UtA-PI in addition to maternal factors and EFW in screening for SGA fetuses. 
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Consistent with this, a publication278 arising from this Thesis shows that the addition of the UtA-PI 
>95th centile to the CPR <10th centile marginally improves the sensitivity in screening for CS-IFC 
from 27.8% to 33.3%. Similarly for CNO, addition of the UtA-PI >95th centile to the CPR <10th 
centile improved sensitivity from 16.1% to 27.2%. The further addition of EFW to this model for 
CNO marginally improved sensitivity to 28.4%, albeit with a concurrent increase in the FPR from 
14.1% to 17.0%. The results arising from this Thesis demonstrate that in a low risk cohort at term, 
the UtA-PI provides limited benefit to screening at term. 
In chapter 3 of this Thesis, the UtA-PI was shown to change at a greater rate from first to last 
assessment for CS-IFC and Op-IFC deliveries, compared to those without these complications. 
Interestingly, UtA-PI increased from first to last assessment for those with CS-IFC and Op-IFC 
deliveries whilst it decreased in those without these complications, suggesting that maternal vascular 
resistance was continuing to evolve even in term pregnancies and differed between the mode of 
delivery outcome groups.  
Estimated fetal weight centile, a key component of fetal growth assessment in clinical practice, 
showed no association with CS-IFC or CNO. However, EFWc was lower at 38 weeks’ gestation and 
at last assessment preceding delivery for babies born by Op-IFC. However, the EFWc changed at a 
greater rate for babies with CNO vs. those without CNO, reducing in the former and increasing in the 
latter. Notably, the median EFWc values in this study would be considered normal (>10th centile) by 
standard classification, with little difference between pregnancies with and without the CS-IFC, Op-
IFC and CNO outcomes. 
Placental growth factor results were reported in chapters 4 and 5, reported by two assay techniques; 
DELFIA cohort and Alere cohort For the DELFIA cohort, PlGF was lower at last assessment for 
babies delivered by Op-IFC and at assessments for babies born with CNO. Notably, lower PlGF was 
not associated with CS-IFC at any gestation in the DELFIA cohort analysis. In contrast, the Alere 
cohort analysis showed that PlGF was lower at 38 and 40 weeks’ gestation and at last assessment 
preceding delivery for babies for by CS-IFC; and at 38 weeks’ gestation and at last assessment for 
babies born with Op-IFC and/or CNO. The differing results from the two cohorts raises important 
questions which will be addressed in the strengths and limitations section of this chapter. However, 
irrespective of assay platform, lower PlGFc was associated with, and predictive of, Op-IFC and CNO, 
corroborating the ultrasound findings presented in the earlier chapters of this thesis that placental 
dysfunction is compromised in some low risk women at term that subsequently develop Op-IFC or 
CNO. These findings are also broadly consistent with other reports that have shown predictive 
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performance of PlGF for antenatal identification adverse pregnancy outcome,40 FGR of placental 
origin274 and placental underperfusion,302 with AUROCs of 0.66 and 0.96, and an odds ratio of 0.11, 
respectively, albeit in high risk populations. Despite the demonstrated association between PlGF and 
adverse perinatal outcome in low risk women at term, PlGF did not demonstrate significant additional 
AUROC for any of these outcomes in multivariate analysis.283 PlGF did, however, improve the 
negative predictive value,283 which may be where the potential benefit for a combined screening test 
lies. 
The assessment of longitudinal change as reported in this Thesis was important for several reasons. 
Theoretically, the gradual deterioration in fetal hemodynamics and EFWc would be expected to 
accelerate with increasing gestation and therefore be greatest immediately preceding delivery. 
However, longitudinal data had not previously been reported for low risk women at term. In order to 
conduct meaningful analysis the first and last assessment were used, maximising the number of 
women included in the longitudinal analysis as the vast majority of women had more than one 
assessment. Additionally, longitudinal assessment was thought to be potentially superior to cross-
sectional assessment as it is a more clinically useful assessment approach, independent of gestation, 
unlike cross-sectional assessment. Furthermore, longitudinal analysis provides each fetus with its 
own baseline rather than a population-based normal or abnormal classification used in cross-sectional 
analysis, which may not adequately profile each fetus.  
6.3 Contribution to knowledge 
The findings reported in this study provide important results to inform clinicians of associations and 
screening performance of commonly used hemodynamic ultrasound parameters in pregnant women 
at term. Additionally it introduces a novel placental biomarker as a potential screening test for 
intrapartum fetal compromise and adverse neonatal outcome. For women considered low risk in 
pregnancy, fetal heart rate monitoring is ubiquitous with intrapartum care in high income countries. 
Its use, however, has not delivered the anticipated reduction in serious neonatal morbidities that 
prompted its introduction. The fetal hemodynamic changes and/or biomarkers of placental 
dysfunction in growth restricted cohorts and women who develop pre-eclampsia have sparked the 
hope that these same changes may be evident and useful for screening in low risk women to identify 
those who will subsequently develop late pregnancy complications. Given the climate of spiralling 
litigation, compensation and medical indemnity costs, clinical equipoise regarding the use of late 
pregnancy ultrasound currently exists.  In fact, late pregnancy ultrasound is increasingly used in 
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routine practice without evidence to support its use nor appreciation of its potential harm, particularly 
increased intervention rates and early birth.  
The findings reported from this study show that the CPR is the parameter that provided the best 
screening performance across intrapartum and neonatal outcomes, CS-IFC, Op-IFC or CNO, with 
minimal improvement afforded by the addition of maternal PlGF levels. However, as a stand-alone 
screening modality the CPR’s AUROC curve would be considered poor for the DELFIA cohort. 
Publications arising from this Thesis show that the CPR 10th centile threshold outperforms thresholds 
that other investigators have proposed (CPR≤1 and CPR <5th centile).136,137 Additionally, a 
publication of combined screening performance of the CPR and PlGF from this Thesis suggests that 
in a low risk cohort, consideration of a higher CPR threshold (20th centile), with a subsequently higher 
sensitivity and FPR, may be worthy of consideration.283 Precedence exists for higher FPRs in medical 
screening programs, such as those applied in obstetrics and cancer screening; electronic fetal heart 
rate monitoring has a 60% FPR for detection of fetal hypoxia,303 mammography for breast cancer has 
a 10-year cumulative FPR of 62%,304 and elevated Prostate Specific Antigen for men with who 
underwent biopsy for suspected prostate cancer305 has a reported  FPR of 75.9%. Induction of labour 
is the current management of a woman at term where there are fetal concerns. The DIGITAT 
randomised clinical306 trial has demonstrated that induction does not increase the risk of adverse 
perinatal outcomes. Furthermore, a recent report307 from a large randomised clinical trial (ARRIVE), 
comparing induction of labour at 39 weeks’ gestation with expectant management, in low risk women 
demonstrated decreased risk of CS and composite perinatal outcome amongst women who were 
induced. Thus, if a higher FPR is accepted for IFC screening, where there is the risk of lifelong 
neurological disability, as it is accepted in oncology, then a higher CPR threshold with increased 
sensitivity may offer an improvement to currently applied methods. However, the current study 
demonstrated modest screening performance for CNO, a more clinically significant outcome than 
IFC. Clearly, a trial that can demonstrate a high risk screening result followed by induction results in 
an improvement in perinatal outcomes is necessary prior to the recommendation of this screening 
method in a low risk population at term. If a high risk screening result was obtained by the parameters 
assessed in this Thesis and used clinically, higher intervention rates (induction and cesarean section) 
with simultaneous lowering of gestation at delivery would be anticipated, without evidence of 
perinatal benefit. The clinical implications of a high risk screening result mean that implementation 
of this screening assessment cannot be recommended in its current form. 
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Data from this study demonstrate that defined thresholds produce poorer screening performance than 
continuous data. Although the screening performance of ultrasound and PlGF in their present form 
are insufficient for clinical uptake, they may be useful as part of an algorithm for risk assessment of 
intrapartum complications, similar to that developed in first trimester aneuploidy screening. 
6.4 Strengths and limitations 
Strengths of this study arise primarily from the study’s design. Importantly, the prospective design, 
blinding of participants and healthcare providers, technical rigour in data collection and measurement, 
consistency of ultrasound operators and achievement of sufficient sample size make this study able 
to answer the primary aims with minimal bias. Additionally, the study has provided a published 
contribution to knowledge in a timely fashion, a time when there has been much interest in the clinical 
application of the CPR and PlGF, and evidence of screening performance amongst low risk women 
at term has been lacking. Longitudinal assessment across fetal hemodynamics, EFW and PlGF has 
provided information that has not previously been reported, and furthered the understanding of late 
pregnancy changes in these parameters.   
PlGF exists in four known isoforms, PlGF-1, PlGF-2, PlGF-3 and PlGF-4. As both assay platforms 
used in this study measure PlGF-1, and PlGF-2 to a smaller degree, the question regarding different 
results from the two cohorts remains unanswered. Possible explanations are:  
1. differing sample sizes  
2. differing platform assay characteristics 
Firstly, the DELFIA cohort was almost double that of the Alere cohort, as reflected by only seven 
women delivering by CS-IFC in the Alere cohort compared to 18 in the DELFIA cohort. 
Consequently, differences that were detected in the Alere cohort may have been due purely due to 
insufficient sample size and chance: Type I error. With this premise, the chance difference that was 
detected in the Alere cohort became diluted in the DELFIA cohort analysis, reflecting a true lack of 
association between PlGF and CS-IFC. Secondly, different assay platforms produce different results 
in the measurement of PlGF, as has been noted previously. It is widely accepted that PlGF 
concentration measured on one platform is not directly comparable to another result processed on a 
different platform. Thus, a correction equation was applied to results performed on the Alere platform 
to enable direct comparison with the DELFIA platform. Whilst this approach functions well for 
correction of a group’s results, the individual results may be substantially altered. This would be most 
apparent in a small sample, such as the seven cases of CS-IFC in the Alere cohort.  
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As an extension of the point regarding different PlGF assay platforms, it is also possible that intrinsic 
differences exist between the two platforms. Previous authors308 have shown that PlGF concentrations 
measured from plasma vs. serum produced different PlGF concentration results. Additionally, it has 
been suggested that different PlGF epitopes, the section of antigen to which an antibody attaches,309 
are bound by antibodies employed by the different platforms, thus producing different concentration 
results.  
The PlGF platforms utilised in the study presented in this Thesis were the result of circumstance. At 
study commencement no local laboratory offered PlGF analysis. However, a desktop point-of-care 
system (Alere Triage) was available, offering single sample analysis and results in approximately 15 
minutes. However, during the course of the study, local laboratories began offering PlGF assays. 
Market competition resulted in the cessation of supply of cartridges for the Alere Triage platform, 
rendering the platform unusable. Thus, study samples were analysed at the local institution’s 
laboratory utilising the DELFIA Xpress platform from midway through the study.  
Other limitations of the study relate to outcomes and possibility of Type 1 statistical error. The small 
number of CS-IFC outcomes and large number of analyses increases the risk of Type 1 error and 
reduces confidence in drawing conclusions. The primary outcome, CS-IFC, is a surrogate for adverse 
pregnancy outcome and whilst the CNO provided stronger evidence of adverse neonatal outcome, it 
was compromised by the lack of umbilical cord gas analysis in nearly 50% of participants. Type 1 
error may also influence the cross-sectional results, given that assessments later in gestation are prone 
to natural selection bias arising from iatrogenic delivery. Although this is theoretically true, cross-
sectional data produced in this study provided results similar to those of other studies as previously 
discussed. Finally, the higher proportion of nulliparous women with the Op-IFC outcome represent a 
confounder. 
6.5 Further research 
The results generated by this research study has informed the design of a randomised control trial 
currently underway. The aim of this study is to determine if the induction of low risk women that 
screen positive utilising a combined screening test of the CPR and maternal PlGF at 37 - 38 weeks’ 
gestation, reduces the incidence of CS-IFC. The rationale for induction in this study is that the 
shortfall between placental function and fetal requirements increases with increasing gestation at 
term, and induction may prevent exposure of the fetus to this shortfall with minimal adverse neonatal 
impact, as demonstrated by the DIGITAT trial. Ideally, a thorough cost analysis of such an 
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intervention, including numbers needed to treat, rates of induction of labour and potential resource 
implications, and the impact on neonatal outcomes (short and long term) would be ideal to inform 
clinicians of the potential implication on induction rates, cesarean section rates and neonatal 
outcomes.  
Although the results from the present study preclude recommendation of screening by ultrasound 
and/or PlGF alone for IFC, results may differ in low income countries. The present study assessed 
low risk women in a high income country where the prevalence of IFC is lower than the low income 
equivalent. It follows that screening performance may be higher in these countries. Well-designed 
research in a low resource setting to assess the screening performance of the CPR for detection of 
IFC would be informative. 
6.6 Conclusion 
This Thesis finds that although there are several ultrasound parameters that are associated with CS-
IFC, Op-IFC and CNO, the CPR and MCA-PI produces the highest AUROC. Lower PlGF 
concentrations were associated with Op-IFC and CNO for the entire cohort analysis compared to 
uncomplicated deliveries, whilst lower PlGF was shown in the Alere cohort for all three outcomes, 
CS-IFC, Op-IFC and CNO, compared to uncomplicated deliveries. Overall, the rate of change did 
not differ with respect to ultrasound parameters and PlGF between normal and abnormal study 
outcome groups.  
The widespread screening of a low risk population in late pregnancy with the CPR or MCA-PI may 
improve perinatal outcomes for mothers and their offspring, with potential for economic benefit to 
healthcare systems. However, the results in this Thesis suggest that the screening performance of the 
CPR, MCA-PI and PlGF are not sufficiently high to be used in isolation but may offer benefit as part 
of a screening algorithm. However, many clinicians are already using the CPR for management of 
low risk pregnant women without justification to support its use. It is vital that a randomised control 
trial to investigate the impact of a screening tool in a low risk population, on intrapartum and neonatal 
outcomes is performed before the practice of late pregnancy ultrasound becomes routine by default.
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